US20070249653A1 - Tetracyclic benzamide derivatives and methods of use thereof - Google Patents

Tetracyclic benzamide derivatives and methods of use thereof Download PDF

Info

Publication number
US20070249653A1
US20070249653A1 US11/786,627 US78662707A US2007249653A1 US 20070249653 A1 US20070249653 A1 US 20070249653A1 US 78662707 A US78662707 A US 78662707A US 2007249653 A1 US2007249653 A1 US 2007249653A1
Authority
US
United States
Prior art keywords
alkyl
substituted
nitrogen
halo
membered monocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/786,627
Inventor
Prakash Jagtap
William Williams
Alexander Nivorozhkin
Csaba Szabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rocket Pharmaceuticals Inc
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Priority to US11/786,627 priority Critical patent/US20070249653A1/en
Publication of US20070249653A1 publication Critical patent/US20070249653A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the invention relates to Tetracyclic Benzamide Derivatives; compositions comprising an effective amount of a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Benzamide Derivative.
  • Inflammatory diseases such as arthritis, colitis, and autoimmune diabetes
  • inflammatory disease and reperfusion disease can induce proinflammatory cytokine and chemokine synthesis which can, in turn, result in production of cytotoxic free radicals such as nitric oxide and superoxide. NO and superoxide can react to form peroxynitrite (ONOO ⁇ ) (Szabó et al., Shock 6:79-88, 1996).
  • the ONOO ⁇ -induced cell necrosis observed in inflammatory disease and in reperfusion disease involves the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS), also known as poly (ADP-ribose) polymerase (PARP).
  • PARP nuclear enzyme poly
  • PARP Activation of PARP is thought to be an important step in the cell-mediated death observed in inflammation and reperfusion disease (Szabó et al., Trends Pharmacol. Sci. 19:287-98, 1998).
  • United Kingdom Patent No. GB 2025932 B2 by Sumitomo Chemical Co. discloses indoloisoquinoline compounds allegedly having bacteriacidal or fungicidal activity.
  • the present invention encompasses compounds having the Formula (I): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), HO-substituted-(C 1 -C 5 alkyl), carboxy-substituted-(C 1 -C 5 alkyl), —C(O)—C 1 -C 10 alkyl, —C(O)-aryl, —C(O)-(3- to 7-membered monocyclic heterocycle), —C(O)-(7- to 10-membered bicyclic heterocycle) or -glycoside;
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —(C(OH)((CH 2 ) n CH 3 ))—, —(C(OH)(aryl))-, —O—, —NH—, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and n is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • the present invention also encompasses compounds of Formula (Ia): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), HO-substituted-(C 1 -C 5 alkyl), carboxy-substituted-(C 1 -C 5 alkyl), —C(O)—C 1 -C 10 alkyl, —C(O)-aryl, —C(O)-(3- to 7-membered monocyclic heterocycle), —C(O)-(7- to 10-membered bicyclic heterocycle) or -glycoside;
  • R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • the present invention also encompasses compounds of Formula (Ib): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), HO-substituted-(C 1 -C 5 alkyl), carboxy-substituted-(C 1 -C 5 alkyl), —C(O)—C 1 -C 10 alkyl, —C(O)-aryl, —C(O)-(3- to 7-membered monocyclic heterocycle), —C(O)-(7- to 10-membered bicyclic heterocycle) or -glycoside;
  • R 11 H, —C 1 -C 5 alkyl, -aryl, —C(O)—C 1 -C 5 alkyl, or —SO 2 Y, wherein Y is —OH, —NH 2 or —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle);
  • R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 -, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • the invention also relates to compounds of Formula (II): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is O, NH or S
  • R 6 is —H or C 1 -C 4 alkyl
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —(C(OH)((CH 2 ) n CH 3 ))-, —(C(OH)(aryl))-, —O—, —NH—, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and n is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —-(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • the invention also relates to compounds of Formula (IIa): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 6 is —H or C 1 -C 4 alkyl
  • R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • the invention further relates to compounds of Formula (III): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is O, NH or S
  • R 6 is —H or —C 1 -C 4 alkyl
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —(C(OH)((CH 2 ) n CH 3 ))—, —(C(OH)(aryl))-, —O—, —NH—, —S—, —CH(NR 11 R 12 )- or —N(SO 2 Y)-, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and n is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • G 1 -G 4 is C—R 7 and the remaining G 1 -G 4 are independently N or C—R 7 ;
  • R 1 , R 2 , R 3 , and R 4 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R 7 is independently —H, —C 1 -C 6 alkyl, —O—(C 1 -C 6 alkyl), —S—(C 1 -C 6 alkyl), —SO 2 NH(C 1 -C 6 alkyl) or C(O)NH—(C 1 -C 6 alkyl).
  • the invention further relates to compounds of Formula (IV): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is O, NH or S
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —CH(OH)—, —(C(OH)((CH 2 ) m CH 3 ))—, —(C(OH)(aryl))-, —O—, —N(Z 5 )—, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or -C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • G 1 -G 4 is C—R 7 and the remaining G 1 -G 4 are independently N or C—R 7 ;
  • R 1 , R 2 , R 3 , and R 4 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R 7 is independently —H, —C 1 -C 6 alkyl,-O—(C 1 -C 6 alkyl), —S—(C 1 -C 6 alkyl), —SO 2 NH(C 1 -C 6 alkyl) or C(O)NH—(C 1 -C 6 alkyl);
  • Z 5 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n —(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n —COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH-aryl, —(CH 2 ) n —CONH
  • each n is an integer ranging from 0 to 10;
  • q is an integer ranging from 0 to 10.
  • the invention also relates to compounds of Formula (V): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is O, S, or NH
  • R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently -hydrogen, -halo, -hydroxy, —NH 2 NO 2 , or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 10 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n -(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n —COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH-aryl, —(CH 2 ) n —CONH
  • each n is an integer ranging from 0 to 10;
  • p is an integer ranging from 0 to 5, with p being other than 0 when R 10 is —H;
  • q is an integer ranging from 0 to 10.
  • the invention also relates to compounds of Formula (VI): and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R 5 is O, S, or NH
  • R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently -hydrogen, -halo, -hydroxy, —NH 2 NO 2 , or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 10 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n -(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n —COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH-aryl, —(CH 2 ) n —CONH
  • each n is an integer ranging from 0 to 10;
  • q is an integer ranging from 0 to 10.
  • the invention also relates to compounds of Formula (VII): and pharmaceutically acceptable salts and hydrates thereof, wherein
  • R 5 is O, NH or S
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —CH(OH)—, —(C(OH)((CH 2 ) m CH 3 ))—, —(C(OH)(aryl))-, —O—, —N(Z 5 )—, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • G 1 -G 4 is C—R 7 and the remaining G 1 -G 4 are independently N or C—R 7 ;
  • R 1 , R 2 , R 3 , and R 4 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3 - to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R 7 is independently —H, —C 1 -C 6 alkyl, —O—(C 1 -C 6 alkyl), —S—(C 1 -C 6 alkyl), —SO 2 NH(C 1 -C 6 alkyl) or C(O)NH—(C 1 -C 6 alkyl);
  • Z 5 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n -(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n -COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH—(C 1 -C 5 alkyl), —CONHNH
  • each n is an integer ranging from 0 to 10;
  • q is an integer ranging from 0 to 10.
  • the invention also relates to compounds of Formula (VIIa): and pharmaceutically acceptable salts and hydrates thereof, wherein
  • R 5 is O, NH or S
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —CH(OH)—, —(C(OH)((CH 2 ) m CH 3 ))—, —(C(OH)(aryl))-, —O—, —N(Z 5 )—, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 1 , R 2 , R 3 , and R 4 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R 7 is independently —H, —C 1 -C 6 alkyl,-O—(C 1 -C 6 alkyl), —S—(C 1 -C 6 alkyl), —SO 2 NH(C 1 -C 6 alkyl) or C(O)NH—(C 1 -C 6 alkyl);
  • Z 5 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n -(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n —COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH-aryl, —(CH 2 ) n —CONH
  • each n is an integer ranging from 0 to 10;
  • q is an integer ranging from 0 to 10.
  • the invention also relates to compounds of Formula (VIIb): and pharmaceutically acceptable salts and hydrates thereof, wherein
  • R 5 is O, NH or S
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —CH(OH)—, —(C(OH)((CH 2 ) m CH 3 ))—, —(C(OH)(aryl))-, —O—, —N(Z 5 )-, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 1 , R 2 , R 3 , and R 4 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a (nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R 7 is independently —H, —C 1 -C 6 alkyl,-O—(C 1 -C 6 alkyl), —S—(C 1 -C 6 alkyl), —SO 2 NH(C 1 -C 6 alkyl) or C(O)NH—(C 1 -C 6 alkyl);
  • Z 5 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n -(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n —COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH-aryl, —(CH 2 ) n —CONH
  • each n is an integer ranging from 0 to 10;
  • q is an integer ranging from 0 to 10.
  • the invention also relates to compounds of Formula (VIIc): and pharmaceutically acceptable salts and hydrates thereof, wherein
  • R 5 is O, NH or S
  • X is —C(O)—, —CH 2 —, —CH(halo)-, —CH(OH)—, —(C(OH)((CH 2 ) m CH 3 ))—, —(C(OH)(aryl))-, —O—, —N(Z 5 )-, —S—, —CH(NR 11 R 12 )— or —N(SO 2 Y)—, wherein Y is —OH, —NH 2 , —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R 11 and R 12 are independently -hydrogen or —C 1 -C 9 alkyl, or N, R 11 and R 12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R 1 , R 2 , R 3 , and R 4 are independently -hydrogen, -halo, -hydroxy, —O—(C 1 -C 5 alkyl), —C 1 -C 10 alkyl, halo-substituted-(C 1 -C 5 alkyl), —C 2 -C 10 alkenyl, —C 3 -C 8 -cycloalkyl, -aryl, —NH 2 , amino-substituted-(C 1 -C 5 alkyl), —C(O)OH, —C(O)O(C 1 -C 5 alkyl), —OC(O)(C 1 -C 5 alkyl), NO 2 or -A-B;
  • A is —SO 2 —, —SO 2 NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C 1 -C 4 alkyl)-, —NH—, —CH 2 —, —S— or —C(S)—;
  • B is —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C 3 -C 8 cycloalkyl, -aryl, —NZ 1 Z 2 , —(C 1 -C 5 alkylene)-NZ 1 Z 2 , amino-substituted-(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C 1 -C 5 alkyl)-(7- to 10-membered bicyclic heterocycle), —
  • Z 1 and Z 2 are independently —H or —C 1 -C 10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z 3 )(Z 4 ), where Z 3 and Z 4 are independently, —H or —C 1 -C 5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH 2 ; or N, Z 3 and Z 4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z 1 and Z 2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R 7 is, independently —H, —C 1 -C 6 alkyl,-O—(C 1 -C 6 alkyl), —S—(C 1 -C 6 alkyl), —SO 2 NH(C 1 -C 6 alkyl) or C(O)NH—(C 1 -C 6 alkyl);
  • Z 5 is —H, —C 1 -C 5 alkyl, —(CH 2 ) n —CN, —(CH 2 ) n -aryl, —(CH 2 ) n -(3- to 7-membered monocyclic heterocycle), —(CH 2 ) n -(7- to 10-membered bicyclic heterocycle), —(CH 2 ) n —COO—(C 1 -C 5 alkyl), —(CH 2 ) n —COO-aryl, —(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COOH, —CONH—(CH 2 ) n —COO—(C 1 -C 5 alkyl), —CONH—(CH 2 ) n -aryl, —CONHNH—(C 1 -C 5 alkyl), —CONHNH-aryl, —(CH 2 ) n —CONH
  • each n is an integer ranging from 0 to 10;
  • q is an integer ranging from 0 to 10.
  • a compound of Formula (I), (Ia), (Ib), (II) (IIa), (III), (IV), (V), (VI), (VII), (VIIa), (VIIb) or (VIIc) or a pharmaceutically acceptable salt or hydrate thereof (a “Tetracyclic Benzamide Derivative”) is useful for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer (each being a “Condition”) in an subject.
  • the invention also relates to compositions comprising an amount of a Tetracyclic Benzamide Derivative that is effective to treat or prevent a Condition, and a pharmaceutically acceptable carrier or vehicle.
  • the compositions are useful for treating or preventing a Condition in a subject.
  • the invention further relates to methods for treating or preventing a Condition, comprising administering to a subject in need thereof an amount of a Tetracyclic Benzamide Derivative that is effective to treat or prevent the Condition.
  • the present invention encompasses compounds of Formula (I) and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (I).
  • X is O.
  • R 1 -R 4 , R 7 and R 10 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 is other than hydrogen.
  • R 5 is —C 2 -C 10 alkyl.
  • R 5 is —C 4 -C 10 alkyl.
  • R 5 is —C 6 -C 10 alkyl.
  • the invention further encompasses compounds of Formula (Ia): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , and R 10 , are defined above for the Tetracyclic Benzamide Derivatives of Formula (Ia).
  • R 1 -R 4 , R 7 and R 10 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 R 7 , R 8 , R 9 or R 10 is other than hydrogen.
  • R 5 is —C 2 -C 10 alkyl.
  • R 5 is —C 4 -C 10 alkyl.
  • R 5 is —C 6 -C 10 alkyl.
  • compounds of Formula (Ia) have the structure of Formula (Ia′):
  • R 5 , R 8 , and R 9 are defined above for compounds of Formula (Ia).
  • the invention also relates to compounds of Formula (Ib): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , and R 11 are defined above for the Tetracyclic Benzamide Derivatives of Formula (Ib).
  • R 1 -R 4 , R 7 and R 10 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 is other than hydrogen.
  • R 5 is —C 2 -C 10 alkyl.
  • R 5 is —C 4 -C 10 alkyl.
  • R 5 is —C 6 -C 10 alkyl.
  • R 5 is —C(O)(C 1 -C 5 alkyl).
  • R 11 is —C(O)(C 1 -C 5 alkyl).
  • R 5 and R 11 are defined above for Formula (Ib).
  • An illustrative compound of Formula (Ib′) is compound 21a, set forth below: and pharmaceutically acceptable salts and hydrates thereof.
  • the present invention encompasses compounds of Formula (II): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (II).
  • R 1 -R 4 , R 7 and R 10 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 is other than hydrogen.
  • R 7 -R 10 are hydrogen.
  • R 6 is hydrogen
  • R 1 -R 4 and R 7 -R 10 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • compounds of Formula (II) have the structure of Formula (II′):
  • R 5 and X of Formula (II′) are as set forth below: R 5 X NH —C(O)— NH —S— NH —NH— NH —CH 2 — NH —N(SO 2 Y)— S —C(O)— S —S— S —NH— S —CH 2 — S —N(SO 2 Y)— O —C(O)— O —S— O —NH— O —CH 2 — O —N(SO 2 Y)— and pharmaceutically acceptable salts and hydrates thereof.
  • the present invention encompasses compounds of Formula (IIa): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are defined above for the Tetracyclic Benzamide Derivatives of Formula (IIa).
  • R 1 -R 4 are hydrogen.
  • R 1 -R 4 , R 7 , R 9 , and R 10 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 is other than hydrogen.
  • R 6 is hydrogen
  • R 1 -R 4 and R 7 -R 10 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • compounds of Formula (IIa) have the structure of Formula (IIa′): wherein R 8 is defined above for Formula (IIa).
  • R 8 is -A-B, where -A- is —SO 2 — and —B is —NZ 1 Z 2 or —(C 1 -C 5 alkylene)-NZ 1 Z 2 .
  • Illustrative compounds of Formula (IIa′) are set forth below: (IIa′) Compound No. R 8 9a —H 11a —SO 2 NH(CH 2 ) 3 -(N-morpholinyl) and pharmaceutically acceptable salts and hydrates thereof.
  • the present invention encompasses compounds of Formula (III): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , G 1 , G 2 , G 3 , G 4, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (III).
  • R 1 -R 4 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 and R 7 is other than hydrogen.
  • R 5 is oxygen
  • one of G 1 -G 4 is N.
  • G 1 is N; and G 2 -G 4 are C—R 7 .
  • G 2 is N; and G 1 , G 3 and G 4 are C—R 7 .
  • G 3 is N; and G 1 , G 2 and G 4 are C—R 7 .
  • G 4 is N; and G 1 , G 2 , and G 3 are C—R 7 .
  • G 1 and G 2 are N and G 3 and G 4 are C—R 7 .
  • G 1 and G 3 are N and G 2 and G 4 are C—R 7 .
  • G 1 and G 4 are N and G 2 and G 3 are C—R 7 .
  • G 2 and G 3 are N and G 1 and G 4 are C—R 7 .
  • G 2 and G 4 are N and G 1 and G 3 are C—R 7 .
  • G 3 and G 4 are N and G 1 and G 2 are C—R 7 .
  • the present invention encompasses compounds of Formula (IV): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , G 1 , G 2 , G 3 , G 4 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (IV).
  • R 1 -R 4 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 or R 7 is other than hydrogen.
  • R 5 is oxygen
  • R 6 is hydrogen
  • one of G 1 -G 4 is N.
  • G 1 is N; and G 2 -G 4 are C—R 7 .
  • G 2 is N
  • G 1 , G 3 , G 4 are C—R 7 .
  • G 3 is N
  • G 1 , G 2 , G 4 are C—R 7 .
  • G 4 is N, G 1 , G 2 , and G 3 are C—R 7 .
  • G 1 and G 2 are N and G 3 and G 4 are C—R 7 .
  • G 1 and G 3 are N and G 2 and G 4 are C—R 7 .
  • G 1 and G 4 are N and G 2 and G 3 are C—R 7 .
  • G 2 and G 3 are N and G 1 and G 4 are C—R 7 .
  • G 2 and G 4 are N and G 1 and G 3 are C—R 7 .
  • G 3 and G 4 are N and G 1 and G 2 are C—R 7 .
  • the present invention encompasses compounds of Formula (V): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and p are defined above for the Tetracyclic Benzamide Derivatives of Formula (V).
  • R 1 -R 4 are hydrogen. In another embodiment, at least one of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 is other than hydrogen. In still another embodiment R 1 -R 4 and R 6 -R 9 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl). In one embodiment R 5 is O. In another embodiment R 5 is NH. In a further embodiment R 5 is S.
  • compounds of Formula (V) have the structure of Formula (V′):
  • R 8 and R 10 are defined above for Formula (V).
  • V′ Compound R 8 R 10 V′1 —H —CH 3 V′2 —H —CH 2 CH 3 V′3 —H —CH 2 Ph V′4 —H —COOCH 3 V′5 —H —COCH 2 COOMe V′6 —H —COCH 2 COOH V′7 —H —COCH 3 V′8 —H —CONH(CH 2 ) 2 N(CH 3 ) 2 V′9 —H —CONH(CH 2 ) 2 -(N-morpholinyl) V′10 —H —CONH(CH 2 ) 3 -(N-morpholinyl) V′11 —H —CONH(CH 2 ) 2 COOCH 2 CH 3 V′12 —H —CONH(CH 2 ) 2 COOH V′13 —H —CONH(CH 2 ) 2 CONHCH 3 V′14 —H —CONH-
  • the present invention encompasses compounds of Formula (VI): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are defined above for the Tetracyclic Benzamide Derivatives of Formula (VI).
  • R 1 -R 4 are hydrogen.
  • R 6 , R 7 , and R 9 are hydrogen.
  • R 6 -R 9 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 is other than hydrogen.
  • R 1 -R 4 and R 6 -R 9 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • compounds of Formula (VI) have the structure of Formula (VI′):
  • R 4 , R 7 , R 9 , and R 10 are defined above for Formula (VI).
  • VI′ Compound R 4 R 7 R 9 R 10 VI′-1 —H —H —H —H VI′-2 —H —H —H —CH 3 VI′-3 —H —H —H —CH 2 CH 3 VI′-4 —H —H —H —CH 2 COO CH 2 CH 3 VI′-5 —H —H —H —CH 2 COOH VI′-6 —H —H —H —CH 2 CONHCH 3 VI′-7 —H —H —H —CH 2 Ph VI′-8 —H —H —H —COOCH 3 VI′-9 —H —H —H —SO 2 NH 2 VI′-10 —H —H —H —COOtBu VI′-11 —H —H —H —COO CH 2 CH 3 VI′-12 —H —H —H —COCH 3 VI′-13 —H
  • the present invention encompasses compounds of Formula (VII): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , G 1 , G 2 , G 3 , G 4 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VII).
  • R 1 -R 4 are hydrogen.
  • R 5 is O.
  • At least one of R 1 , R 2 , R 3 , and R 4 is other than hydrogen.
  • R 1 -R 4 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • X is NH. In still another embodiment X is O.
  • X is S.
  • R 4 is NH 2 , OCH 3 , or NO 2 .
  • one of G 1 -G 4 is N.
  • G 1 is N; and G 2 -G 4 are C—R 7 .
  • G 2 is N; and G 1 , G 3 and G 4 are C—R 7 .
  • G 3 is N; and G 1 , G 2 and G 4 are C—R 7 .
  • G 4 is N; and G 1 , G 2 , and G 3 are C—R 7 .
  • G 1 and G 2 are N and G 3 and G 4 are C—R 7 .
  • G 1 and G 3 are N and G 2 and G 4 are C—R 7 .
  • G 1 and G 4 are N and G 2 and G 3 are C—R 7 .
  • G 2 and G 3 are N and G 1 and G 4 are C—R 7 .
  • G 2 and G 4 are N and G 1 and G 3 are C—R 7 .
  • G 3 and G 4 are N and G 1 and G 2 are C—R 7 .
  • compounds of Formula (VII) have the structure of Formula (VII′):
  • the present invention encompasses compounds of Formula (VIIa): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VIIa).
  • R 1 -R 4 are hydrogen. In another embodiment, at least one of R 1 , R 2 , R 3 , R 4 , R 6 , and R 7 , is other than hydrogen. In one embodiment R 1 -R 4 and R 7 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • X is NH. In still another embodiment X is O. In a further embodiment X is S. In another embodiment R 4 is —NH 2 , —OCH 3 , or —NO 2 .
  • compounds of Formula (VIIa) have the structure of Formula (VIIa′):
  • Illustrative compounds of Formula (VIIa′) are set forth below: (VIIa′) Compound R 4 X VIIa′-1 —H —NH— VIIa′-2 —H —NCH 3 — VIIa′-3 —H —C(H)(CH 2 COOH)— VIIa′-4 —H —O— VIIa′-5 —H —S— VIIa′-6 —H —N(CONHCH 3 )— VIIa′-7 —H —N(CONH(CH 2 ) 2 N(CH 3 ) 2 )— VIIa′-8 —H —C(H)(CONH(CH 2 ) 2 COOCH 2 CH 3 )— VIIa′-9 —H —C(H)(CONH(CH 2 ) 2 CONHCH 3 )— VIla′-10 —H —C(H)(CONH-(N-morpholinyl))- VIIa′-11 —NH 2 —NH— and pharmaceutically acceptable salts and hydrates thereof
  • the present invention encompasses compounds of Formula (VIIb): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VIIb).
  • R 1 -R 4 are hydrogen.
  • At least one of R 1 , R 2 , R 3 , R 4 , R 6 , or R 7 is other than hydrogen.
  • R 1 -R 4 and R 7 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • X is NH. In still another embodiment X is O.
  • X is S.
  • R 4 is NH 2 , OCH 3 , or NO 2 .
  • compounds of Formula (VIIb) have the structure of Formula (VIIb′):
  • Illustrative compounds of Formula (VIIb′) are set forth below: (VIIb′) Compound R 4 X VIIb′-1 —H —NH— VIIb′-2 —H —NCH 3 — VIIb′-3 —H —C(H)(CH 2 CONHCH 3 )— VIIb′-4 —H —O— VIIb′-5 —H —S— VIIb′-6 —H —N(CONHCH 2 CH 3 )— VIIb′-7 —H —N(CONH(CH 2 ) 2 -(N-morpholinyl))- VIIb′-8 —H —C(H)(CONH(CH 2 ) 2 COOH)— VIIb′-9 —H —C(H)(CONH-piperidine-1-yl)- VIIb′-10 —H —C(H)(CO(CH 2 ) 2 -tetrazole-5-yl)- VIIb′-11 —OCH 3 —NH— and pharmaceutically acceptable
  • the present invention encompasses compounds of Formula (VIIc): and pharmaceutically acceptable salts and hydrates thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VIIc).
  • R 1 -R 4 are hydrogen. In another embodiment, at least one of R 1 , R 2 , R 3 , R 4 , R 6 , or R 7 , is other than hydrogen. In one embodiment R 1 -R 4 and R 7 is other than —O—(C 1 -C 5 alkyl), and -A-B is other than —O—(C 1 -C 10 alkyl).
  • X is NH. In still another embodiment X is O. In a further embodiment X is S. In another embodiment R 4 is —NH 2 , —OCH 3 , or —NO 2 .
  • compounds of Formula (VIIc) have the structure of Formula (VIIc′):
  • the Tetracyclic Benzamide Derivatives can exist in a keto or enol tautomeric form.
  • This invention encompasses both the keto and enol forms of the Tetracyclic Benzamide Derivatives. Accordingly, Formulas (I), (Ia) (Ib), (II), (IIa), (III), (IV), (V), (VI), (VII), (VIIa), (VIIb), and (VIIc), although depicting the keto form of the Tetracyclic Benzamide Derivatives, encompass both the keto and enol forms.
  • the present invention also includes Tetracyclic Benzamide Derivatives, wherein one or more hydrogen, carbon or other atoms are replaced by an isotope thereof. Such compounds are useful as research or diagnostic tools in metabolism pharmacokinetic studies and in binding assays.
  • —(C 1 -C 10 )alkyl refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms.
  • Representative straight chain —(C 1 -C 10 )alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonly and -n-decyl.
  • Representative branched —(C 1 -C 10 )alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylbuty, -isopropyl, -sec-butyl, -isobutyl, 1-methylhexyl, 2-methylhex
  • —(C 1 -C 9 )alkyl refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 9 carbon atoms.
  • Representative straight chain —(C 1 -C 9 )alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, and -n-nonly.
  • Representative branched —(C 1 -C 9 )alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylbuty, -isopropyl, -sec-butyl, -isobutyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl
  • —(C 1 -C 5 )alkyl refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 5 carbon atoms.
  • Representative straight chain —(C 1 -C 5 )alkyls include -methyl, -ethyl, -n-propyl, -n-butyl and -n-pentyl.
  • Representative branched —(C 1 -C 5 )alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl and 1,2-dimethylpropyl.
  • —(C 2 -C 10 )alkenyl refers to a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon double bond.
  • Representative straight chain and branched (C 2 -C 10 )alkenyls include -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3 -dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl, -1-heptenyl, -2-heptenyl, -3-heptenyl, -1-octenyl, -2-octenyl, -3-octenyl,
  • —(C 3 -C 8 )cycloalkyl refers to a saturated cyclic hydrocarbon having from 3 to 8 carbon atoms.
  • Representative (C 3 -C 8 )cycloalkyls include -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl and -cyclooctyl.
  • —(C 8 -C 14 )bicycloalkyl refers to a bi-cyclic hydrocarbon ring system having from 8 to 14 carbon atoms and at least one saturated cyclic alkyl ring.
  • Representative —(C 8 -C 14 )bicycloalkyls include -indanyl, -1,2,3,4-tetrahydronaphthyl, -5,6,7,8-tetrahydronaphthyl, -perhydronaphthyl and the like.
  • a “3- to 7-membered monocyclic heterocycle” refers to a monocyclic 3- to 7-membered aromatic or non-aromatic monocyclic cycloalkyl in which 1-4 of the ring carbon atoms have been independently replaced with a N, O or S atom.
  • the 3- to 7-membered monocyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom.
  • 3- to 7-membered monocyclic heterocycle group include, but are not limited to, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, oxazinyl, thiazinyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, tetrazolyl, pyrrolidinyl, isoxazolyl, furanyl, furazanyl, pyridinyl, oxazolyl, thiazolyl, thiophenyl, pyrazolyl, triazolyl, and pyrimidinyl.
  • a “7- to 10-membered bicyclic heterocycle” refers to a bicyclic 7- to 10-membered aromatic or non-aromatic bicyclic cycloalkyl in which 1-4 of the ring carbon atoms have been independently replaced with a N, O or S atom.
  • the 7- to 10-membered bicyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom.
  • Representative examples of a 7- to 10-membered bicyclic heterocycle group include, but are not limited to, benzimidazolyl, indolyl, isoquinolinyl, indazolyl, quinolinyl, quinazolinyl, purinyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzodiazolyl, benzotriazolyl, isoindolyl and indazolyl.
  • a “nitrogen-containing 3- to 7-membered monocyclic heterocycle” refers to a 3- to 7-membered monocyclic heterocycle, defined above, which contains at least one ring nitrogen atom.
  • the nitrogen-containing 3- to 7-membered monocyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom.
  • nitrogen-containing-3- to 7-membered monocyclic heterocycles include, but are not limited to, piperidinyl, piperazinyl, pyrrolyl, oxazinyl, thiazinyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, tetrazolyl, pyrrolidinyl, isoxazolyl, pyridinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrimidinyl, and morpholinyl.
  • a “nitrogen-containing 7- to 10-membered bicyclic heterocycle” refers to a 7- to 10-membered bicyclic heterocycle, defined above, which contains at least one ring nitrogen atom.
  • the nitrogen-containing 7- to 10-membered bicyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom.
  • Representative nitrogen-containing 7- to 10-membered bicyclic heterocycles include -quinolinyl, -isoquinolinyl, -chromonyl, -indolyl, -isoindolyl, -indolizinyl, -indazolyl, -purinyl, -4H-quinolizinyl, -isoquinolyl, -quinolyl, -phthalazinyl, -naphthyridinyl -carbazolyl, - ⁇ -carbolinyl and the like.
  • -aryl refers to a phenyl or naphthyl group.
  • Halo-substituted-(C 1 -C 5 alkyl) refers to a C 1 -C 5 alkyl group, as defined above, wherein one or more of the C 1 -C 5 alkyl group's hydrogen atoms has been replaced with —F, —Cl, —Br or —I.
  • alkylhalo group examples include, but are not limited to, —CH 2 F, —CCl 3 , —CF 3 , —CH 2 Cl, —CH 2 CH 2 Br, —CH 2 CH 2 I, —CH 2 CH 2 CH 2 F, —CH 2 CH 2 CH 2 Cl, —CH 2 CH 2 CH 2 CH 2 Br, —CH 2 CH 2 CH 2 CH 2 I, —CH 2 CH 2 CH 2 CH 2 CH 2 Br, —CH 2 CH 2 CH 2 CH 2 CH 2 I, —CH 2 CH(Br)CH 3 , —CH 2 CH(Cl)CH 2 CH 3 , —CH(F)CH 2 CH 3 and —C(CH 3 ) 2 (CH 2 Cl).
  • Amino-substituted-(C 1 -C 5 alkyl) refers to a C 1 -C 5 alkyl group, as defined above, wherein one or more of the C 1 -C 5 alkyl group's hydrogen atoms has been replaced with —NH 2 .
  • alkyl amino group examples include, but are not limited to, —CH 2 NH 2 , —CH 2 CH 2 NH 2 , —CH 2 CH 2 CH 2 NH 2 , —CH 2 CH 2 CH 2 CH 2 NH 2 , —CH 2 CH(NH 2 )CH 3 , —CH 2 CH(NH 2 )CH 2 CH 3 , —CH(NH 2 )CH 2 CH 3 , —C(CH 3 ) 2 (CH 2 NH 2 ), —CH 2 CH 2 CH 2 CH 2 CH 2 NH 2 , —CH 2 CH 2 CH(NH 2 )CH 3 , —CH 2 CH(NH 2 )CH 2 CH 2 CH 3 , —CH 2 CH(NH 2 )CH 2 CH 3 and —CH 2 C(CH 3 ) 2 (CH 2 NH 2 ).
  • —(NH(C 1 -C 5 alkyl) refers to an —NH group, the nitrogen atom of said group being attached to a C 1 -C 5 alkyl group, as defined above.
  • Representative examples of an aminoalkyl group include, but are not limited to, —NHCH 3 , —NHCH 2 CH 3 , —NHCH 2 CH 2 CH 3 , —NHCH 2 CH 2 CH 2 CH 3 , —NHCH(CH 3 ) 2 , —NHCH 2 CH(CH 3 ) 2 , —NHCH 2 (CH 3 )CH 2 CH 3 , —NH—CH 2 CH 2 C(CH 3 ) 3 , —NHCH 2 CH 2 CH 2 CH 2 CH 3 , —NHCH 2 CH(CH 3 ) 2 , —NHCH 2 CH 2 CH(CH 3 ) 2 , —NHCH 2 CH(CH 3 )CH 2 CH 3 and —NH—CH 2 C(CH 3 ) 3 .
  • —N(C 1 -C 5 alkyl)(C 1 -C 5 alkyl) refers to a nitrogen atom which has attached to it two C 1 -C 5 alkyl groups, as defined above.
  • Representative examples of a aminodialkyl group include, but are not limited to, —N(CH 3 ) 2 , —N(CH 2 CH 3 )(CH 3 ), —N(CH 2 CH 3 ) 2 , —N(CH 2 CH 2 CH 3 ) 2 , —N(CH 2 CH 2 CH 2 CH 3 ) 2 , —N(CH(CH 3 ) 2 ) 2 , —N(CH(CH 3 ) 2 )(CH 3 ), —N(CH 2 CH(CH 3 ) 2 ) 2 , —NH(CH(CH 3 )CH 2 CH 3 ) 2 , —N(C(CH 3 ) 3 ) 2 and —N(C(CH 3 ) 3 )(CH 3 ).
  • —(H 2 NC(O))-substituted aryl refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with one or more —C(O)NH 2 groups.
  • Representative examples of an arylamido group include 2-C(O)NH 2 -phenyl, 3-C(O)NH 2 -phenyl, 4-C(O)NH 2 -phenyl.
  • —(H 2 NC(O))-substituted pyridyl refers to an pyridyl group, wherein one of the pyridyl group's hydrogen atoms has been replaced with one or more —C(O)NH 2 groups.
  • Representative examples of an arylamido group include 2-C(O)NH 2 -pyridyl, 3-C(O)NH 2 -pyridyl and 4-C(O)NH 2 -pyridyl.
  • —(H 2 NC(O))-substituted-(C 1 -C 5 alkyl) refers to a C 1 -C 5 alkyl group, as defined above, wherein one of the C 1 -C 5 alkyl group's hydrogen atoms has been replaced with a —C(O)NH 2 group.
  • alkylamido group examples include, but are not limited to, —CH 2 C(O)NH 2 , —CH 2 CH 2 C(O)NH 2 , —CH 2 CH 2 CH 2 C(O)NH 2 , —CH 2 CH 2 CH 2 CH 2 C(O)NH 2 , —CH 2 CH 2 CH 2 CH 2 C(O)NH 2 , —CH 2 CH(C(O)NH 2 )CH 3 , —CH 2 CH(C(O)NH 2 )CH 2 CH 3 , —CH(C(O)NH 2 )CH 2 CH 3 and —C(CH 3 ) 2 CH 2 C(O)NH 2 .
  • HO-substituted-(C 1 -C 5 alkyl) refers to a C 1 -C 5 alkyl group, as defined above, wherein one of the C 1 -C 5 alkyl group's hydrogen atoms has been replaced with a hydroxyl group.
  • alkanol group examples include, but are not limited to, —CH 2 OH, —CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OH, —CH 2 CH 2 CH 2 CH 2 OH, —CH 2 CH 2 CH 2 CH 2 OH, —CH 2 CH(OH)CH 3 , —CH 2 CH(OH)CH 2 CH 3 , —CH(OH)CH 2 CH 3 and —C(CH 3 ) 2 CH 2 OH.
  • Carboxy-substituted-(C 1 -C 5 alkyl) refers to a C 1 -C 5 alkyl group, as defined above, wherein one of the C 1 -C 5 alkyl group's hydrogen atoms has been replaced with a —COOH group.
  • alkylcarboxy group examples include, but are not limited to, —CH 2 COOH, —CH 2 CH 2 COOH, —CH 2 CH 2 CH 2 COOH, —CH 2 CH 2 CH 2 CH 2 COOH, —CH 2 CH(COOH)CH 3 , —CH 2 CH 2 CH 2 CH 2 CH 2 COOH, —CH 2 CH(COOH)CH 2 CH 3 , —CH(COOH)CH 2 CH 3 and —C(CH 3 ) 2 CH 2 COOH.
  • glycoside refers to a hexose or a pentose sugar forming an ⁇ - or ⁇ -glycosidic linkage.
  • Representative examples of glycosides include, but are not limited to ribose, deoxyribose, fructose, galactose, glucuronic acid and glucose.
  • a “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, or baboon.
  • phrases “pharmaceutically acceptable salt,” as used herein, is a salt formed from an acid and a basic nitrogen group of one of the Tetracyclic Benzamide Derivatives.
  • Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1
  • pharmaceutically acceptable salt also refers to a salt prepared from a Tetracyclic benzamide Derivative having an acidic functional group, such as a carboxylic acid functional group or a sulfonic acid functional group, and a pharmaceutically acceptable inorganic or organic base.
  • Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-OHethyl)amine, 2-OH tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxy lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxye
  • an “effective amount” when used in connection a Tetracyclic Benzamide Derivative is an amount effective for: (a) treating or preventing a Condition or (b) inhibiting PARP in an in vivo or an in vitro cell.
  • Scheme 1 illustrates methods useful for making Tetracyclic Benzamide Derivatives of Formula (IIa), where R 1 -R 4 and R 6 -R 10 are defined for Formula (IIa).
  • R 1 -R 4 and R 6 -R 10 are as defined above for the compounds of Formula (IIa);
  • each R a is independently C 1 -C 3 alkyl; and X is —Cl, —Br, —I, —OTf, —OMs or —OTs.
  • Tetracyclic Benzamide Derivatives of Formula (II) and Formula (IIa) can be made by a method comprising the steps of Scheme 1 above herein.
  • a compound of Formula 3 can be made by a method comprising contacting a compound of Formula 1 with a compound of Formula 2 in the presence of a base for a time and at a temperature sufficient to make a compound of Formula 3.
  • R a is methyl and X is —Br.
  • Suitable bases for use in the method are organic bases such as triethylamine, diisopropylamine, diisopropylethylamine, pyridine, lutidine and imidazole; and inorganic bases such as alkali metal carbonates, including sodium carbonate, potassium carbonate and cesium carbonate.
  • the base is potassium carbonate.
  • the method can be carried out in the presence of a solvent, such as acetonitrile, methylene chloride, chloroform, THF, DMF, DMSO, ethyl acetate, acetone, benzene, diethyl ether, water or mixtures thereof.
  • a solvent such as acetonitrile, methylene chloride, chloroform, THF, DMF, DMSO, ethyl acetate, acetone, benzene, diethyl ether, water or mixtures thereof.
  • the solvent is DMF.
  • the solvent is substantially anhydrous, i.e., comprises less than about 1% water.
  • the method is carried out for a time of about 2 hours to about 36 hours.
  • the method of Scheme 1 is carried out for a time of about 8 hours to about 24 hours.
  • the method of Scheme 1 is carried out for a time of about 12 hours to about 18 hours.
  • the method of Scheme 1 is carried out at a temperature of about 0° C. to about 100° C.
  • the method of Scheme 1 is carried out at a temperature of about 35° C. to about 70° C.
  • the method of Scheme 1 is carried out at a temperature of about 25° C.
  • a compound of Formula 4 can be made by a method comprising (a) contacting a compound of Formula 3 with ammonia in methanol; and (b) contacting the product of step (a) with dilute acid for a time and at a temperature sufficient to make a compound of Formula 4.
  • ammonia in methanol is from about 1 N to about 10 N.
  • ammonia in methanol is from about 3 N to about 7 N.
  • the dilute acid is from about 0.01 N to about 3 N.
  • the dilute acid is from about 0.1 N to about 1 N.
  • the acid is HCl.
  • the method is carried out for a time of about 1 hour to about 48 hours.
  • the method is carried out for a time of about 8 hours to about 36 hours.
  • the method is carried out for a time of about 12 hours to about 24 hours.
  • the method is carried out at a temperature of about 0° C. to about 100° C.
  • the method is carried out at a temperature of about 25° C. to about 75° C.
  • the method is carried out at a temperature of about 40° C. to about 60° C.
  • a compound of Formula 5 can be made by a method comprising contacting a compound of Formula 4 with a dehydrating agent for a time and at a temperature sufficient to make a compound of Formula 5.
  • Suitable dehydrating agents include, but are not limited to, PPA, sulfuric acid, chlorosulfonic acid, sulfuryl chloride and thionyl chloride.
  • the dehydrating agent is PPA.
  • the method can be carried out in the presence of a solvent, including, but not limited to, xylenes.
  • a solvent including, but not limited to, xylenes.
  • the solvent is xylenes.
  • the solvent is substantially anhydrous, i.e., comprises less than about 1% water.
  • the method is carried out for a time of about 1 hour to about 24 hours.
  • the method is carried out for a time of about 4 hours to about 18 hours.
  • the method is carried out for a time of about 6 hours to about 12 hours.
  • the method is carried out at a temperature of about 25° C. to about 200° C.
  • the method is carried out at a temperature of about 100° C. to about 160° C.
  • a compound of Formula (IIa) can be made by a method comprising contacting a compound of Formula 5 with a reducing agent for a time (e.g. Wolff-Kishner reagents) and at a temperature sufficient to make a compound of Formula (IIa).
  • a reducing agent e.g. Wolff-Kishner reagents
  • Suitable reducing agents for this carbonyl reduction include, but are not limited to, sodium borohydride, diisobutylaluminum hydride, alpineborane, and TFA/triethylsilane.
  • the reducing agent is a hydride reducing agent.
  • the reducing agent is sodium borohydride.
  • the reducing agent is TFA/triethylsilane.
  • the method can be carried out in the presence of a solvent, including, but not limited to, methanol, ethanol, THF and benzene. Alternatively the method can be carried out in the absence of a solvent.
  • a solvent including, but not limited to, methanol, ethanol, THF and benzene.
  • the method can be carried out in the absence of a solvent.
  • the solvent is methanol.
  • the solvent is substantially anhydrous, i.e., comprises less than about 1% water.
  • the method is carried out for a time of about 1 minute to about 12 hours.
  • the method is carried out for a time of about 5 minutes hours to about 6 hours.
  • the method is carried out for a time of about 15 minutes hours to about 2 hours.
  • the method is carried out at a temperature of about ⁇ 20° C. to about 40° C.
  • the method is carried out at a temperature of about 10° C. to about 30° C.
  • the method is carried out at a temperature of about 25° C.
  • a Tetracyclic Benzamide Derivative of the Formula 9 can be further derivatized using methodology familiar to one skilled in the art of organic synthesis to prepared a variety of analogs of Formula (II) and Formula (IIa) having various substituents at one or more of R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 and R 10 .
  • Useful derivatization methods include, but are not limited to, aromatic nucleophilic substitution reactions and aromatic electrophilic substitution reactions, such as nitration, iodination, bromination, chlorination, sulfonylation, sulfonylchlorination, alkylation and acylation. See M. B. Smith and J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 675-758 and 850-893 (5 th ed. 2001).
  • the Tetracyclic Benzamide Derivative of Formula 9 is transformed into the chlorosulfonyl compound of Formula 10 using chlorosulfonic acid.
  • the Chlorosulfonyl compound of Formula 10 is then derivatized to the corresponding 3-(N morpholinyl)-propylsulfonamide derivative of Formula 11 by reacting the chlorosulfonyl compound of 10 with 3-(N-morpholinyl)-propylamine in the presence of a triethylamine.
  • Scheme 2 illustrates methods useful for making compounds of Formula (I), Formula (Ia) and Formula (Ib), wherein R 1 -R 4 and R 7 -R 1 are defined above for the compounds of Formula (I), Formula (Ia) and Formula (Ib);
  • X′ is —OH, —NHR 11 , or —SH;
  • X is —O—, —N(H)—, or —S—;
  • each R a is independently C 1 -C 3 alkyl; and
  • R b is —Cl, —Br, —I, —OTs, —OMs or —OTf.
  • a tetracyclic isoquinoline compound of Formula 15 can be prepared by reacting a homophthalate of Formula 13 with a cyanophenol of Formula 14 in the presence of a base, such as triethylamine, sodium carbonate, or potassium carbonate, in a solvent such as acetonitrile, acetone or dimethylformamide (DMF).
  • a base such as triethylamine, sodium carbonate, or potassium carbonate
  • a solvent such as acetonitrile, acetone or dimethylformamide (DMF).
  • a compound of Formula 15 can be transformed to a Tetracyclic Benzamide Derivative of Formula (I) upon treating 15 with an alkylating agent, an acylating agent or a glucuronidating agent, and further derivatization if necessary.
  • Suitable alkylating and acylating agents include, but are not limited to, alkylhalides, such as iodomethane, iodoethane, 1-iodopropane and 2-bromopropane, 1-bromopropane, 1-bromobutane, 1-bromopentane and 1-bromohexane, the alkyl group of which can be optionally substituted with —OH or —C(O)OH; acyl halides, such as acetyl chloride and propionyl chloride; and anhydrides, such as acetic anhydride and propionic anhydride.
  • alkylhalides such as iodomethane, iodoethane, 1-iodopropane and 2-bromopropane, 1-bromopropane, 1-bromobutane, 1-bromopentane and 1-bromohexane, the alkyl group of which can be optionally substitute
  • the alkylating agent is methyl iodide.
  • the allkylating agent is a hydroxy-substituted alkylhalide.
  • the alkylating agent is a carboxy-substituted alkylhalide.
  • the acylating agent is acetyl chloride.
  • the acylating agent is acetic anhydride.
  • R 5 is glucuronidyl and the glucuronidating agent is acetobromo- ⁇ -D-glucuronic acid methyl ester.
  • Scheme 3 illustrates methodology useful for making Tetracyclic Benzamide Derivatives of Formula III, wherein R 1 -R 4 and G 1 -G 4 are defined above for the compounds of Formula III; R b is —Cl, —Br, —I, —OTs, —OMs or —OTf; and R c is —C 1 -C 3 alkyl.
  • Tetracyclic Benzamide Devivatives Derivatives of Formulas 22, 24, 26 and 28 can be made by reacting a homophthalic anhydride of Formula 17 with a compound of Formula 21, 23, 25 or 27, respectively in the presence of a base.
  • Tetracyclic Benzamide Devivatives Derivatives of Formulas 22, 24, 26 and 28 can be made by reacting a homophthalate of Formula 13 with a compound of Formula 21, 23, 25 or 27, respectively in the presence of a base.
  • Suitable bases for use in the methods of Scheme 5 are organic bases such as triethylamine, diisopropylamine, diisopropylethylamine, pyridine, lutidine sodium butoxide, sodium methoxide, and imidazole; and inorganic bases such as alkali metal carbonates, including sodium hydride, sodium carbonate, potassium carbonate and cesium carbonate.
  • the base is triethylamine.
  • the base is potassium carbonate.
  • the method can be carried out in the presence of a solvent, such as acetonitrile, methylene chloride, chloroform, THF, DMF, DMSO, ethyl acetate, acetone, benzene, diethyl ether, water or mixtures thereof.
  • a solvent such as acetonitrile, methylene chloride, chloroform, THF, DMF, DMSO, ethyl acetate, acetone, benzene, diethyl ether, water or mixtures thereof.
  • the solvent is acetonitrile.
  • the solvent is DMF.
  • Scheme 4 illustrates methods useful for making compounds of Formula (V) wherein R 1 -R 4 and R 7 -R 10 are defined above for the compounds of Formula (V).
  • a ketone of Formula A can be cyclized to the bicyclic intermediates of Formula B using bromo ethyl malonate in the presence of potassium carbonate.
  • the intermediates of Formula B can then be converted to the lactam intermediates of Formula C in the presence of ammonia in methanol.
  • Fridel-Crafts mediated ring closure of C provides the tetracyclic keto intermediates of Formula D which when reacted with a phosponate or phosphorus ylide via a Wittig-Horner procedure provides the Tetracyclic Benzamide Derivatives of Formula E, whose exocyclic double bond can subsequently be reduced using catalytic hydrogenation to provide the compounds of Formula (V) where p is ⁇ 2.
  • the keto intermediates of Formula D can be reduced to the corresponding alcohol intermediates of Formula D′ with subsequent conversion of the alcohol to the triflate intermediates of Formula D′′ to produce a good leaving group.
  • the compounds of Formula A can be produced from commercially starting materials using techniques known to one skilled in the art of organic synthesis.
  • the carboxylic acid group of a compound of Formula N can be coupled with DPPA to provide the corresponding carbamate intermediates of Formula O, which can then be thermally cyclized to provide the Tetracyclic Benzamide derivatives of Formula (II).
  • the bicyclic carboxylic acids of Formula Q see Wacker et al., Tet. Lett., 43:5189-5191, 2002; and Bourdais, et al., J. Het.
  • Tetracyclic Benzamide Derivatives of Formula (IV) can be made using a one pot coupling/cyclization process by reacting an intermediate of Formula W with an aromatic nitrile of Formula Y in the presence of sodium hydride.
  • the carboxylic acid group of a compound of Formula Z can be coupled with DPPA to provide the corresponding carbonate intermediates of Formula AA, which can then be thermally cyclized to provide the Tetracyclic Benzamide Derivatives of Formula (IV).
  • the invention also includes pharmaceutical compositions comprising an effective amount of a Tetracyclic Benzamide Derivative and a pharmaceutically acceptable carrier or vehicle.
  • the invention includes a Tetracyclic Benzamide Derivative when provided as a pharmaceutically acceptable prodrug, hydrated salt, such as a pharmaceutically acceptable salt, or mixtures thereof.
  • the Tetracyclic Benzamide Derivatives are administered to a subject in need of treatment or prevention of a Condition.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent an inflammatory disease.
  • Inflammatory diseases can arise where there is an inflammation of the body tissue. These include local inflammatory responses and systemic inflammation.
  • Examples of inflammatory diseases treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, organ transplant rejection; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; inflammatory lung diseases such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; tuberculosis; leprosy;
  • the inflammatory disease can also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, e.g., shock associated with pro-inflammatory cytokines.
  • shock can be induced, e.g., by a chemotherapeutic agent that is administered as a treatment for cancer.
  • the inflammatory disease is arthritis. In another embodiment the inflammatory disease is colitis.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent a reperfusion disease.
  • Reperfusion refers to the process whereby blood flow in the blood vessels is resumed following ischemia, such as occurs following constriction or obstruction of the vessel.
  • Reperfusion disease can result following a naturally occurring episode, such as a myocardial infarction, stroke, or during a surgical procedure where blood flow in vessels is intentionally or unintentionally blocked.
  • Examples of reperfusion injuries treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, intestinal reperfusion disease, myocardial reperfusion disease, and reperfusion disease resulting from cardiopulmonary bypass surgery, thoracoabrominal aneurysm repair surgery, carotid endarerectomy surgery, or hemorrhagic shock.
  • the reperfusion disease results from cardiopulmonary bypass surgery, thoracoabrominal aneurysm repair surgery, carotid endarerectomy surgery, or hemorrhagic shock.
  • the reperfusion disease is a reoxygenation injury resulting from surgery, particularly that relating to organ transplantation.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent a reoxygenation injury resulting from surgery, particularly that relating to organ transplantation.
  • reoxygenation injuries treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, transplantation of the following organs: heart, lung, liver and kidney.
  • a reoxygenation injury resulting from organ transplantation occurs during the organ transplantation.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent an ischemic condition.
  • ischemic conditions treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, stable angina, unstable angina, myocardial ischemia, hepatic ischemia, mesenteric artery ischemia, intestinal ischemia, critical limb ischemia, chronic critical limb ischemia, erebral ischemia, acute cardiac ischemia, and an ischemic disease of the central nervous system, such as stroke or cerebral ischemia.
  • the ischemic condition is myocardial ischemia, stable angina, unstable angina, stroke, ischemic heart disease or cerebral ischemia.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent chronic renal failure.
  • the renal failure is chronic renal failure.
  • the renal failure is acute renal failure.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent a vascular disease.
  • vascular diseases treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, peripheral arterial occlusion, thromboangitis obliterans, Reynaud's disease and phenomenon, acrocyanosis, erythromelalgia, venous thrombosis, varicose veins, arteriovenous fistula, lymphedema, and lipedema.
  • the vascular disease is a cardiovascular disease.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent cardiovascular diseases.
  • cardiovascular diseases treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, cardiovascular diseases that can be treated or prevented by administering an effective amount of a Tetracyclic Benzamide Derivative include, but are not limited to, chronic heart failure, atherosclerosis, congestive heart failure, circulatory shock, cardiomyopathy, cardiac transplant, myocardial infarction, and a cardiac arrhythmia, such as atrial fibrillation, supraventricular tachycardia, atrial flutter, and paroxysmal atrial tachycardia.
  • the cardiovascular disease is chronic heart failure.
  • the cardiovascular disease is a cardiac arrhyhmia.
  • the cardiac arrhythmia is atrial fibrillation, supraventricular tachycardia, atrial flutter or paroxysmal atrial tachycardia.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent diabetes.
  • diabetes treatable or preventable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, Type I diabetes (Insulin Dependent Diabetes Mellitus), Type II diabetes (Non-Insulin Dependent Diabetes Mellitus), gestational diabetes, insulinopathies, diabetes due to pancreatic disease, diabetes associated with other endocrine diseases (such as Cushing's Syndrome, acromegaly, pheochromocytoma, glucagonoma, primary aldosteronism or somatostatinoma), Type A insulin resistance syndrome, Type B insulin resistance syndrome, lipatrophic diabetes, and diabetes induced by ⁇ -cell toxins.
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent a diabetic complication.
  • diabetic complications treatable or preventable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, diabetic cataract, glaucoma, retinopathy, nephropathy, (such as microaluminuria and progressive diabetic nephropathy), polyneuropathy, gangrene of the feet, atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic-hyperosmolar coma, mononeuropathy, autonomic neuropathy, foot ulcer, joint problem, and a skin or mucous membrane complication (such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabeticorumobesity), hyperlipidemia, hypertension, syndrome of insulin resistance, coronary artery disease, retinopathy, diabetic neuropathy, polyneuropathy, mononeuropathy, autonom
  • the Tetracyclic Benzamide Derivatives can be used to treat or prevent cancer.
  • cancers treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, the cancers disclosed below in Table 1 and metastases thereof.
  • Solid tumors including but not limited to: fibrosarcoma myxosarcoma liposarcoma chondrosarcoma osteogenic sarcoma chordoma angiosarcoma endotheliosarcoma lymphangiosarcoma lymphangioendotheliosarcoma synovioma mesothelioma Ewing's tumor leiomyosarcoma rhabdomyosarcoma colon cancer colorectal cancer kidney cancer pancreatic cancer bone cancer breast cancer ovarian cancer prostate cancer esophageal cancer stomach cancer oral cancer nasal cancer throat cancer squamous cell carcinoma basal cell carcinoma adenocarcinoma sweat gland carcinoma sebaceous gland carcinoma papillary carcinoma papillary adenocarcinomas cystadenocarcinoma medullary carcinoma bronchogenic carcinoma renal cell carcinoma hepatoma bile duct carcinoma choriocarcinoma seminoma embryonal carcinoma Wilms' tumor cervical cancer uter
  • the cancer is pancreatic cancer, colorectal cancer, mesothelioma, a malignant pleural effusion, peritoneal carcinomatosis, peritoneal sarcomatosis, renal cell carcinoma, small cell lung cancer, non-small cell lung cancer, testicular cancer, bladder cancer, breast cancer, head and neck cancer, or ovarian cancer.
  • the subject in need of treatment has previously undergone treatment for cancer.
  • Such previous treatments include, but are not limited to, prior chemotherapy, radiation therapy, surgery or immunotherapy, such as cancer vaccines.
  • the Tetracyclic Benzamide Derivatives are also useful for the treatment or prevention of a cancer caused by a virus.
  • human papilloma virus can lead to cervical cancer (see, e.g., Hernandez-Avila et al., Archives of Medical Research (1997) 28:265-271)
  • Epstein-Barr virus (EBV) can lead to lymphoma (see, e.g., Herrmann et al., J Pathol (2003) 199(2):140-5)
  • hepatitis B or C virus can lead to liver carcinoma (see, e.g., El-Serag, J Clin Gastroenterol (2002) 35(5 Suppl 2):S72-8)
  • human T cell leukemia virus (HTLV)-I can lead to T-cell leukemia (see e.g., Mortreux et al., Leukemia (2003) 17(1):26-38)
  • human herpesvirus-8 infection can lead to Kaposi's sarcoma (see,
  • the Tetracyclic Benzamide Derivatives of the Invention can also be administered to prevent the progression of a cancer, including but not limited to the cancers listed in Table 1.
  • a cancer including but not limited to the cancers listed in Table 1.
  • Such prophylactic use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-79).
  • Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function.
  • Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in epithelial or connective tissue cells.
  • a typical metaplasia involves a somewhat disorderly metaplastic epithelium.
  • Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells.
  • Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder.
  • the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed in vivo or displayed in vitro by a cell sample from a patient can indicate the desirability of prophylactic/therapeutic administration of the composition of the invention.
  • characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also id., at pp. 84-90 for characteristics associated with a transformed or malignant phenotype).
  • leukoplakia a benign-appearing hyperplastic or dysplastic lesion of the epithelium, or Bowen's disease, a carcinoma in situ, are pre-neoplastic lesions indicative of the desirability of prophylactic intervention.
  • fibrocystic disease cystic hyperplasia, mammary dysplasia, particularly adenosis (benign epithelial hyperplasia) is indicative of the desirability of prophylactic intervention.
  • a patient which exhibits one or more of the following predisposing factors for malignancy can be treated by administration of an amount of a Tetracyclic Benzamide Derivative which is effective to treat or prevent cancer: a chromosomal translocation associated with a malignancy (e.g., the Philadelphia chromosome for chronic myelogenous leukemia, t(14;18) for follicular lymphoma, etc.), familial polyposis or Gardner's syndrome (possible forerunners of colon cancer), benign monoclonal gammopathy (a possible forerunner of multiple myeloma), a first degree kinship with persons having a cancer or precancerous disease showing a Mendelian (genetic) inheritance pattern (e.g., familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, medullary thyroid carcinoma with amyloid production and pheochromocytoma,
  • the Tetracyclic Benzamide Derivatives are administered to a human patient to prevent progression to breast, colon, ovarian, or cervical cancer.
  • the Tetracyclic Benzamide Derivatives are advantageously useful in veterinary and human medicine. As described above, the Tetracyclic Benzamide Derivatives are useful for treating or preventing a Condition in a subject in need thereof.
  • the Tetracyclic Benzamide Derivatives can be administered as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle.
  • the present compositions, which comprise a Tetracyclic Benzamide Derivative can be administered orally.
  • the Tetracyclic Benzamide Derivatives of the invention can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral, rectal, and intestinal mucosa, etc.) and can be administered together with another biologically active agent. Administration can be systemic or local.
  • Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be administered.
  • Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin.
  • administration will result in the release of the Tetracyclic Benzamide Derivatives into the bloodstream.
  • the mode of administration is left to the discretion of the practitioner.
  • the Tetracyclic Benzamide Derivatives are administered orally.
  • Tetracyclic Benzamide Derivatives can be desirable to administer the Tetracyclic Benzamide Derivatives locally. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
  • the Tetracyclic Benzamide Derivatives into the central nervous system or gastrointestinal tract by any suitable route, including intraventricular, intrathecal, and epidural injection, and enema.
  • Intraventricular injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler of nebulizer, and Formulation with an aerosolizing agent, or via perfusion in a fluorocarbon oar, synthetic pulmonary surfactant.
  • the Tetracyclic Benzamide Derivatives can be Formulated as a suppository, with traditional binders and excipients such as triglycerides.
  • Tetracyclic Benzamide Derivatives can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990) and Treat or prevent et al., Liposomes in the Therapy of Infectious Disease and Cancer 317-327 and 353-365 (1989)).
  • the Tetracyclic Benzamide Derivatives can be delivered in a controlled-release system or sustained-release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).
  • Other controlled or sustained-release systems discussed in the review by Langer, Science 249:1527-1533 (1990) can be used.
  • a pump can be used (Langer, Science 249:1527-1533 (1990); Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); and Saudek et al., N. Engl. J Med. 321:574 (1989)).
  • polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 2:61 (1983); Levy et al., Science 228:190 (1935); During et al., Ann. Neural. 25:351 (1989); and Howard et al., J. Neurosurg. 71:105 (1989)).
  • a controlled- or sustained-release system can be placed in proximity of a target of the Tetracyclic Benzamide Derivatives, e.g., the spinal column, brain, skin, lung, or gastrointestinal tract, thus requiring only a fraction of the systemic dose.
  • compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the animal.
  • Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • the pharmaceutical excipients can be saline, gum acacia; gelatin, starch paste, talc, keratin, colloidal silica, urea and the like.
  • auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used.
  • the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a particularly useful excipient when the Tetracyclic Benzamide Derivative is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions.
  • suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • compositions can take the form of solutions, suspensions, emulsion, tablets, pills; pellets, capsules, capsules containing liquids, powders, sustained-release Formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use.
  • the composition is in the form of a capsule (see e.g. U.S. Pat. No. 5,698,155).
  • suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference.
  • compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example.
  • Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
  • compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
  • Selectively permeable membranes surrounding an osmotically active driving a Tetracyclic Benzamide Derivativere also suitable for orally administered compositions.
  • fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture.
  • delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release Formulations.
  • a time-delay material such as glycerol monostearate or glycerol stearate can also be used.
  • Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment the excipients are of pharmaceutical grade.
  • compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaien to lessen pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized-powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent.
  • Tetracyclic Benzamide Derivatives are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the Tetracyclic Benzamide Derivatives are administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
  • Tetracyclic Benzamide Derivatives can be administered by controlled-release or sustained-release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but arc not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354;556; and 5,733,556, each of which is incorporated herein by reference.
  • Such dosage forms can be used to provide controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled- or sustained-release Formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
  • Controlled- or sustained-release pharmaceutical compositions can have a common goal of improving drug therapy over that achieved by their non-controlled or non-sustained counterparts.
  • a controlled- or sustained-release composition comprises a minimal amount of a Tetracyclic Benzamide Derivative to cure or control the condition in a minimum amount of time.
  • Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • controlled- or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the Tetracyclic Benzamide Derivative, and can thus reduce the occurrence of adverse side effects.
  • Controlled- or sustained-release compositions can initially release an amount of a Tetracyclic Benzamide Derivative that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the Tetracyclic Benzamide Derivative to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the Tetracyclic Benzamide Derivative can be released from the dosage form at a rate that will replace the amount of Tetracyclic Benzamide Derivative being metabolized and excreted from the body.
  • Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.
  • the amount of the Tetracyclic Benzamide Derivative that is effective in the treatment or prevention of a Condition can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, and the seriousness of the condition being treated and should be decided according to the judgment of the practitioner and each patient's circumstances in view of, e.g., published clinical studies. Effective dosage amounts of the present invention, when used for the indicated effects, range from about 0.05 to about 1000 mg of Tetracyclic Benzamide Derivative per day.
  • compositions for in vivo or in vitro use can contain about 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0, 250.0, 500.0 or 1000.0 mg of Tetracyclic Benzamide Derivative.
  • the compositions are in the form of a tablet that can be scored. Effective plasma levels of the Tetracyclic Benzamide Derivatives can range from about 0.002 mg to about 50 mg per kg of body weight per day.
  • Tetracyclic Benzamide Derivatives can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, Tetracyclic Benzamide Derivatives can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration can be continuous rather than intermittent throughout the dosage regimen.
  • Topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of Tetracyclic Benzamide Derivative ranges from about 0.1% to about 15%, w/w or w/v.
  • Tetracyclic Benzamide Derivatives can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans.
  • Animal model systems can be used to demonstrate safety and efficacy.
  • the present methods for treating or preventing a Condition in a subject in need thereof can further comprise administering another therapeutic agent to the subject being administered a Tetracyclic Benzamide Derivative.
  • the other therapeutic agent is administered in an effective amount.
  • Effective amounts of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective amount range. In one embodiment of the invention, where, another therapeutic agent is administered to a subject, the effective amount of the Tetracyclic Benzamide Derivative is less than its effective amount would be where the other therapeutic agent is not administered. In this case, without being bound by theory, it is believed that the Tetracyclic Benzamide Derivatives and the other therapeutic agent act synergistically to treat or prevent a Condition.
  • the other therapeutics agent is an anti-inflammatory agent.
  • Anti-inflammatory agents include but are not limited to adrenocorticosteroids, such as cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6a-methylprednisolone, triamcinolone, betamethasone, and dexamethasone; and non-steroidal anti-inflammatory agents (NSAIDs), such as aspirin, acetaminophen, indomethacin, sulindac, tolmetin, diclofenac, ketorolac, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin, mefenamic acid, meclofenamic acid, piroxicam, meloxicam, nabumetone, rofecoxib, celecoxib, etodolac, and nimesulide.
  • the other therapeutice agent is an anti-renal failure agent.
  • Anti-renal failure agents include but are not limited to ACE (angiotensin-converting enzyme) inhibitors, such as captopril, enalaprilat, lisinopril, benazepril, fosinopril, trandolapril, quinapril, and ramipril; diuretics, such as mannitol, glycerin, furosemide, toresemide, tripamide, chlorothiazide, methyclothiazide, indapamide, amiloride, and spironolactone; and fibric acid agents, such as clofibrate, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate.
  • ACE angiotensin-converting enzyme
  • the other therapeutice agent is an anti-diabetic agent.
  • Anti-diabetic agents include but are not limited to glucagons; somatostatin; diazoxide; sulfonylureas, such as tolbutamide, acetohexamide, tolazamide, chloropropamide, glybenclamide, glipizide, gliclazide, and glimepiride; insulin secretagogues, such as repaglinide, and nateglinide; biguanides, such as metformin and phenformin; thiazolidinediones, such as pioglitazone, rosiglitazone, and troglitazone; and ⁇ -glucosidase inhibitors, such as acarbose and miglitol.
  • the other therapeutic agent is an anti-cardiovascular disease agent.
  • Anti-cardiovascular disease agents include but are not limited to carnitine; thiamine; and muscarinic receptor antagonists, such as atropine, scopolamine, homatropine, tropicamide, pirenzipine, ipratropium, tiotropium, and tolterodine.
  • the other therapeutic agent can also be an agent useful for reducing any potential side effects of a Tetracyclic Benzamide Derivatives.
  • the other therapeutic agent can be an antiemetic agent.
  • useful antiemetic agents include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethy
  • the present methods for the treatment or prevention of cancer can further comprise administering another anticancer agent.
  • the methods comprise the sequential administration of a Tetracyclic Benzamide Derivative and another anticancer agent.
  • the methods comprise the administration of a composition comprising a pharmaceutically acceptable carrier, a Tetracyclic Benzamide Derivative, and another anticancer agent.
  • the Tetracyclic Benzamide Derivative and the other anticancer agent can act additively or synergistically.
  • a synergistic use of a Tetracyclic Benzamide Derivative and another anticancer agent permits the use of lower dosages of one or more of these agents and/or less frequent administration of said agents to a subject with cancer.
  • the ability to utilize lower dosages of a Tetracyclic Benzamide Derivative and/or additional anticancer agents and/or to administer said agents less frequently can reduce the toxicity associated with the administration of said agents to a subject without reducing the efficacy of said agents in the treatment of cancer.
  • a synergistic effect can result in the improved efficacy of these agents in the treatment of cancer and/or the reduction of adverse or unwanted side effects associated with the use of either agent alone.
  • the Tetracyclic Benzamide Derivative and the anticancer agent can act synergistically when administered in doses typically employed when such agents are used as monotherapy for the treatment of cancer. In another embodiment, the Tetracyclic Benzamide Derivative and the anticancer agent can act synergistically when administered in doses that are less than doses typically employed when such agents are used as monotherapy for the treatment of cancer.
  • Suitable additional anticancer agents useful in the methods and compositions of the present invention include, but are not limited to, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, taxanes such as docetaxel and paclitaxel, leucovorin, levamisole, irinotecan, est
  • the additional anticancer agent can be, but is not limited to, a drug listed in Table 2.
  • TABLE 2 Alkylating agents Nitrogen mustards: Cyclophosphamide Ifosfamide Trofosfamide Chlorambucil Nitrosoureas: Carmustine (BCNU) Lomustine (CCNU) Alkylsulphonates: Busulfan Treosulfan Triazenes: dacarbazine Platinum containing complexes: Cisplatin Carboplatin Aroplatin Oxaliplatin Plant Alkaloids Vinca alkaloids: Vincristine Vinbiastine Vindesine Vinorelbine Taxoids: Paclitaxel Docetaxel DNA Topoisomerase Inhibitors Epipodophyllins: Etoposide Teniposide Topotecan 9-aminocamptothecin Camptothecin Crisnatol Mitomycins: Mitomycin C Anti-metabolites Anti-folates: DHFR inhibitors: Methotrexate Trimetre
  • additional anticancer agents that can be used in the compositions and methods of the present invention include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin
  • anticancer drugs that can be used in the methods and compositions of the invention include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid
  • Tetracyclic Benzamide Derivatives can be administered to a subject that has undergone or is currently undergoing one or more additional anticancer treatment modalities including, but not limited to, surgery, radiation therapy, or immunotherapy, such as cancer vaccines.
  • the invention provides methods for treating cancer comprising (a) administering to a subject in need thereof an amount of a Tetracyclic Benzamide Derivative effective to treat or prevent cancer; and (b) administering to said subject one or more additional anticancer treatment modalities including, but not limited to, surgery, radiation therapy, or immunotherapy, such as a cancer vaccine.
  • the additional anticancer treatment modality is radiation therapy.
  • the additional anticancer treatment modality is surgery.
  • the additional anticancer treatment modality is immunotherapy.
  • the Tetracyclic Benzamide Derivatives are administered concurrently with radiation therapy.
  • the additional anticancer treatment modality is administered prior or subsequent to the Tetracyclic Benzamide Derivative, preferably at least an hour, five hours, 12 hours, a day, a week, a month, more preferably several months (e.g., up to three months), prior or subsequent to administration of the Tetracyclic Benzamide Derivatives.
  • any radiation therapy protocol can be used depending upon the type of cancer to be treated.
  • X-ray radiation can be administered; in particular, high-energy megavoltage (radiation of greater that 1 MeV energy) can be used for deep tumors, and electron beam and orthovoltage X-ray radiation can be used for skin cancers.
  • Gamma-ray emitting radioisotopes such as radioactive isotopes of radium, cobalt and other elements, can also be administered.
  • the invention provides methods of treatment of cancer using the Tetracyclic Benzamide Derivatives as an alternative to chemotherapy or radiation therapy where the chemotherapy or the radiation therapy results in negative side effects, in the subject being treated.
  • the subject being treated can, optionally, be treated with another anticancer treatment modality such as surgery, radiation therapy, or immunotherapy, depending on which treatment is found to be acceptable or bearable.
  • the Tetracyclic Benzamide Derivatives can also be used in an in vitro or ex vivo fashion, such as for the treatment of certain cancers, including, but not limited to leukemias and lymphomas, such treatment involving autologous stem cell transplants.
  • This can involve a multi-step process in which the animal's autologous hematopoietic stem cells are harvested and purged of all cancer cells, the patient's remaining bone-marrow cell population is then eradicated via the administration of high doses of the Tetracyclic Benzamide Derivatives and/or high dose radiation therapy, and the stem cell graft is infused back into the animal. Supportive care is then provided while bone marrow function is restored and the subject recovers.
  • a Tetracyclic Benzamide Derivative and the other therapeutic agent can act additively or, in one embodiment synergistically.
  • a Tetracyclic Benzamide Derivative is administered concurrently with another therapeutic agent.
  • a composition comprising an effective amount of a Tetracyclic Benzamide Derivative and an effective amount of another therapeutic agent can be administered.
  • a composition comprising an effective amount of a Tetracyclic Benzamide Derivative and a different composition comprising an effective amount of another therapeutic agent can be concurrently administered.
  • an, effective amount of a Tetracyclic Benzamide Derivative is administered prior or subsequent to administration of an effective amount of another therapeutic agent.
  • the Tetracyclic Benzamide Derivative is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the Tetracyclic Benzamide Derivative exerts its preventative or therapeutic effect for treating or preventing a Condition.
  • a composition of the invention is prepared by a method comprising admixing a Tetracyclic Benzamide Derivative or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or vehicle. Admixing can be accomplished using methods well known for admixing a compound (or salt) and a pharmaceutically acceptable carrier or vehicle. In one embodiment the Tetracyclic Benzamide Derivative or the pharmaceutically acceptable salt of the Compound is present in the composition in an effective amount.
  • kits that can simplify the administration of a Tetracyclic Benzamide Derivative to a subject.
  • a typical kit of the invention comprises a unit dosage form of a Tetracyclic Benzamide Derivative.
  • the unit dosage form is a container, which can be sterile, containing an effective amount of a Tetracyclic Benzamide Derivative and a pharmaceutically acceptable carrier or vehicle.
  • the kit can further comprise a label or printed instructions instructing the use of the Tetracyclic Benzamide Derivative to treat or prevent a Condition.
  • the kit can also further comprise a unit dosage form of another therapeutic agent, for example, a container containing an effective amount of the other therapeutic agent.
  • the kit comprises a container containing an effective amount of a Tetracyclic Benzamide Derivative and an effective amount of another therapeutic agent. Examples of other therapeutic agents include, but are not limited to, those listed above.
  • Kits of the invention can further comprise a device that is useful for administering the unit dosage forms.
  • a device includes, but are not limited to, a syringe, a drip bag, a patch, an inhaler, and an enema bag.
  • the addition funnel was charged with acetobromo- ⁇ -D-glucuronic acid methyl ester (930 mg, 1.1 eq) dissolved in 25 mL toluene, and this solution was added dropwise over 0.5 h to the refluxing reaction mixture.
  • the reaction mixture was heated at reflux for another 6 h, then slowly cooled to room temperature overnight.
  • the resulting suspension was vacuum filtered to remove solids, and the filter cake was washed three times with 100 mL of ethyl acetate.
  • the filtrate was concentrated to an oil on the rotary evaporator.
  • Peroxynitrite a prototypical oxidant which induces DNA single strand breakage, was used to induce PARP activation.
  • Peroxynitrite was diluted in phosphate buffered saline (PBS) (pH 11.0) and added to the cells in a bolus of 50 ⁇ l. Cells were then incubated for 20 min. Peroxynitrite was decomposed by incubation for 30 min at pH 7.0, used as a control, and failed to influence the parameter studied.
  • PBS phosphate buffered saline
  • the potency of inhibition on purified PARP enzyme was subsequently determined for selected Tetracyclic Benzamide Derivatives, and the potency was compared with that of 3-aminobenzamide, a prototypical benchmark PARP inhibitor.
  • the assay was performed in 96 well ELISA plates according to instructions provided with a commercially available PARP inhibition assay kit (Trevigen, Gaithersburg, Md.). Briefly, wells were coated with 1 mg/mL histone (50 ⁇ l/well) at 4° C. overnight. Plates were then washed four times with PBS and then blocked by adding 50 ⁇ l Strep-Diluent (supplied with the kit). After incubation (1 h, room temperature), the plates were washed four times with PBS.
  • the PARP inhibitor 16a exerted 56% inhibition of PARP activity in this assay at 1 ⁇ M, and thus was approximately 56,000 times more potent than the reference compound 3-aminobenzamide at this concentration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Benzamide Derivative.

Description

  • This application is a continuation of U.S. application Ser. No. 10/788,228, filed Feb. 26, 2004, which claims the benefit of U.S. provisional application no. 60/450,925, filed Feb. 28, 2003, the entire disclosures of U.S. application no. 10/788,228 and of U.S. provisional application no. 60/450,925 being hereby incorporated by reference.
  • This invention was made with government support under grant no. R44 DK54099-03 and grant no. 1R43 CA90016-01A1, which were awarded by the National Institutes of Health. The government has certain rights in the invention.
    • 1. FIELD OF THE INVENTION
  • The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising an effective amount of a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Benzamide Derivative.
    • 2. BACKGROUND OF THE INVENTION
  • Inflammatory diseases, such as arthritis, colitis, and autoimmune diabetes, typically manifest themselves as disorders distinct from those associated with reperfusion diseases, e.g., stroke and heart attack, and can clinically manifest themselves as different entities. However, there can be common underlying mechanisms between these two types of disorders. In particular, inflammatory disease and reperfusion disease can induce proinflammatory cytokine and chemokine synthesis which can, in turn, result in production of cytotoxic free radicals such as nitric oxide and superoxide. NO and superoxide can react to form peroxynitrite (ONOO−) (Szabó et al., Shock 6:79-88, 1996).
  • The ONOO−-induced cell necrosis observed in inflammatory disease and in reperfusion disease involves the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS), also known as poly (ADP-ribose) polymerase (PARP). Activation of PARP is thought to be an important step in the cell-mediated death observed in inflammation and reperfusion disease (Szabó et al., Trends Pharmacol. Sci. 19:287-98, 1998).
  • A number of PARP inhibitors have been described in the art. See, e.g., Banasik et al., J. Biol. Chem., 267:1569-75, 1992, and Banasik et al., Mol. Cell. Biochem., 138:185-97, 1994; WO 00/39104; WO 00/39070; WO 99/59975; WO 99/59973; WO 99/11649; WO 99/11645; WO 99/11644; WO 99/11628; WO 99/11623; WO 99/11311; WO 00/42040; Zhang et al., Biochem. Biophys. Res. Commun., 278:590-98, 2000; White et al., J. Med. Chem., 43:4084-4097, 2000; Griffin et al., J. Med. Chem., 41:5247-5256, 1998; Shinkwin et al., Bioorg. Med. Chem., 7:297-308, 1999; and Soriano et al., Nature Medicine, 7:108-113, 2001. Adverse effects associated with administration of PARP inhibitors have been discussed in Milan et al., Science, 223:589-591, 1984.
  • S. P. Hiremath et al., Oriental Journal of Chemistry 13(2):173-176 (1997) discloses isoquinoline compounds allegedly useful as antifungal, antibacterial or anthelmintic agents.
  • S. P. Hiremath et al., Journal of the Indian Chemical Society 72(10):735-738 (1995) discloses isoquinolinone compounds
  • S. P. Hiremath et al., Indian Journal of Heterocyclic Chemistry 3(1):37-42 (1993) discloses isoquinolinethione compounds allegedly useful as antifungal, antibacterial, oxytocic or anthelmintic agents.
  • S. P. Hiremath et al., Indian Journal of Chemistry, Section B 24B(12):1235-1238 (1985) discloses indoloisoquinoline compounds.
  • U.S. Pat. No. 4,623,304 to Ishizumi et al. discloses indoloisoquinoline compounds allegedly having anti-tumor activity.
  • United Kingdom Patent No. GB 2025932 B2 by Sumitomo Chemical Co. discloses indoloisoquinoline compounds allegedly having bacteriacidal or fungicidal activity.
  • G. Winters et al., Farmaco. Ed. Sci. 34(6):507-517 (1979) discloses indoloisoquinolinones allegedly having antibacterial or fungicidal activity.
  • U.S. Pat. No. 4,113,731 to G. Winters et al. discloses indoloisoquinolines.
  • U.S. Pat. Nos. 5,733,918, 5,710,162, and 6,028,079 to Okazaki et al. disclose indenoquinolines allegedly useful as antitumor agents.
  • S. Srivastava et al., Journal of the Indian Chemical Society 66(4):276-81 (1989) discloses a synthesis of indenoisocoumarins and indenoisoquinolones.
  • G. Jha et al., Indian Journal of Chemistry, Section B 24B(4):440-444 (1985) discloses a synthesis of indenoisocoumarins and indenoisoquinolones.
  • J. N. Chatterjea et al., J. Indian Chem. Soc. 44(11):911-919 (1967) discloses a synthesis of dihydroisocoumarins.
  • There remains, however, a need in the art for compounds useful for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer.
  • Citation of any reference in Section 2 of this application is not an admission that the reference is prior art.
    • 3. SUMMARY OF THE INVENTION
  • The present invention encompasses compounds having the Formula (I):
    Figure US20070249653A1-20071025-C00001
    and pharmaceutically acceptable salts and hydrates thereof, wherein:
  • R5 is —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)—C1-C10 alkyl, —C(O)-aryl, —C(O)-(3- to 7-membered monocyclic heterocycle), —C(O)-(7- to 10-membered bicyclic heterocycle) or -glycoside;
  • X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, —O—, —NH—, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and n is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(C(O)NH2)-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • The present invention also encompasses compounds of Formula (Ia):
    Figure US20070249653A1-20071025-C00002
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)—C1-C10 alkyl, —C(O)-aryl, —C(O)-(3- to 7-membered monocyclic heterocycle), —C(O)-(7- to 10-membered bicyclic heterocycle) or -glycoside;
  • R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • The present invention also encompasses compounds of Formula (Ib):
    Figure US20070249653A1-20071025-C00003
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)—C1-C10 alkyl, —C(O)-aryl, —C(O)-(3- to 7-membered monocyclic heterocycle), —C(O)-(7- to 10-membered bicyclic heterocycle) or -glycoside;
  • R11 —H, —C1-C5 alkyl, -aryl, —C(O)—C1-C5 alkyl, or —SO2Y, wherein Y is —OH, —NH2 or —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle);
  • R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2-, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(-(nitrogen-containing 3- to 7-membered monocyclic heterocycle)), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • The invention also relates to compounds of Formula (II):
    Figure US20070249653A1-20071025-C00004
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is O, NH or S;
  • R6 is —H or C1-C4 alkyl;
  • X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))-, —(C(OH)(aryl))-, —O—, —NH—, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and n is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —-(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(-(nitrogen-containing 3- to 7-membered monocyclic heterocycle)), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • The invention also relates to compounds of Formula (IIa):
    Figure US20070249653A1-20071025-C00005
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R6 is —H or C1-C4 alkyl;
  • R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(-(nitrogen-containing 3- to 7-membered monocyclic heterocycle)), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle).
  • The invention further relates to compounds of Formula (III):
    Figure US20070249653A1-20071025-C00006
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is O, NH or S;
  • R6 is —H or —C1-C4 alkyl;
  • X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, —O—, —NH—, —S—, —CH(NR11R12)- or —N(SO2Y)-, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and n is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • one of G1-G4 is C—R7 and the remaining G1-G4 are independently N or C—R7;
  • R1, R2, R3, and R4 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(-(nitrogen-containing 3- to 7-membered monocyclic heterocycle)), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R7 is independently —H, —C1-C6 alkyl, —O—(C1-C6 alkyl), —S—(C1-C6 alkyl), —SO2NH(C1-C6 alkyl) or C(O)NH—(C1-C6 alkyl).
  • The invention further relates to compounds of Formula (IV):
    Figure US20070249653A1-20071025-C00007
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is O, NH or S;
  • X is —C(O)—, —CH2—, —CH(halo)-, —CH(OH)—, —(C(OH)((CH2)mCH3))—, —(C(OH)(aryl))-, —O—, —N(Z5)—, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or -C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • one of G1 -G4 is C—R7 and the remaining G1-G4 are independently N or C—R7;
  • R1, R2, R3, and R4 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(-(nitrogen-containing 3- to 7-membered monocyclic heterocycle)), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl);
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R7 is independently —H, —C1-C6 alkyl,-O—(C1-C6 alkyl), —S—(C1-C6 alkyl), —SO2NH(C1-C6 alkyl) or C(O)NH—(C1-C6 alkyl);
  • Z5 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n—(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n—COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n—CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n—(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10; and
  • q is an integer ranging from 0 to 10.
  • The invention also relates to compounds of Formula (V):
    Figure US20070249653A1-20071025-C00008
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is O, S, or NH;
  • R1, R2, R3, R4, R6, R7, R8, and R9 are independently -hydrogen, -halo, -hydroxy, —NH2 NO2, or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(-(nitrogen-containing 3- to 7-membered monocyclic heterocycle)), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R10 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n-(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n—COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n—CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n—(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10;
  • p is an integer ranging from 0 to 5, with p being other than 0 when R10 is —H; and
  • q is an integer ranging from 0 to 10.
  • The invention also relates to compounds of Formula (VI):
    Figure US20070249653A1-20071025-C00009
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein:
  • R5 is O, S, or NH;
  • R1, R2, R3, R4, R6, R7, R8, and R9 are independently -hydrogen, -halo, -hydroxy, —NH2 NO2, or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl);
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R10 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n -(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n—COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n—CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n—(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10; and
  • q is an integer ranging from 0 to 10.
  • The invention also relates to compounds of Formula (VII):
    Figure US20070249653A1-20071025-C00010
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein
  • R5 is O, NH or S;
  • X is —C(O)—, —CH2—, —CH(halo)-, —CH(OH)—, —(C(OH)((CH2)mCH3))—, —(C(OH)(aryl))-, —O—, —N(Z5)—, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • one of G1-G4 is C—R7 and the remaining G1-G4 are independently N or C—R7;
  • R1, R2, R3, and R4 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl);
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3 - to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R7 is independently —H, —C1-C6 alkyl, —O—(C1-C6 alkyl), —S—(C1-C6 alkyl), —SO2NH(C1-C6 alkyl) or C(O)NH—(C1-C6 alkyl);
  • Z5 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n-(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n-COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n-CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n—(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10; and
  • q is an integer ranging from 0 to 10.
  • The invention also relates to compounds of Formula (VIIa):
    Figure US20070249653A1-20071025-C00011
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein
  • R5 is O, NH or S;
  • X is —C(O)—, —CH2—, —CH(halo)-, —CH(OH)—, —(C(OH)((CH2)mCH3))—, —(C(OH)(aryl))-, —O—, —N(Z5)—, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R1, R2, R3, and R4 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R7 is independently —H, —C1-C6 alkyl,-O—(C1-C6 alkyl), —S—(C1-C6 alkyl), —SO2NH(C1-C6 alkyl) or C(O)NH—(C1-C6 alkyl);
  • Z5 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n-(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n—COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n—CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n—(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10; and
  • q is an integer ranging from 0 to 10.
  • The invention also relates to compounds of Formula (VIIb):
    Figure US20070249653A1-20071025-C00012
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein
  • R5 is O, NH or S;
  • X is —C(O)—, —CH2—, —CH(halo)-, —CH(OH)—, —(C(OH)((CH2)mCH3))—, —(C(OH)(aryl))-, —O—, —N(Z5)-, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R1, R2, R3, and R4 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a (nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R7 is independently —H, —C1-C6 alkyl,-O—(C1-C6 alkyl), —S—(C1-C6 alkyl), —SO2NH(C1-C6 alkyl) or C(O)NH—(C1-C6 alkyl);
  • Z5 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n-(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n—COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n—CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n-(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10; and
  • q is an integer ranging from 0 to 10.
  • The invention also relates to compounds of Formula (VIIc):
    Figure US20070249653A1-20071025-C00013
    and pharmaceutically acceptable salts and hydrates thereof,
    wherein
  • R5 is O, NH or S;
  • X is —C(O)—, —CH2—, —CH(halo)-, —CH(OH)—, —(C(OH)((CH2)mCH3))—, —(C(OH)(aryl))-, —O—, —N(Z5)-, —S—, —CH(NR11R12)— or —N(SO2Y)—, wherein Y is —OH, —NH2, —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle) and m is an integer ranging from 0-5;
  • R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • R1, R2, R3, and R4 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
  • A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
  • B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
  • Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
  • each R7 is, independently —H, —C1-C6 alkyl,-O—(C1-C6 alkyl), —S—(C1-C6 alkyl), —SO2NH(C1-C6 alkyl) or C(O)NH—(C1-C6 alkyl);
  • Z5 is —H, —C1-C5 alkyl, —(CH2)n—CN, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle), —(CH2)n-(7- to 10-membered bicyclic heterocycle), —(CH2)n—COO—(C1-C5 alkyl), —(CH2)n—COO-aryl, —(CH2)n—COOH, —CONH—(CH2)n—COOH, —CONH—(CH2)n—COO—(C1-C5 alkyl), —CONH—(CH2)n-aryl, —CONHNH—(C1-C5 alkyl), —CONHNH-aryl, —(CH2)n—CONH2, —(CH2)n—CONH—(C1-C5 alkyl), —(CH2)n—CONH-aryl, —(CH2)n—CONH—(CH2)q-aryl, —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q-(3- to 7-membered monocyclic heterocycle), —(CH2)n—CONH—(CH2)q—CONH2 —(CH2)n—CONH—(CH2)q—CONH—(C1-C5 alkyl), —(CH2)n—CONH—(CH2)q—CON(C1-C5 alkyl)2, —C(O)(CH2)n—(C1-C5 alkyl), —C(O)(CH2)n-aryl, —C(O)(CH2)n—COOH, —C(O)(CH2)n—COO—(C1-C5alkyl), —C(O)(CH2)n—COO-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n—COO-(7- to 10-membered bicyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)O(CH2)n-phenyl, —C(O)O(CH2)n-(3- to 7-membered monocyclic heterocycle), —C(O)(CH2)n-phenyl, —C(O)(CH2)n-(7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-phenyl)2, —C(O)N((CH2)n-phenyl)((CH2)q-3- to 7-membered monocyclic heterocycle), —C(O)N((CH2)n-phenyl)((CH2)q 7- to 10-membered bicyclic heterocycle), —C(O)N((CH2)n-(3- to 7-membered monocyclic heterocycle)2, —C(O)N((CH2)n-7- to 10-membered bicyclic heterocycle)2, or —SO2NH2;
  • each n is an integer ranging from 0 to 10; and
  • q is an integer ranging from 0 to 10.
  • A compound of Formula (I), (Ia), (Ib), (II) (IIa), (III), (IV), (V), (VI), (VII), (VIIa), (VIIb) or (VIIc) or a pharmaceutically acceptable salt or hydrate thereof (a “Tetracyclic Benzamide Derivative”) is useful for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer (each being a “Condition”) in an subject.
  • The invention also relates to compositions comprising an amount of a Tetracyclic Benzamide Derivative that is effective to treat or prevent a Condition, and a pharmaceutically acceptable carrier or vehicle. The compositions are useful for treating or preventing a Condition in a subject.
  • The invention further relates to methods for treating or preventing a Condition, comprising administering to a subject in need thereof an amount of a Tetracyclic Benzamide Derivative that is effective to treat or prevent the Condition.
  • The present invention may be understood more fully by reference to the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention.
    • 4. DETAILED DESCRIPTION OF THE INVENTION 4.1 Tetracyclic Benzamide Derivatives of Formula (I)
  • As stated above, the present invention encompasses compounds of Formula (I)
    Figure US20070249653A1-20071025-C00014
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R7, R8, R9, R10, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (I).
  • In one embodiment X is O.
  • In one embodiment R1-R4, R7 and R10 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4, R7, R8, R9 and R10 is other than hydrogen.
  • In one embodiment R5 is —C2-C10 alkyl.
  • In another embodiment R5 is —C4-C10 alkyl.
  • In another embodiment R5 is —C6-C10 alkyl.
  • In another embodiment the compounds of Formula (I) have the structure of Formula (I′):
    Figure US20070249653A1-20071025-C00015
  • wherein X, R5, R8 and R9 are defined above for the Tetracyclic Benzamide Derivatives of Formula (I).
    • 4.2 Tetracyclic Benzamide Derivatives of Formula (Ia)
  • As stated above, the invention further encompasses compounds of Formula (Ia):
    Figure US20070249653A1-20071025-C00016
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R7, R8, R9, and R10, are defined above for the Tetracyclic Benzamide Derivatives of Formula (Ia).
  • In one embodiment R1-R4, R7 and R10 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4 R7, R8, R9 or R10 is other than hydrogen.
  • In one embodiment R5 is —C2-C10 alkyl.
  • In another embodiment R5 is —C4-C10 alkyl.
  • In another embodiment R5 is —C6-C10 alkyl.
  • In another embodiment compounds of Formula (Ia) have the structure of Formula (Ia′):
    Figure US20070249653A1-20071025-C00017
  • wherein R5, R8, and R9 are defined above for compounds of Formula (Ia).
  • Illustrative compounds of Formula (Ia′) are set forth below:
    (Ia′)
    Figure US20070249653A1-20071025-C00018
    Compound No. R5 R8 R9
    16a —CH2COOH —OCH2COOH —H
    16b —(CH2)3OH —O(CH2)3OH —H
    16c —(CH2)5OH —O(CH2)5OH —H
    16d —(CH2)6OH —O(CH2)6OH —H
    16e —(CH2)4COOH —O(CH2)4COOH —H
    16f —CH3 —H —H
    16g —C(O)CH3 —H —H
    16h -glucuronide —H —H
    16i —CH3 —H —OCH3
    16j —(CH2)3OH —H —O(CH2)3OH
    16k —(CH2)6OH —H —O(CH2)6OH

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.3 Tetracyclic Benzamide Derivatives of Formula (Ib)
  • The invention also relates to compounds of Formula (Ib):
    Figure US20070249653A1-20071025-C00019
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R7, R8, R9, R10, and R11 are defined above for the Tetracyclic Benzamide Derivatives of Formula (Ib).
  • In one embodiment, R1-R4, R7 and R10 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4, R7, R8, R9 and R10 is other than hydrogen.
  • In one embodiment R5 is —C2-C10 alkyl.
  • In another embodiment R5 is —C4-C10 alkyl.
  • In another embodiment R5 is —C6-C10 alkyl.
  • In a further embodiment R5 is —C(O)(C1-C5 alkyl).
  • In yet another embodiment R11 is —C(O)(C1-C5 alkyl).
  • In another embodiment the compounds of Formula (Ib) have the structure of Formula (Ib′):
    Figure US20070249653A1-20071025-C00020
  • wherein R5 and R11 are defined above for Formula (Ib).
  • An illustrative compound of Formula (Ib′) is compound 21a, set forth below:
    Figure US20070249653A1-20071025-C00021
    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.4 Tetracyclic Benzamide Derivatives of Formula (II)
  • As stated above, the present invention encompasses compounds of Formula (II):
    Figure US20070249653A1-20071025-C00022
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (II).
  • In one embodiment, R1-R4, R7 and R10 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4, R7, R8, R9 and R10 is other than hydrogen.
  • In another embodiment R7-R10 are hydrogen.
  • In still another embodiment, R6 is hydrogen.
  • In one embodiment R1-R4 and R7-R10 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl).
  • In another embodiment compounds of Formula (II) have the structure of Formula (II′):
    Figure US20070249653A1-20071025-C00023
  • wherein X and R5 are defined above for Formula (II).
  • In other illustrative embodiments R5 and X of Formula (II′) are as set forth below:
    R5 X
    NH —C(O)—
    NH —S—
    NH —NH—
    NH —CH2—
    NH —N(SO2Y)—
    S —C(O)—
    S —S—
    S —NH—
    S —CH2—
    S —N(SO2Y)—
    O —C(O)—
    O —S—
    O —NH—
    O —CH2—
    O —N(SO2Y)—

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.5 Tetracyclic Benzamide Derivatives of Formula (IIa)
  • As stated above, the present invention encompasses compounds of Formula (IIa):
    Figure US20070249653A1-20071025-C00024
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined above for the Tetracyclic Benzamide Derivatives of Formula (IIa).
  • In one embodiment, R1-R4 are hydrogen.
  • In one embodiment, R1-R4, R7, R9, and R10 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4, R7, R8, R9 and R10 is other than hydrogen.
  • In still another embodiment, R6 is hydrogen.
  • In one embodiment R1-R4 and R7-R10 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl).
  • In another embodiment compounds of Formula (IIa) have the structure of Formula (IIa′):
    Figure US20070249653A1-20071025-C00025
    wherein R8 is defined above for Formula (IIa).
  • In one embodiment R8 is -A-B, where -A- is —SO2— and —B is —NZ1Z2 or —(C1-C5alkylene)-NZ1Z2.
  • Illustrative compounds of Formula (IIa′) are set forth below:
    (IIa′)
    Figure US20070249653A1-20071025-C00026
    Compound No. R8
     9a —H
    11a —SO2NH(CH2)3-(N-morpholinyl)

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.6 Tetracyclic Benzamide Derivatives of Formula (III)
  • As stated above, the present invention encompasses compounds of Formula (III):
    Figure US20070249653A1-20071025-C00027
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R6, G1, G2, G3, G4, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (III).
  • In one embodiment R1-R4 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4 and R7 is other than hydrogen.
  • In yet another embodiment R5 is oxygen.
  • In still another embodiment, one of G1-G4 is N.
  • In another embodiment G1 is N; and G2-G4 are C—R7.
  • In another embodiment G2 is N; and G1, G3 and G4 are C—R7.
  • In another embodiment G3 is N; and G1, G2 and G4 are C—R7.
  • In another embodiment G4 is N; and G1, G2, and G3 are C—R7.
  • In another embodiment G1 and G2 are N and G3 and G4 are C—R7.
  • In another embodiment G1 and G3 are N and G2 and G4 are C—R7.
  • In another embodiment G1 and G4 are N and G2 and G3 are C—R7.
  • In another embodiment G2 and G3 are N and G1 and G4 are C—R7.
  • In another embodiment G2 and G4 are N and G1 and G3 are C—R7.
  • In another embodiment G3 and G4 are N and G1 and G2 are C—R7.
  • In another embodiment compounds of Formula (III) have the structure of Formula (III′):
    Figure US20070249653A1-20071025-C00028
  • wherein X, and R9 are defined above for Formula (III).
  • An illustrative example of a compound of Formula (III′) is set forth below:
    Figure US20070249653A1-20071025-C00029
    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.7 Tetracyclic Benzamide Derivatives of Formula (IV)
  • As stated above, the present invention encompasses compounds of Formula (IV):
    Figure US20070249653A1-20071025-C00030
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, G1, G2, G3, G4, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (IV).
  • In one embodiment R1-R4 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4 or R7 is other than hydrogen.
  • In yet another embodiment R5 is oxygen.
  • In still another embodiment, R6 is hydrogen.
  • In still another embodiment, one of G1-G4 is N.
  • In another embodiment G1 is N; and G2-G4 are C—R7.
  • In another embodiment G2 is N, G1, G3, G4 are C—R7.
  • In another embodiment G3 is N, G1, G2, G4 are C—R7.
  • In another embodiment G4 is N, G1, G2, and G3 are C—R7.
  • In another embodiment G1 and G2 are N and G3 and G4 are C—R7.
  • In another embodiment G1 and G3 are N and G2 and G4 are C—R7.
  • In another embodiment G1 and G4 are N and G2 and G3 are C—R7.
  • In another embodiment G2 and G3 are N and G1 and G4 are C—R7.
  • In another embodiment G2 and G4 are N and G1 and G3 are C—R7.
  • In another embodiment G3 and G4 are N and G1 and G2 are C—R7.
  • In another embodiment compounds of Formula (IV) have the structure of Formula (IV′):
    Figure US20070249653A1-20071025-C00031
  • wherein X, R9 and R10 are defined above for Formula (IV).
    • 4.8 Tetracyclic Benzamide Derivatives of Formula (V)
  • As stated above, the present invention encompasses compounds of Formula (V):
    Figure US20070249653A1-20071025-C00032
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and p are defined above for the Tetracyclic Benzamide Derivatives of Formula (V).
  • In one embodiment, R1-R4 are hydrogen. In another embodiment, at least one of R1, R2, R3, R4, R6, R7, R8, and R9 is other than hydrogen. In still another embodiment R1-R4 and R6-R9 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl). In one embodiment R5is O. In another embodiment R5 is NH. In a further embodiment R5 is S.
  • In another embodiment compounds of Formula (V) have the structure of Formula (V′):
    Figure US20070249653A1-20071025-C00033
  • wherein R8 and R10 are defined above for Formula (V).
  • Illustrative compounds of Formula (V′) are set forth below:
    (V′)
    Figure US20070249653A1-20071025-C00034
    Compound R8 R10
    V′1  —H —CH3
    V′2  —H —CH2CH3
    V′3  —H —CH2Ph
    V′4  —H —COOCH3
    V′5  —H —COCH2COOMe
    V′6  —H —COCH2COOH
    V′7  —H —COCH3
    V′8  —H —CONH(CH2)2N(CH3)2
    V′9  —H —CONH(CH2)2-(N-morpholinyl)
    V′10 —H —CONH(CH2)3-(N-morpholinyl)
    V′11 —H —CONH(CH2)2COOCH2CH3
    V′12 —H —CONH(CH2)2COOH
    V′13 —H —CONH(CH2)2CONHCH3
    V′14 —H —CONH-piperidine-1-yl
    V′15 —H —CONH-(N-morpholinyl)
    V′16 —H —CO(CH2)2-tetrazole-5-yl
    V′17 —NHCOCH2N(CH3)2 —COOCH2CH3
    V′18 —SO2NH(CH2)3-(N-morpholinyl) —COOCH2CH3
    V′19 —NHCOCH2N(CH3)2 —COOH
    V′20 —SO2NH(CH2)3-(N-morpholinyl) —COOH
    V′21 —NHCOCH2N(CH3)2 —CONHCH3
    V′22 —SO2NH(CH2)3-(N-morpholinyl) —CONHCH3
    V′23 —NHCOCH2N(CH3)2 —CONH(CH2)2-(N-morpholinyl)
    V′24 —SO2NH(CH2)3-(N-morpholinyl) —CONH(CH2)2N(CH3)2
    V′25 —NHCOCH2N(CH3)2 —CONH(CH2)2-(N-morpholinyl)
    V′26 —SO2NH(CH2)3-(N-morpholinyl) —CONH(CH2)2N(CH3)2

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.9 Tetracyclic Benzamide Derivatives of Formula (VI)
  • As stated above, the present invention encompasses compounds of Formula (VI):
    Figure US20070249653A1-20071025-C00035
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined above for the Tetracyclic Benzamide Derivatives of Formula (VI).
  • In one embodiment, R1-R4 are hydrogen. In another embodiment R6, R7, and R9 are hydrogen. In another embodiment R6-R9 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4, R6, R7, R8, and R9 is other than hydrogen.
  • In one embodiment R1-R4 and R6-R9 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl).
  • In another embodiment compounds of Formula (VI) have the structure of Formula (VI′):
    Figure US20070249653A1-20071025-C00036
  • wherein R4, R7, R9, and R10 are defined above for Formula (VI).
  • Illustrative compounds of Formula (VI′) are set forth below:
    (VI′)
    Figure US20070249653A1-20071025-C00037
    Compound R4 R7 R9 R10
    VI′-1  —H —H —H —H
    VI′-2  —H —H —H —CH3
    VI′-3  —H —H —H —CH2CH3
    VI′-4  —H —H —H —CH2COO CH2CH3
    VI′-5  —H —H —H —CH2COOH
    VI′-6  —H —H —H —CH2CONHCH3
    VI′-7  —H —H —H —CH2Ph
    VI′-8  —H —H —H —COOCH3
    VI′-9  —H —H —H —SO2NH2
    VI′-10 —H —H —H —COOtBu
    VI′-11 —H —H —H —COO CH2CH3
    VI′-12 —H —H —H —COCH3
    VI′-13 —H —H —H —CONHCH3
    VI′-14 —H —H —H —CONH CH2CH3
    VI′-15 —H —H —H —CONH(CH2)2N(CH3)2
    VI′-16 —H —H —H —CONH(CH2)2-(N-morpholinyl)
    VI′-17 —H —H —H —CONH(CH2)3-(N-morpholinyl)
    VI′-18 —H —H —H —CONH(CH2)2COO CH2CH3
    VI′-19 —H —H —H —CONH(CH2)2COOH
    VI′-20 —H —H —H —CONH(CH2)2CONHCH3
    VI′-21 —H —H —H —CONH-piperidine-1-yl
    VI′-22 —H —H —H —CONH-(N-morpholinyl)
    VI′-23 —H —H —H —CO(CH2)2-tetrazole-5-yl
    VI′-24 —H —H —NHCOCH2N(CH3)2 —H
    VI′-25 —H —H —SO2NH(CH2)3-(N-morpholinyl) —H
    VI′-26 —H —NHCOCH2N(CH3)2 —H —COOCH3
    VI′-27 —H —SO2NH(CH2)3-(N- —H —COOCH3
    morpholinyl)
    VI′-28 —H —H —NHCOCH2NMe2 —CONHCH3
    VI′-29 —H —H —SO2NH(CH2)3-(N-morpholinyl) —CONHCH3
    VL′-30 —NH2 —H —NHCOCH2N(CH3)2 —CONHCH3
    VI′-31 —OH —SO2NH(CH2)3-(N- —H —CONHCH3
    morpholinyl)
    VI′-32 —F —NHCOCH2N(CH3)2 —H —CONHCH3
    VI′-33 —OMe —H —SO2NH(CH2)3-(N-morpholinyl) —CONHCH3

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.10 Tetracyclic Benzamide Derivatives of Formula (VII)
  • As stated above, the present invention encompasses compounds of Formula (VII):
    Figure US20070249653A1-20071025-C00038
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, G1, G2, G3, G4, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VII).
  • In one embodiment, R1-R4 are hydrogen.
  • In another embodiment R5 is O.
  • In another embodiment, at least one of R1, R2, R3, and R4 is other than hydrogen.
  • In one embodiment R1-R4 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl).
  • In another embodiment X is NH. In still another embodiment X is O.
  • In a further embodiment X is S. In another embodiment R4 is NH2, OCH3, or NO2.
  • In still another embodiment, one of G1-G4 is N.
  • In another embodiment G1 is N; and G2-G4 are C—R7.
  • In another embodiment G2 is N; and G1, G3 and G4 are C—R7.
  • In another embodiment G3 is N; and G1, G2 and G4 are C—R7.
  • In another embodiment G4 is N; and G1, G2, and G3 are C—R7.
  • In another embodiment G1 and G2 are N and G3 and G4 are C—R7.
  • In another embodiment G1 and G3 are N and G2 and G4 are C—R7.
  • In another embodiment G1 and G4 are N and G2 and G3 are C—R7.
  • In another embodiment G2 and G3 are N and G1 and G4 are C—R7.
  • In another embodiment G2 and G4 are N and G1 and G3 are C—R7.
  • In another embodiment G3 and G4 are N and G1 and G2 are C—R7.
  • In another embodiment compounds of Formula (VII) have the structure of Formula (VII′):
    Figure US20070249653A1-20071025-C00039
  • wherein X, G1, G3, and R4 are defined above for Formula (VII).
  • Illustrative compounds of Formula (VII′) are set forth below:
    (VII′)
    Figure US20070249653A1-20071025-C00040
    Compound R4 G1 G3 X
    VII′-1  —H —CH —N —NH—
    VII′-2  —H —N —CH —NH—
    VII′-3  —H —CH —N —N(CH3)—
    VII′-4  —H —N —CH —N(CH3)—
    VII′-5  —H —CH —N —C(H)(CH2COOH)—
    VII′-6  —H —N —CH —C(H)(CH2CONHCH3)—
    VII′-7  —H —CH —N —O—
    VII′-8  —H —N —CH —O—
    VII′-9  —H —CH —N —S—
    VII′-10 —H —N —CH —S—
    VII′-11 —H —CH —N —N(CONHCH3)—
    VII′-12 —H —N —CH —N(CONHCH2CH3)—
    VII′-13 —H —CH —N —N(CONH(CH2)2N(CH3)2)—
    VII′-14 —H —N —CH —N(CONH(CH2)2-(N-morpholinyl))-
    VII′-15 —H —CH —N —C(H)(CONH(CH2)2COOCH2CH3)—
    VII′-16 —H —N —CH —C(H)CONH(CH2)2COOH)—
    VII′-17 —H —CH —N —C(H)(CONH(CH2)2CONHCH3)—
    VII′-18 —H —N —CH —C(H)CONH-piperidine-1-yl)-
    VII′-19 —H —CH —N —C(H)(CONH-(N-morpholinyl))-
    VII′-20 —H —N —CH —C(H)(CO(CH2)2-tetrazole-5-yl)-
    VII′-21 —NH2 —CH —N —NH—
    VII′-22 —OCH3 —N —CH —NH—

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.11 Tetracyclic Benzamide Derivatives of Formula (VIIa)
  • As stated above, the present invention encompasses compounds of Formula (VIIa):
    Figure US20070249653A1-20071025-C00041
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R7, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VIIa).
  • In one embodiment, R1-R4 are hydrogen. In another embodiment, at least one of R1, R2, R3, R4, R6, and R7, is other than hydrogen. In one embodiment R1-R4 and R7 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl). In another embodiment X is NH. In still another embodiment X is O. In a further embodiment X is S. In another embodiment R4 is —NH2, —OCH3, or —NO2.
  • In another embodiment compounds of Formula (VIIa) have the structure of Formula (VIIa′):
    Figure US20070249653A1-20071025-C00042
  • wherein R4, and X are defined above for Formula (VIIa).
  • Illustrative compounds of Formula (VIIa′) are set forth below:
    (VIIa′)
    Figure US20070249653A1-20071025-C00043
    Compound R4 X
    VIIa′-1  —H —NH—
    VIIa′-2  —H —NCH3—
    VIIa′-3  —H —C(H)(CH2COOH)—
    VIIa′-4  —H —O—
    VIIa′-5  —H —S—
    VIIa′-6  —H —N(CONHCH3)—
    VIIa′-7  —H —N(CONH(CH2)2N(CH3)2)—
    VIIa′-8  —H —C(H)(CONH(CH2)2COOCH2CH3)—
    VIIa′-9  —H —C(H)(CONH(CH2)2CONHCH3)—
    VIla′-10 —H —C(H)(CONH-(N-morpholinyl))-
    VIIa′-11 —NH2 —NH—

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.12 Tetracyclic Benzamide Derivatives of Formula (VIIb)
  • As stated above, the present invention encompasses compounds of Formula (VIIb):
    Figure US20070249653A1-20071025-C00044
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R7, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VIIb).
  • In one embodiment, R1-R4 are hydrogen.
  • In another embodiment, at least one of R1, R2, R3, R4, R6, or R7, is other than hydrogen.
  • In one embodiment R1-R4 and R7 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl).
  • In another embodiment X is NH. In still another embodiment X is O.
  • In a further embodiment X is S. In another embodiment R4 is NH2, OCH3, or NO2.
  • In another embodiment compounds of Formula (VIIb) have the structure of Formula (VIIb′):
    Figure US20070249653A1-20071025-C00045
  • wherein X and R4 are defined above for Formula (VIIb).
  • Illustrative compounds of Formula (VIIb′) are set forth below:
    (VIIb′)
    Figure US20070249653A1-20071025-C00046
    Compound R4 X
    VIIb′-1  —H —NH—
    VIIb′-2  —H —NCH3—
    VIIb′-3  —H —C(H)(CH2CONHCH3)—
    VIIb′-4  —H —O—
    VIIb′-5  —H —S—
    VIIb′-6  —H —N(CONHCH2CH3)—
    VIIb′-7  —H —N(CONH(CH2)2-(N-morpholinyl))-
    VIIb′-8  —H —C(H)(CONH(CH2)2COOH)—
    VIIb′-9  —H —C(H)(CONH-piperidine-1-yl)-
    VIIb′-10 —H —C(H)(CO(CH2)2-tetrazole-5-yl)-
    VIIb′-11 —OCH3 —NH—

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.13 Tetracyclic Benzamide Derivatives of Formula (VIIc)
  • As stated above, the present invention encompasses compounds of Formula (VIIc):
    Figure US20070249653A1-20071025-C00047
    and pharmaceutically acceptable salts and hydrates thereof, where R1, R2, R3, R4, R5, R7, and X are defined above for the Tetracyclic Benzamide Derivatives of Formula (VIIc).
  • In one embodiment, R1-R4 are hydrogen. In another embodiment, at least one of R1, R2, R3, R4, R6, or R7, is other than hydrogen. In one embodiment R1-R4 and R7 is other than —O—(C1-C5 alkyl), and -A-B is other than —O—(C1-C10 alkyl). In another embodiment X is NH. In still another embodiment X is O. In a further embodiment X is S. In another embodiment R4 is —NH2, —OCH3, or —NO2.
  • In another embodiment compounds of Formula (VIIc) have the structure of Formula (VIIc′):
    Figure US20070249653A1-20071025-C00048
  • wherein X and R4 are defined above for Formula (VIIc).
  • Illustrative compounds of Formula (VIIc) are set forth below:
    (VIIc′)
    Figure US20070249653A1-20071025-C00049
    Compound R4 X
    VIIc′-1  —H —NH—
    VIIc′-2  —H —NH—
    VIIc′-3  —H —NCH3—
    VIIc′-4  —H —NCH3—
    VIIc′-5  —H —C(H)(CH2COOH)
    VIIc′-6  —H —C(H)(CH2CONHCH3)—
    VIIc′-7  —H —O—
    VIIc′-8  —H —O—
    VIIc′-9  —H —S—
    VIIc′-10 —H —S—
    VIIc′-11 —H —N(CONHCH3)—
    VIIc′-12 —H —N(CONHCH2CH3)—
    VIIc′-13 —H —N(CONH(CH2)2N(CH3)2)—
    VIIc′-14 —H —N(CONH(CH2)2-(N-morpholinyl))-
    VIIc′-15 —H —C(H)(CONH(CH2)2COOCH2CH3)—
    VIIc′-16 —H —C(H)(CONH(CH2)2COOH)—
    VIIc′-17 —H —C(H)(CONH(CH2)2CONHCH3)—
    VIIc′-18 —H —C(H)(CONH-piperidine-1-yl)-
    VIIc′-19 —H —C(H)(CONH-(N-morpholinyl))-
    VIIc′-20 —H —C(H)(CO(CH2)2-tetrazole-5-yl)-
    VIIc′-22 —NH2 —NH—
    VIIc′-22 —OCH3 —NH—

    and pharmaceutically acceptable salts and hydrates thereof.
    • 4.14 Tetracyclic Benzamide Derivatives of Formulas (I), (Ia), (Ib), (II), (IIa), (III), (IV), (V), (VI), (VII), (VIIa), (VIIb), and (VIIc)
  • The Tetracyclic Benzamide Derivatives can exist in a keto or enol tautomeric form. This invention encompasses both the keto and enol forms of the Tetracyclic Benzamide Derivatives. Accordingly, Formulas (I), (Ia) (Ib), (II), (IIa), (III), (IV), (V), (VI), (VII), (VIIa), (VIIb), and (VIIc), although depicting the keto form of the Tetracyclic Benzamide Derivatives, encompass both the keto and enol forms.
  • The present invention also includes Tetracyclic Benzamide Derivatives, wherein one or more hydrogen, carbon or other atoms are replaced by an isotope thereof. Such compounds are useful as research or diagnostic tools in metabolism pharmacokinetic studies and in binding assays.
    • 4.15 Definitions
  • The term “—(C1-C10)alkyl” as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms. Representative straight chain —(C1-C10)alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonly and -n-decyl. Representative branched —(C1-C10)alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylbuty, -isopropyl, -sec-butyl, -isobutyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,2-dimethylhexyl, 1,3-dimethylhexyl, 3,3-dimethylhexyl, 1,2-dimethylheptyl, 1,3-dimethylheptyl, and 3,3-dimethylheptyl.
  • The term “—(C1-C9)alkyl” as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 9 carbon atoms. Representative straight chain —(C1-C9)alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, and -n-nonly. Representative branched —(C1-C9)alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylbuty, -isopropyl, -sec-butyl, -isobutyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 5-methylhexyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,2-dimethylhexyl, 1,3-dimethylhexyl, 3,3-dimethylhexyl, 1,2-dimethylheptyl, 1,3-dimethylheptyl, and 3,3-dimethylheptyl.
  • The term “—(C1-C5)alkyl” as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 1 to 5 carbon atoms. Representative straight chain —(C1-C5)alkyls include -methyl, -ethyl, -n-propyl, -n-butyl and -n-pentyl. Representative branched —(C1-C5)alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl and 1,2-dimethylpropyl.
  • The term “—(C2-C10)alkenyl” as used herein, refers to a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon double bond. Representative straight chain and branched (C2-C10)alkenyls include -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3 -dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl, -1-heptenyl, -2-heptenyl, -3-heptenyl, -1-octenyl, -2-octenyl, -3-octenyl, -1-nonenyl, -2-nonenyl, -3-nonenyl, -1-decenyl, -2-decenyl, -3-decenyl and the like.
  • The term “—(C3-C8)cycloalkyl” as used herein, refers to a saturated cyclic hydrocarbon having from 3 to 8 carbon atoms. Representative (C3-C8)cycloalkyls include -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl and -cyclooctyl.
  • The term “—(C8-C14)bicycloalkyl” as used herein, refers to a bi-cyclic hydrocarbon ring system having from 8 to 14 carbon atoms and at least one saturated cyclic alkyl ring. Representative —(C8-C14)bicycloalkyls include -indanyl, -1,2,3,4-tetrahydronaphthyl, -5,6,7,8-tetrahydronaphthyl, -perhydronaphthyl and the like.
  • A “3- to 7-membered monocyclic heterocycle” refers to a monocyclic 3- to 7-membered aromatic or non-aromatic monocyclic cycloalkyl in which 1-4 of the ring carbon atoms have been independently replaced with a N, O or S atom. The 3- to 7-membered monocyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom. Representative examples of a 3- to 7-membered monocyclic heterocycle group include, but are not limited to, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, oxazinyl, thiazinyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, tetrazolyl, pyrrolidinyl, isoxazolyl, furanyl, furazanyl, pyridinyl, oxazolyl, thiazolyl, thiophenyl, pyrazolyl, triazolyl, and pyrimidinyl.
  • A “7- to 10-membered bicyclic heterocycle” refers to a bicyclic 7- to 10-membered aromatic or non-aromatic bicyclic cycloalkyl in which 1-4 of the ring carbon atoms have been independently replaced with a N, O or S atom. The 7- to 10-membered bicyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom. Representative examples of a 7- to 10-membered bicyclic heterocycle group include, but are not limited to, benzimidazolyl, indolyl, isoquinolinyl, indazolyl, quinolinyl, quinazolinyl, purinyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzodiazolyl, benzotriazolyl, isoindolyl and indazolyl.
  • A “nitrogen-containing 3- to 7-membered monocyclic heterocycle” refers to a 3- to 7-membered monocyclic heterocycle, defined above, which contains at least one ring nitrogen atom. The nitrogen-containing 3- to 7-membered monocyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom. Representative examples of nitrogen-containing-3- to 7-membered monocyclic heterocycles include, but are not limited to, piperidinyl, piperazinyl, pyrrolyl, oxazinyl, thiazinyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, tetrazolyl, pyrrolidinyl, isoxazolyl, pyridinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrimidinyl, and morpholinyl.
  • A “nitrogen-containing 7- to 10-membered bicyclic heterocycle” refers to a 7- to 10-membered bicyclic heterocycle, defined above, which contains at least one ring nitrogen atom. The nitrogen-containing 7- to 10-membered bicyclic heterocycles can be attached via a nitrogen, sulfur, or carbon atom. Representative nitrogen-containing 7- to 10-membered bicyclic heterocycles include -quinolinyl, -isoquinolinyl, -chromonyl, -indolyl, -isoindolyl, -indolizinyl, -indazolyl, -purinyl, -4H-quinolizinyl, -isoquinolyl, -quinolyl, -phthalazinyl, -naphthyridinyl -carbazolyl, -β-carbolinyl and the like.
  • The term “-aryl” as used herein, refers to a phenyl or naphthyl group.
  • “Halo-substituted-(C1-C5 alkyl)” refers to a C1-C5 alkyl group, as defined above, wherein one or more of the C1-C5 alkyl group's hydrogen atoms has been replaced with —F, —Cl, —Br or —I. Representative examples of an alkylhalo group include, but are not limited to, —CH2F, —CCl3, —CF3, —CH2Cl, —CH2CH2Br, —CH2CH2I, —CH2CH2CH2F, —CH2CH2CH2Cl, —CH2CH2CH2CH2Br, —CH2CH2CH2CH2I, —CH2CH2CH2CH2CH2Br, —CH2CH2CH2CH2CH2I, —CH2CH(Br)CH3, —CH2CH(Cl)CH2CH3, —CH(F)CH2CH3 and —C(CH3)2(CH2Cl).
  • “Amino-substituted-(C1-C5 alkyl)” refers to a C1-C5 alkyl group, as defined above, wherein one or more of the C1-C5 alkyl group's hydrogen atoms has been replaced with —NH2. Representative examples of an alkyl amino group include, but are not limited to, —CH2NH2, —CH2CH2NH2, —CH2CH2CH2NH2, —CH2CH2CH2CH2NH2, —CH2CH(NH2)CH3, —CH2CH(NH2)CH2CH3, —CH(NH2)CH2CH3, —C(CH3)2(CH2NH2), —CH2 CH2CH2CH2CH2NH2, —CH2CH2CH(NH2)CH3, —CH2CH(NH2)CH2CH2CH3, —CH2CH(NH2)CH2CH3 and —CH2C(CH3)2(CH2NH2).
  • “—(NH(C1-C5 alkyl)” refers to an —NH group, the nitrogen atom of said group being attached to a C1-C5 alkyl group, as defined above. Representative examples of an aminoalkyl group include, but are not limited to, —NHCH3, —NHCH2CH3, —NHCH2CH2CH3, —NHCH2CH2CH2CH3, —NHCH(CH3)2, —NHCH2CH(CH3)2, —NHCH2(CH3)CH2CH3, —NH—CH2CH2C(CH3)3, —NHCH2CH2CH2CH2CH3, —NHCH2CH(CH3)2, —NHCH2CH2CH(CH3)2, —NHCH2CH(CH3)CH2CH3 and —NH—CH2C(CH3)3.
  • “—N(C1-C5 alkyl)(C1-C5 alkyl)” refers to a nitrogen atom which has attached to it two C1-C5 alkyl groups, as defined above. Representative examples of a aminodialkyl group include, but are not limited to, —N(CH3)2, —N(CH2CH3)(CH3), —N(CH2CH3)2, —N(CH2CH2CH3)2, —N(CH2CH2CH2CH3)2, —N(CH(CH3)2)2, —N(CH(CH3)2)(CH3), —N(CH2CH(CH3)2)2, —NH(CH(CH3)CH2CH3)2, —N(C(CH3)3)2 and —N(C(CH3)3)(CH3).
  • “—(H2NC(O))-substituted aryl” refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with one or more —C(O)NH2 groups. Representative examples of an arylamido group include 2-C(O)NH2-phenyl, 3-C(O)NH2-phenyl, 4-C(O)NH2-phenyl.
  • “—(H2NC(O))-substituted pyridyl” refers to an pyridyl group, wherein one of the pyridyl group's hydrogen atoms has been replaced with one or more —C(O)NH2 groups. Representative examples of an arylamido group include 2-C(O)NH2-pyridyl, 3-C(O)NH2-pyridyl and 4-C(O)NH2-pyridyl.
  • “—(H2NC(O))-substituted-(C1-C5 alkyl)” refers to a C1-C5 alkyl group, as defined above, wherein one of the C1-C5 alkyl group's hydrogen atoms has been replaced with a —C(O)NH2 group. Representative examples of an alkylamido group include, but are not limited to, —CH2C(O)NH2, —CH2CH2C(O)NH2, —CH2CH2CH2C(O)NH2, —CH2CH2CH2CH2C(O)NH2, —CH2CH2CH2CH2CH2C(O)NH2, —CH2CH(C(O)NH2)CH3, —CH2CH(C(O)NH2)CH2CH3, —CH(C(O)NH2)CH2CH3 and —C(CH3)2CH2C(O)NH2.
  • “HO-substituted-(C1-C5 alkyl)” refers to a C1-C5 alkyl group, as defined above, wherein one of the C1-C5 alkyl group's hydrogen atoms has been replaced with a hydroxyl group. Representative examples of an alkanol group include, but are not limited to, —CH2OH, —CH2CH2OH, —CH2CH2CH2OH, —CH2CH2CH2CH2OH, —CH2CH2CH2CH2CH2OH, —CH2CH(OH)CH3, —CH2CH(OH)CH2CH3, —CH(OH)CH2CH3 and —C(CH3)2CH2OH.
  • “Carboxy-substituted-(C1-C5 alkyl)” refers to a C1-C5 alkyl group, as defined above, wherein one of the C1-C5 alkyl group's hydrogen atoms has been replaced with a —COOH group. Representative examples of an alkylcarboxy group include, but are not limited to, —CH2COOH, —CH2CH2COOH, —CH2CH2CH2COOH, —CH2CH2CH2CH2COOH, —CH2CH(COOH)CH3, —CH2CH2CH2CH2CH2COOH, —CH2CH(COOH)CH2CH3, —CH(COOH)CH2CH3 and —C(CH3)2CH2COOH.
  • The term “glycoside” as used herein refers to a hexose or a pentose sugar forming an α- or β-glycosidic linkage. Representative examples of glycosides include, but are not limited to ribose, deoxyribose, fructose, galactose, glucuronic acid and glucose.
  • A “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, or baboon.
  • The phrase “pharmaceutically acceptable salt,” as used herein, is a salt formed from an acid and a basic nitrogen group of one of the Tetracyclic Benzamide Derivatives. Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1′-methylene-bis-(2-OH-3-naphthoate)) salts. The term “pharmaceutically acceptable salt” also refers to a salt prepared from a Tetracyclic benzamide Derivative having an acidic functional group, such as a carboxylic acid functional group or a sulfonic acid functional group, and a pharmaceutically acceptable inorganic or organic base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-OHethyl)amine, 2-OH tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxy lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-OHethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.
  • An “effective amount” when used in connection a Tetracyclic Benzamide Derivative is an amount effective for: (a) treating or preventing a Condition or (b) inhibiting PARP in an in vivo or an in vitro cell.
  • The following abbreviations are used herein and have the indicated definitions: AcOH is acetic acid, CEP is Cecal Ligation and Puncture, DMEM is Dulbecco's Modified Eagle Medium, DMF is N,N-dimethylformamide, DMSO is dimethylsulfoxide, Et is ethyl, EtOAc is ethyl acetate, EtOH is ethanol, HEPES is 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, HPLC is high performance liquid chromatography, LPS is lipopolysaccharide, MeCN is acetonitrile, MeOH is methanol, MS is mass spectrometry, Ms is mesyl (methanesulfonyl), NaBH4 is sodium borohydride, NEt3 is triethylamine, NMR is nuclear magnetic resonance, PBS is phosphate-buffered saline (pH 7.4), PARP is poly(ADP-ribose)polymerase, PPA is polyphosphoric acid, Py is pyridine, SDS is dodecyl sulfate (sodium salt), STZ is streptozotocin, TCA is tricholoroacetic acid, Tf is triflyl (trifluoromethanesulfonyl), TFA is trifluoroacetic acid, THF is tetrahydrofuran; TLC is thin-layer chromatography, TNF is tumor necrosis factor, TRIS is Tris(hydroxymethyl)aminomethane and Ts is tosyl (p-toluenesulfonyl).
    • 4.16 Methods for Making the Tetracyclic Benzamide Derivatives
  • Examples of synthetic pathways useful for making Tetracyclic Benzamide Derivatives are set forth in the Examples below and generalized in Schemes 1-6.
  • Scheme 1 illustrates methods useful for making Tetracyclic Benzamide Derivatives of Formula (IIa), where R1-R4 and R6-R10 are defined for Formula (IIa).
    Figure US20070249653A1-20071025-C00050
  • wherein
  • R1-R4 and R6-R10 are as defined above for the compounds of Formula (IIa);
  • each Ra is independently C1-C3 alkyl; and X is —Cl, —Br, —I, —OTf, —OMs or —OTs.
  • Tetracyclic Benzamide Derivatives of Formula (II) and Formula (IIa) can be made by a method comprising the steps of Scheme 1 above herein.
  • A compound of Formula 3 can be made by a method comprising contacting a compound of Formula 1 with a compound of Formula 2 in the presence of a base for a time and at a temperature sufficient to make a compound of Formula 3.
  • In one embodiment Ra is methyl and X is —Br.
  • In one embodiment about 0.1 to about 10 equivalents of a compound of Formula 2 are used per about 1 equivalent of a compound of Formula 1.
  • In another embodiment about 0.5 to about 5 equivalents of a compound of Formula 2 are used per about 1 equivalent of a compound of Formula 1.
  • In still another embodiment, about 1 to about 2 equivalents of a compound of Formula 2 are used per about 1 equivalent of a compound of Formula 1.
  • In one embodiment about 1 to about 5 equivalents of base are used per about 1 equivalent of a compound of Formula 1.
  • In another embodiment about 2 to about 3 equivalents of base are used per about 1 equivalent of a compound of Formula 1.
  • Suitable bases for use in the method are organic bases such as triethylamine, diisopropylamine, diisopropylethylamine, pyridine, lutidine and imidazole; and inorganic bases such as alkali metal carbonates, including sodium carbonate, potassium carbonate and cesium carbonate.
  • In another embodiment, the base is potassium carbonate.
  • The method can be carried out in the presence of a solvent, such as acetonitrile, methylene chloride, chloroform, THF, DMF, DMSO, ethyl acetate, acetone, benzene, diethyl ether, water or mixtures thereof.
  • In another embodiment, the solvent is DMF.
  • In still another embodiment, the solvent is substantially anhydrous, i.e., comprises less than about 1% water.
  • In another embodiment the method is carried out for a time of about 2 hours to about 36 hours.
  • In still another embodiment the method of Scheme 1 is carried out for a time of about 8 hours to about 24 hours.
  • In yet another embodiment the method of Scheme 1 is carried out for a time of about 12 hours to about 18 hours.
  • In a further embodiment, the method of Scheme 1 is carried out at a temperature of about 0° C. to about 100° C.
  • In another embodiment, the method of Scheme 1 is carried out at a temperature of about 35° C. to about 70° C.
  • In yet another embodiment, the method of Scheme 1 is carried out at a temperature of about 25° C.
  • A compound of Formula 4 can be made by a method comprising (a) contacting a compound of Formula 3 with ammonia in methanol; and (b) contacting the product of step (a) with dilute acid for a time and at a temperature sufficient to make a compound of Formula 4.
  • In one embodiment about I to about 1000 equivalents of a solution of ammonia in methanol are used per about 1 equivalent of a compound of Formula 3.
  • In another embodiment about 5 to about 500 equivalents of ammonia in methanol are used per about 1 equivalent of a compound of Formula 3.
  • In still another embodiment, about 10 to about 100 equivalents of ammonia in methanol are used per about 1 equivalent of a compound of Formula 3.
  • In yet another embodiment about 20 to about 50 equivalents of ammonia in methanol are used per about I equivalent of a compound of Formula 3.
  • In one embodiment the ammonia in methanol is from about 1 N to about 10 N.
  • In another embodiment the ammonia in methanol is from about 3 N to about 7 N.
  • In one embodiment the dilute acid is from about 0.01 N to about 3 N.
  • In another embodiment the dilute acid is from about 0.1 N to about 1 N.
  • In another embodiment, the acid is HCl.
  • In one embodiment the method is carried out for a time of about 1 hour to about 48 hours.
  • In still another embodiment the method is carried out for a time of about 8 hours to about 36 hours.
  • In yet another embodiment the method is carried out for a time of about 12 hours to about 24 hours.
  • In one embodiment, the method is carried out at a temperature of about 0° C. to about 100° C.
  • In another embodiment, the method is carried out at a temperature of about 25° C. to about 75° C.
  • In yet another embodiment, the method is carried out at a temperature of about 40° C. to about 60° C.
  • A compound of Formula 5 can be made by a method comprising contacting a compound of Formula 4 with a dehydrating agent for a time and at a temperature sufficient to make a compound of Formula 5.
  • In one embodiment about 0.1 to about 10 equivalents of a dehydrating agent are used per about 1 equivalent of a compound of Formula 4.
  • In another embodiment about 0.5 to about 5 equivalents of a dehydrating agent are used per about 1 equivalent of a compound of Formula 4.
  • In still another embodiment, about I to about 2 equivalents of a dehydrating agent are used per about 1 equivalent of a compound of Formula 4.
  • Suitable dehydrating agents include, but are not limited to, PPA, sulfuric acid, chlorosulfonic acid, sulfuryl chloride and thionyl chloride.
  • In another embodiment, the dehydrating agent is PPA.
  • The method can be carried out in the presence of a solvent, including, but not limited to, xylenes.
  • In one embodiment, the solvent is xylenes.
  • In another embodiment, the solvent is substantially anhydrous, i.e., comprises less than about 1% water.
  • In one embodiment the method is carried out for a time of about 1 hour to about 24 hours.
  • In still another embodiment the method is carried out for a time of about 4 hours to about 18 hours.
  • In yet another embodiment the method is carried out for a time of about 6 hours to about 12 hours.
  • In one embodiment, the method is carried out at a temperature of about 25° C. to about 200° C.
  • In another embodiment, the method is carried out at a temperature of about 100° C. to about 160° C.
  • A compound of Formula (IIa) can be made by a method comprising contacting a compound of Formula 5 with a reducing agent for a time (e.g. Wolff-Kishner reagents) and at a temperature sufficient to make a compound of Formula (IIa).
  • In one embodiment about 0.1 to about 10 equivalents of a reducing agent are used per about 1 equivalent of a compound of Formula 5.
  • In another embodiment about 0.5 to about 5 equivalents of a reducing agent are used per about 1 equivalent of a compound of Formula 5.
  • In still another embodiment, about 1 to about 2 equivalents of a reducing agent are used per about 1 equivalent of a compound of Formula 5.
  • Suitable reducing agents for this carbonyl reduction include, but are not limited to, sodium borohydride, diisobutylaluminum hydride, alpineborane, and TFA/triethylsilane.
  • In one embodiment, the reducing agent is a hydride reducing agent.
  • In another embodiment, the reducing agent is sodium borohydride.
  • In another embodiment, the reducing agent is TFA/triethylsilane.
  • The method can be carried out in the presence of a solvent, including, but not limited to, methanol, ethanol, THF and benzene. Alternatively the method can be carried out in the absence of a solvent.
  • In one embodiment, the solvent is methanol.
  • In another embodiment, the solvent is substantially anhydrous, i.e., comprises less than about 1% water.
  • In one embodiment the method is carried out for a time of about 1 minute to about 12 hours.
  • In still another embodiment the method is carried out for a time of about 5 minutes hours to about 6 hours.
  • In yet another embodiment the method is carried out for a time of about 15 minutes hours to about 2 hours.
  • In one embodiment, the method is carried out at a temperature of about −20° C. to about 40° C.
  • In another embodiment, the method is carried out at a temperature of about 10° C. to about 30° C.
  • In still another embodiment, the method is carried out at a temperature of about 25° C.
  • A Tetracyclic Benzamide Derivative of the Formula 9 can be further derivatized using methodology familiar to one skilled in the art of organic synthesis to prepared a variety of analogs of Formula (II) and Formula (IIa) having various substituents at one or more of R1, R2, R3, R4, R7, R8, R9 and R10. Useful derivatization methods include, but are not limited to, aromatic nucleophilic substitution reactions and aromatic electrophilic substitution reactions, such as nitration, iodination, bromination, chlorination, sulfonylation, sulfonylchlorination, alkylation and acylation. See M. B. Smith and J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 675-758 and 850-893 (5th ed. 2001).
  • In one embodiment, the Tetracyclic Benzamide Derivative of Formula 9 is transformed into the chlorosulfonyl compound of Formula 10 using chlorosulfonic acid. The Chlorosulfonyl compound of Formula 10 is then derivatized to the corresponding 3-(N morpholinyl)-propylsulfonamide derivative of Formula 11 by reacting the chlorosulfonyl compound of 10 with 3-(N-morpholinyl)-propylamine in the presence of a triethylamine.
  • Scheme 2 below illustrates methods useful for making compounds of Formula (I), Formula (Ia) and Formula (Ib), wherein R1-R4 and R7-R1 are defined above for the compounds of Formula (I), Formula (Ia) and Formula (Ib); X′ is —OH, —NHR11, or —SH; X is —O—, —N(H)—, or —S—; each Ra is independently C1-C3 alkyl; and Rb is —Cl, —Br, —I, —OTs, —OMs or —OTf.
    Figure US20070249653A1-20071025-C00051
    Figure US20070249653A1-20071025-C00052
  • A tetracyclic isoquinoline compound of Formula 15 can be prepared by reacting a homophthalate of Formula 13 with a cyanophenol of Formula 14 in the presence of a base, such as triethylamine, sodium carbonate, or potassium carbonate, in a solvent such as acetonitrile, acetone or dimethylformamide (DMF).
  • A compound of Formula 15 can be transformed to a Tetracyclic Benzamide Derivative of Formula (I) upon treating 15 with an alkylating agent, an acylating agent or a glucuronidating agent, and further derivatization if necessary.
  • Suitable alkylating and acylating agents include, but are not limited to, alkylhalides, such as iodomethane, iodoethane, 1-iodopropane and 2-bromopropane, 1-bromopropane, 1-bromobutane, 1-bromopentane and 1-bromohexane, the alkyl group of which can be optionally substituted with —OH or —C(O)OH; acyl halides, such as acetyl chloride and propionyl chloride; and anhydrides, such as acetic anhydride and propionic anhydride.
  • In one embodiment, the alkylating agent is methyl iodide.
  • In another embodiment, the allkylating agent is a hydroxy-substituted alkylhalide.
  • In still another embodiment, the alkylating agent is a carboxy-substituted alkylhalide.
  • In one embodiment, the acylating agent is acetyl chloride.
  • In another embodiment, the acylating agent is acetic anhydride.
  • In yet another embodiment, R5 is glucuronidyl and the glucuronidating agent is acetobromo-α-D-glucuronic acid methyl ester.
  • Scheme 3 below illustrates methodology useful for making Tetracyclic Benzamide Derivatives of Formula III, wherein R1-R4 and G1-G4 are defined above for the compounds of Formula III; Rb is —Cl, —Br, —I, —OTs, —OMs or —OTf; and Rc is —C1-C3 alkyl.
    Figure US20070249653A1-20071025-C00053
    Figure US20070249653A1-20071025-C00054
  • Tetracyclic Benzamide Devivatives Derivatives of Formulas 22, 24, 26 and 28 can be made by reacting a homophthalic anhydride of Formula 17
    Figure US20070249653A1-20071025-C00055
    with a compound of Formula 21, 23, 25 or 27, respectively in the presence of a base.
  • In an alternate embodiment, Tetracyclic Benzamide Devivatives Derivatives of Formulas 22, 24, 26 and 28 can be made by reacting a homophthalate of Formula 13 with a compound of Formula 21, 23, 25 or 27, respectively in the presence of a base.
  • Suitable bases for use in the methods of Scheme 5 are organic bases such as triethylamine, diisopropylamine, diisopropylethylamine, pyridine, lutidine sodium butoxide, sodium methoxide, and imidazole; and inorganic bases such as alkali metal carbonates, including sodium hydride, sodium carbonate, potassium carbonate and cesium carbonate.
  • In one embodiment, the base is triethylamine.
  • In another embodiment, the base is potassium carbonate.
  • The method can be carried out in the presence of a solvent, such as acetonitrile, methylene chloride, chloroform, THF, DMF, DMSO, ethyl acetate, acetone, benzene, diethyl ether, water or mixtures thereof.
  • In one embodiment, the solvent is acetonitrile.
  • In another embodiment, the solvent is DMF.
  • Scheme 4 below illustrates methods useful for making compounds of Formula (V) wherein R1-R4 and R7-R10 are defined above for the compounds of Formula (V).
    Figure US20070249653A1-20071025-C00056
  • A ketone of Formula A can be cyclized to the bicyclic intermediates of Formula B using bromo ethyl malonate in the presence of potassium carbonate. The intermediates of Formula B can then be converted to the lactam intermediates of Formula C in the presence of ammonia in methanol. Fridel-Crafts mediated ring closure of C provides the tetracyclic keto intermediates of Formula D which when reacted with a phosponate or phosphorus ylide via a Wittig-Horner procedure provides the Tetracyclic Benzamide Derivatives of Formula E, whose exocyclic double bond can subsequently be reduced using catalytic hydrogenation to provide the compounds of Formula (V) where p is ≧2.
  • In an alternate embodiment, compounds of Formula (V) where p=0, can be synthesized via intermediates of Formula D. The keto intermediates of Formula D can be reduced to the corresponding alcohol intermediates of Formula D′ with subsequent conversion of the alcohol to the triflate intermediates of Formula D″ to produce a good leaving group. The triflate intermediate can then be reacted with nucleophiles of the Formula
    R10 −M+
    where M+ is a alkali metal such as Na+, or K+, thereby producing Tetracyclic Benzamide Derivatives of Formula (V) where p=0. The compounds of Formula A can be produced from commercially starting materials using techniques known to one skilled in the art of organic synthesis.
  • Scheme 5 below illustrates methods useful for making compounds of Formula (II), Formula (VI), Formula (VII), Formula (VIIa), Formula (VIIb), and Formula (VIIc) wherein R1-R4, R7-R10, G1-G4, and X are defined above for the compounds of Formula (II), Formula (VI), Formula (VII), Formula (VIIa), Formula (VIIb), and Formula (VIIc):
    Figure US20070249653A1-20071025-C00057
    Figure US20070249653A1-20071025-C00058
  • The carboxylic acid group of a compound of Formula N can be coupled with DPPA to provide the corresponding carbamate intermediates of Formula O, which can then be thermally cyclized to provide the Tetracyclic Benzamide derivatives of Formula (II). Using the same synthetic method, the bicyclic carboxylic acids of Formula Q (see Wacker et al., Tet. Lett., 43:5189-5191, 2002; and Bourdais, et al., J. Het. Chem., 12:1111-1115, 1975, for methods useful to make compounds of Formula Q) can be converted to the Tetracyclic Benzamide derivatives of Formula (VI), Formula (VII), Formula (VIIa), Formula (VIIb), and Formula (VIIc) via the intermediacy of the carbamates of Formula R.
  • Scheme 6 below illustrates methods useful for making compounds of Formula (IV) wherein R1-R4, R7-R10, and G1-G4 are defined above for the compounds of Formula (IV):
    Figure US20070249653A1-20071025-C00059
  • The Tetracyclic Benzamide Derivatives of Formula (IV) can be made using a one pot coupling/cyclization process by reacting an intermediate of Formula W with an aromatic nitrile of Formula Y in the presence of sodium hydride.
  • Alternatively, the carboxylic acid group of a compound of Formula Z (see Wacker et al., Tet. Lett., 43:5189-5191, 2002; and Bourdais, et al., J. Het. Chem., 12:1111-1115, 1975, for methods useful to make compounds of Formula Z) can be coupled with DPPA to provide the corresponding carbonate intermediates of Formula AA, which can then be thermally cyclized to provide the Tetracyclic Benzamide Derivatives of Formula (IV).
    • 4.17 Therapeutic Uses of the Tetracyclic Benzamide Derivatives
  • The invention also includes pharmaceutical compositions comprising an effective amount of a Tetracyclic Benzamide Derivative and a pharmaceutically acceptable carrier or vehicle. The invention includes a Tetracyclic Benzamide Derivative when provided as a pharmaceutically acceptable prodrug, hydrated salt, such as a pharmaceutically acceptable salt, or mixtures thereof.
  • In accordance with the invention, the Tetracyclic Benzamide Derivatives are administered to a subject in need of treatment or prevention of a Condition.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent an inflammatory disease. Inflammatory diseases can arise where there is an inflammation of the body tissue. These include local inflammatory responses and systemic inflammation. Examples of inflammatory diseases treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, organ transplant rejection; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; inflammatory lung diseases such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney including uremic complications, glomerulonephritis and nephrosis; inflammatory diseases of the skin including dermatitis, sclerodermatitis, psoriasis and eczema; inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimers disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and viral or autoimmune encephalitis; immune-complex vasculitis; systemic lupus erythematosus (SLE); inflammatory diseases of the heart such as cardiomyopathy, ischemic heart disease, hypercholesterolemia, and atherosclerosis; as well as various other diseases that can have significant inflammatory components, including preeclampsia, chronic liver failure, and brain and spinal cord trauma. The inflammatory disease can also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, e.g., shock associated with pro-inflammatory cytokines. Such shock can be induced, e.g., by a chemotherapeutic agent that is administered as a treatment for cancer.
  • In one embodiment the inflammatory disease is arthritis. In another embodiment the inflammatory disease is colitis.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent a reperfusion disease. Reperfusion refers to the process whereby blood flow in the blood vessels is resumed following ischemia, such as occurs following constriction or obstruction of the vessel. Reperfusion disease can result following a naturally occurring episode, such as a myocardial infarction, stroke, or during a surgical procedure where blood flow in vessels is intentionally or unintentionally blocked. Examples of reperfusion injuries treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, intestinal reperfusion disease, myocardial reperfusion disease, and reperfusion disease resulting from cardiopulmonary bypass surgery, thoracoabrominal aneurysm repair surgery, carotid endarerectomy surgery, or hemorrhagic shock.
  • In one embodiment, the reperfusion disease results from cardiopulmonary bypass surgery, thoracoabrominal aneurysm repair surgery, carotid endarerectomy surgery, or hemorrhagic shock.
  • In one embodiment, the reperfusion disease is a reoxygenation injury resulting from surgery, particularly that relating to organ transplantation.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent a reoxygenation injury resulting from surgery, particularly that relating to organ transplantation. Examples of reoxygenation injuries treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, transplantation of the following organs: heart, lung, liver and kidney.
  • In one embodiment, a reoxygenation injury resulting from organ transplantation occurs during the organ transplantation.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent an ischemic condition. Examples of ischemic conditions treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, stable angina, unstable angina, myocardial ischemia, hepatic ischemia, mesenteric artery ischemia, intestinal ischemia, critical limb ischemia, chronic critical limb ischemia, erebral ischemia, acute cardiac ischemia, and an ischemic disease of the central nervous system, such as stroke or cerebral ischemia.
  • In one embodiment, the ischemic condition is myocardial ischemia, stable angina, unstable angina, stroke, ischemic heart disease or cerebral ischemia.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent chronic renal failure. In one embodiment the renal failure is chronic renal failure. In another embodiment, the renal failure is acute renal failure.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent a vascular disease. Examples of vascular diseases treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, peripheral arterial occlusion, thromboangitis obliterans, Reynaud's disease and phenomenon, acrocyanosis, erythromelalgia, venous thrombosis, varicose veins, arteriovenous fistula, lymphedema, and lipedema.
  • In one embodiment the vascular disease is a cardiovascular disease. The Tetracyclic Benzamide Derivatives can be used to treat or prevent cardiovascular diseases. Examples of cardiovascular diseases treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, cardiovascular diseases that can be treated or prevented by administering an effective amount of a Tetracyclic Benzamide Derivative include, but are not limited to, chronic heart failure, atherosclerosis, congestive heart failure, circulatory shock, cardiomyopathy, cardiac transplant, myocardial infarction, and a cardiac arrhythmia, such as atrial fibrillation, supraventricular tachycardia, atrial flutter, and paroxysmal atrial tachycardia.
  • In one embodiment, the cardiovascular disease is chronic heart failure.
  • In another embodiment, the cardiovascular disease is a cardiac arrhyhmia.
  • In still another embodiment, the cardiac arrhythmia is atrial fibrillation, supraventricular tachycardia, atrial flutter or paroxysmal atrial tachycardia.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent diabetes. Examples of diabetes treatable or preventable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, Type I diabetes (Insulin Dependent Diabetes Mellitus), Type II diabetes (Non-Insulin Dependent Diabetes Mellitus), gestational diabetes, insulinopathies, diabetes due to pancreatic disease, diabetes associated with other endocrine diseases (such as Cushing's Syndrome, acromegaly, pheochromocytoma, glucagonoma, primary aldosteronism or somatostatinoma), Type A insulin resistance syndrome, Type B insulin resistance syndrome, lipatrophic diabetes, and diabetes induced by β-cell toxins.
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent a diabetic complication. Examples of diabetic complications treatable or preventable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, diabetic cataract, glaucoma, retinopathy, nephropathy, (such as microaluminuria and progressive diabetic nephropathy), polyneuropathy, gangrene of the feet, atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic-hyperosmolar coma, mononeuropathy, autonomic neuropathy, foot ulcer, joint problem, and a skin or mucous membrane complication (such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabeticorumobesity), hyperlipidemia, hypertension, syndrome of insulin resistance, coronary artery disease, retinopathy, diabetic neuropathy, polyneuropathy, mononeuropathy, autonomic neuropathy, foot ulcers, joint problems, fungal infections, and bacterial infections.
    • 4.17.1 Treatment or Prevention of Cancer
  • The Tetracyclic Benzamide Derivatives can be used to treat or prevent cancer. Examples of cancers treatable or preventable using the Tetracyclic Benzamide Derivatives include, but are not limited to, the cancers disclosed below in Table 1 and metastases thereof.
    TABLE 1
    Solid tumors, including but not limited to:
    fibrosarcoma
    myxosarcoma
    liposarcoma
    chondrosarcoma
    osteogenic sarcoma
    chordoma
    angiosarcoma
    endotheliosarcoma
    lymphangiosarcoma
    lymphangioendotheliosarcoma
    synovioma
    mesothelioma
    Ewing's tumor
    leiomyosarcoma
    rhabdomyosarcoma
    colon cancer
    colorectal cancer
    kidney cancer
    pancreatic cancer
    bone cancer
    breast cancer
    ovarian cancer
    prostate cancer
    esophageal cancer
    stomach cancer
    oral cancer
    nasal cancer
    throat cancer
    squamous cell carcinoma
    basal cell carcinoma
    adenocarcinoma
    sweat gland carcinoma
    sebaceous gland carcinoma
    papillary carcinoma
    papillary adenocarcinomas
    cystadenocarcinoma
    medullary carcinoma
    bronchogenic carcinoma
    renal cell carcinoma
    hepatoma
    bile duct carcinoma
    choriocarcinoma
    seminoma
    embryonal carcinoma
    Wilms' tumor
    cervical cancer
    uterine cancer
    testicular cancer
    small cell lung carcinoma
    bladder carcinoma
    lung cancer
    epithelial carcinoma
    glioma
    glioblastoma multiforme
    astrocytoma
    medulloblastoma
    craniopharyngioma
    ependymoma
    pinealoma
    hemangioblastoma
    acoustic neuroma
    oligodendroglioma
    meningioma
    skin cancer
    melanoma
    neuroblastoma
    retinoblastoma
    blood-borne cancers, including but not limited to:
    acute lymphoblastic leukemia (“ALL”)
    acute lymphoblastic B-cell leukemia
    acute lymphoblastic T-cell leukemia
    acute myeloblastic leukemia (“AML”)
    acute promyelocytic leukemia (“APL”)
    acute monoblastic leukemia
    acute erythroleukemic leukemia
    acute megakaryoblastic leukemia
    acute myelomonocytic leukemia
    acute nonlymphocyctic leukemia
    acute undifferentiated leukemia
    chronic myelocytic leukemia (“CML”)
    chronic lymphocytic leukemia (“CLL”)
    hairy cell leukemia
    multiple myeloma
    acute and chronic leukemias:
    lymphoblastic
    myelogenous
    lymphocytic
    myelocytic leukemias
    Lymphomas:
    Hodgkin's disease
    non-Hodgkin's Lymphoma
    Multiple myeloma
    Waldenström's macroglobulinemia
    Heavy chain disease
    Polycythemia vera
  • In one embodiment, the cancer is pancreatic cancer, colorectal cancer, mesothelioma, a malignant pleural effusion, peritoneal carcinomatosis, peritoneal sarcomatosis, renal cell carcinoma, small cell lung cancer, non-small cell lung cancer, testicular cancer, bladder cancer, breast cancer, head and neck cancer, or ovarian cancer.
  • In still another embodiment, the subject in need of treatment has previously undergone treatment for cancer. Such previous treatments include, but are not limited to, prior chemotherapy, radiation therapy, surgery or immunotherapy, such as cancer vaccines.
  • The Tetracyclic Benzamide Derivatives are also useful for the treatment or prevention of a cancer caused by a virus. For example, human papilloma virus can lead to cervical cancer (see, e.g., Hernandez-Avila et al., Archives of Medical Research (1997) 28:265-271), Epstein-Barr virus (EBV) can lead to lymphoma (see, e.g., Herrmann et al., J Pathol (2003) 199(2):140-5), hepatitis B or C virus can lead to liver carcinoma (see, e.g., El-Serag, J Clin Gastroenterol (2002) 35(5 Suppl 2):S72-8), human T cell leukemia virus (HTLV)-I can lead to T-cell leukemia (see e.g., Mortreux et al., Leukemia (2003) 17(1):26-38), human herpesvirus-8 infection can lead to Kaposi's sarcoma (see, e.g., Kadow et al., Curr Opin Investig Drugs (2002) 3(11):1574-9), and Human Immune deficiency Virus (HIV) infection contribute to cancer development as a consequence of immunodeficiency (see, e.g., Dal Maso et al., Lancet Oncol (2003) 4(2):110-9).
    • 4.17.1.1 Prophylactic Methods
  • The Tetracyclic Benzamide Derivatives of the Invention can also be administered to prevent the progression of a cancer, including but not limited to the cancers listed in Table 1. Such prophylactic use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-79). Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. For example, endometrial hyperplasia often precedes endometrial cancer and precancerous colon polyps often transform into cancerous lesions. Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in epithelial or connective tissue cells. A typical metaplasia involves a somewhat disorderly metaplastic epithelium. Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder.
  • Alternatively or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed in vivo or displayed in vitro by a cell sample from a patient, can indicate the desirability of prophylactic/therapeutic administration of the composition of the invention. Such characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also id., at pp. 84-90 for characteristics associated with a transformed or malignant phenotype).
  • In a specific embodiment, leukoplakia, a benign-appearing hyperplastic or dysplastic lesion of the epithelium, or Bowen's disease, a carcinoma in situ, are pre-neoplastic lesions indicative of the desirability of prophylactic intervention.
  • In another embodiment, fibrocystic disease (cystic hyperplasia, mammary dysplasia, particularly adenosis (benign epithelial hyperplasia)) is indicative of the desirability of prophylactic intervention.
  • In other embodiments, a patient which exhibits one or more of the following predisposing factors for malignancy can be treated by administration of an amount of a Tetracyclic Benzamide Derivative which is effective to treat or prevent cancer: a chromosomal translocation associated with a malignancy (e.g., the Philadelphia chromosome for chronic myelogenous leukemia, t(14;18) for follicular lymphoma, etc.), familial polyposis or Gardner's syndrome (possible forerunners of colon cancer), benign monoclonal gammopathy (a possible forerunner of multiple myeloma), a first degree kinship with persons having a cancer or precancerous disease showing a Mendelian (genetic) inheritance pattern (e.g., familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, medullary thyroid carcinoma with amyloid production and pheochromocytoma, Peutz-Jeghers syndrome, neurofibromatosis of Von Recklinghausen, retinoblastoma, carotid body tumor, cutaneous melanocarcinoma, intraocular melanocarcinoma, xeroderma pigmnentosum, ataxia telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi's aplastic anemia, and Bloom's syndrome; see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 112-113) etc.), and exposure to carcinogens (e.g., smoking, and inhalation of or contacting with certain chemicals).
  • In another specific embodiment, the Tetracyclic Benzamide Derivatives are administered to a human patient to prevent progression to breast, colon, ovarian, or cervical cancer.
    • 4.17.2 Therapeutic/Prophylactic Administration and Compositions of the Invention
  • Due to their activity, the Tetracyclic Benzamide Derivatives are advantageously useful in veterinary and human medicine. As described above, the Tetracyclic Benzamide Derivatives are useful for treating or preventing a Condition in a subject in need thereof.
  • When administered to a subject, the Tetracyclic Benzamide Derivatives can be administered as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle. The present compositions, which comprise a Tetracyclic Benzamide Derivative, can be administered orally. The Tetracyclic Benzamide Derivatives of the invention can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral, rectal, and intestinal mucosa, etc.) and can be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be administered.
  • Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin. In some instances, administration will result in the release of the Tetracyclic Benzamide Derivatives into the bloodstream. The mode of administration is left to the discretion of the practitioner.
  • In one embodiment, the Tetracyclic Benzamide Derivatives are administered orally.
  • In other embodiments, it can be desirable to administer the Tetracyclic Benzamide Derivatives locally. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
  • In certain embodiments, it can be desirable to introduce the Tetracyclic Benzamide Derivatives into the central nervous system or gastrointestinal tract by any suitable route, including intraventricular, intrathecal, and epidural injection, and enema. Intraventricular injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler of nebulizer, and Formulation with an aerosolizing agent, or via perfusion in a fluorocarbon oar, synthetic pulmonary surfactant. In certain embodiments, the Tetracyclic Benzamide Derivatives can be Formulated as a suppository, with traditional binders and excipients such as triglycerides.
  • In another embodiment the Tetracyclic Benzamide Derivatives can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990) and Treat or prevent et al., Liposomes in the Therapy of Infectious Disease and Cancer 317-327 and 353-365 (1989)).
  • In yet another embodiment the Tetracyclic Benzamide Derivatives can be delivered in a controlled-release system or sustained-release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled or sustained-release systems discussed in the review by Langer, Science 249:1527-1533 (1990) can be used. In one embodiment a pump can be used (Langer, Science 249:1527-1533 (1990); Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); and Saudek et al., N. Engl. J Med. 321:574 (1989)). In another embodiment polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 2:61 (1983); Levy et al., Science 228:190 (1935); During et al., Ann. Neural. 25:351 (1989); and Howard et al., J. Neurosurg. 71:105 (1989)).
  • In yet another embodiment, a controlled- or sustained-release system can be placed in proximity of a target of the Tetracyclic Benzamide Derivatives, e.g., the spinal column, brain, skin, lung, or gastrointestinal tract, thus requiring only a fraction of the systemic dose.
  • The present compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the animal.
  • Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia; gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a particularly useful excipient when the Tetracyclic Benzamide Derivative is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills; pellets, capsules, capsules containing liquids, powders, sustained-release Formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment the composition is in the form of a capsule (see e.g. U.S. Pat. No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference.
  • In one embodiment the Tetracyclic Benzamide Derivatives are Formulated in accordance with routine procedures as a composition adapted for oral administration to human beings. Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example. Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving a Tetracyclic Benzamide Derivativere also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release Formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be used. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment the excipients are of pharmaceutical grade.
  • In another embodiment the Tetracyclic Benzamide Derivatives can be Formulated for intravenous administration. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaien to lessen pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized-powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the Tetracyclic Benzamide Derivatives are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the Tetracyclic Benzamide Derivatives are administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
  • The Tetracyclic Benzamide Derivatives can be administered by controlled-release or sustained-release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but arc not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354;556; and 5,733,556, each of which is incorporated herein by reference. Such dosage forms can be used to provide controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release Formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.
  • Controlled- or sustained-release pharmaceutical compositions can have a common goal of improving drug therapy over that achieved by their non-controlled or non-sustained counterparts. In one embodiment a controlled- or sustained-release composition comprises a minimal amount of a Tetracyclic Benzamide Derivative to cure or control the condition in a minimum amount of time. Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled- or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the Tetracyclic Benzamide Derivative, and can thus reduce the occurrence of adverse side effects.
  • Controlled- or sustained-release compositions can initially release an amount of a Tetracyclic Benzamide Derivative that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the Tetracyclic Benzamide Derivative to maintain this level of therapeutic or prophylactic effect over an extended period of time. To maintain a constant level of the Tetracyclic Benzamide Derivative in the body, the Tetracyclic Benzamide Derivative can be released from the dosage form at a rate that will replace the amount of Tetracyclic Benzamide Derivative being metabolized and excreted from the body. Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.
  • The amount of the Tetracyclic Benzamide Derivative that is effective in the treatment or prevention of a Condition can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, and the seriousness of the condition being treated and should be decided according to the judgment of the practitioner and each patient's circumstances in view of, e.g., published clinical studies. Effective dosage amounts of the present invention, when used for the indicated effects, range from about 0.05 to about 1000 mg of Tetracyclic Benzamide Derivative per day. Compositions for in vivo or in vitro use can contain about 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0, 250.0, 500.0 or 1000.0 mg of Tetracyclic Benzamide Derivative. In one embodiment, the compositions are in the form of a tablet that can be scored. Effective plasma levels of the Tetracyclic Benzamide Derivatives can range from about 0.002 mg to about 50 mg per kg of body weight per day.
  • Tetracyclic Benzamide Derivatives can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, Tetracyclic Benzamide Derivatives can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration can be continuous rather than intermittent throughout the dosage regimen. Other illustrative topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of Tetracyclic Benzamide Derivative ranges from about 0.1% to about 15%, w/w or w/v.
  • The Tetracyclic Benzamide Derivatives can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy.
  • The present methods for treating or preventing a Condition in a subject in need thereof can further comprise administering another therapeutic agent to the subject being administered a Tetracyclic Benzamide Derivative. In one embodiment the other therapeutic agent is administered in an effective amount.
  • Effective amounts of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective amount range. In one embodiment of the invention, where, another therapeutic agent is administered to a subject, the effective amount of the Tetracyclic Benzamide Derivative is less than its effective amount would be where the other therapeutic agent is not administered. In this case, without being bound by theory, it is believed that the Tetracyclic Benzamide Derivatives and the other therapeutic agent act synergistically to treat or prevent a Condition.
  • In one embodiment the other therapeutics agent is an anti-inflammatory agent. Anti-inflammatory agents include but are not limited to adrenocorticosteroids, such as cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6a-methylprednisolone, triamcinolone, betamethasone, and dexamethasone; and non-steroidal anti-inflammatory agents (NSAIDs), such as aspirin, acetaminophen, indomethacin, sulindac, tolmetin, diclofenac, ketorolac, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin, mefenamic acid, meclofenamic acid, piroxicam, meloxicam, nabumetone, rofecoxib, celecoxib, etodolac, and nimesulide.
  • In one embodiment the other therapeutice agent is an anti-renal failure agent. Anti-renal failure agents include but are not limited to ACE (angiotensin-converting enzyme) inhibitors, such as captopril, enalaprilat, lisinopril, benazepril, fosinopril, trandolapril, quinapril, and ramipril; diuretics, such as mannitol, glycerin, furosemide, toresemide, tripamide, chlorothiazide, methyclothiazide, indapamide, amiloride, and spironolactone; and fibric acid agents, such as clofibrate, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate.
  • In one embodiment the other therapeutice agent is an anti-diabetic agent. Anti-diabetic agents include but are not limited to glucagons; somatostatin; diazoxide; sulfonylureas, such as tolbutamide, acetohexamide, tolazamide, chloropropamide, glybenclamide, glipizide, gliclazide, and glimepiride; insulin secretagogues, such as repaglinide, and nateglinide; biguanides, such as metformin and phenformin; thiazolidinediones, such as pioglitazone, rosiglitazone, and troglitazone; and α-glucosidase inhibitors, such as acarbose and miglitol.
  • In one embodiment the other therapeutic agent is an anti-cardiovascular disease agent. Anti-cardiovascular disease agents include but are not limited to carnitine; thiamine; and muscarinic receptor antagonists, such as atropine, scopolamine, homatropine, tropicamide, pirenzipine, ipratropium, tiotropium, and tolterodine.
  • The other therapeutic agent can also be an agent useful for reducing any potential side effects of a Tetracyclic Benzamide Derivatives. For example, the other therapeutic agent can be an antiemetic agent. Examples of useful antiemetic agents include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, and mixtures thereof.
  • The present methods for the treatment or prevention of cancer can further comprise administering another anticancer agent. In one embodiment, the methods comprise the sequential administration of a Tetracyclic Benzamide Derivative and another anticancer agent. In another embodiment, the methods comprise the administration of a composition comprising a pharmaceutically acceptable carrier, a Tetracyclic Benzamide Derivative, and another anticancer agent.
  • The Tetracyclic Benzamide Derivative and the other anticancer agent can act additively or synergistically. A synergistic use of a Tetracyclic Benzamide Derivative and another anticancer agent permits the use of lower dosages of one or more of these agents and/or less frequent administration of said agents to a subject with cancer. The ability to utilize lower dosages of a Tetracyclic Benzamide Derivative and/or additional anticancer agents and/or to administer said agents less frequently can reduce the toxicity associated with the administration of said agents to a subject without reducing the efficacy of said agents in the treatment of cancer. In addition, a synergistic effect can result in the improved efficacy of these agents in the treatment of cancer and/or the reduction of adverse or unwanted side effects associated with the use of either agent alone.
  • In one embodiment, the Tetracyclic Benzamide Derivative and the anticancer agent can act synergistically when administered in doses typically employed when such agents are used as monotherapy for the treatment of cancer. In another embodiment, the Tetracyclic Benzamide Derivative and the anticancer agent can act synergistically when administered in doses that are less than doses typically employed when such agents are used as monotherapy for the treatment of cancer.
  • Suitable additional anticancer agents useful in the methods and compositions of the present invention include, but are not limited to, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, taxanes such as docetaxel and paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, nitrosoureas such as carmustine and lomustine, vinca alkaloids such as vinblastine, vincristine and vinorelbine, platinum complexes such as cisplatin, carboplatin and oxaliplatin, imatinib mesylate, hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins herbimycin A, genistein, erbstatin, and lavendustin A.
  • In one embodiment, the additional anticancer agent can be, but is not limited to, a drug listed in Table 2.
    TABLE 2
    Alkylating agents
    Nitrogen mustards: Cyclophosphamide
    Ifosfamide
    Trofosfamide
    Chlorambucil
    Nitrosoureas: Carmustine (BCNU)
    Lomustine (CCNU)
    Alkylsulphonates: Busulfan
    Treosulfan
    Triazenes: Dacarbazine
    Platinum containing complexes: Cisplatin
    Carboplatin
    Aroplatin
    Oxaliplatin
    Plant Alkaloids
    Vinca alkaloids: Vincristine
    Vinbiastine
    Vindesine
    Vinorelbine
    Taxoids: Paclitaxel
    Docetaxel
    DNA Topoisomerase Inhibitors
    Epipodophyllins: Etoposide
    Teniposide
    Topotecan
    9-aminocamptothecin
    Camptothecin
    Crisnatol
    Mitomycins: Mitomycin C
    Anti-metabolites
    Anti-folates:
    DHFR inhibitors: Methotrexate
    Trimetrexate
    IMP dehydrogenase Inhibitors: Mycophenolic acid
    Tiazofurin
    Ribavirin
    EICAR
    Ribonuclotide reductase Hydroxyurea
    Inhibitors: Deferoxamine
    Pyrimidine analogs:
    Uracil analogs: 5-Fluorouracil
    Fluoxuridine
    Doxifluridine
    Ralitrexed
    Cytosine analogs: Cytarabine (ara C)
    Cytosine arabinoside
    Fludarabine
    Gemcitabine
    Capecitabine
    Purine analogs: Mercaptopurine
    Thioguanine
    DNA Antimetabolites: 3-HP
    2′-deoxy-5-fluorouridine
    5-HP
    alpha-TGDR
    aphidicolin glycinate
    ara-C
    5-aza-2′-deoxycytidine
    beta-TGDR
    cyclocytidine
    guanazole
    inosine glycodialdehyde
    macebecin II
    Pyrazoloimidazole
    Hormonal therapies:
    Receptor antagonists:
    Anti-estrogen: Tamoxifen
    Raloxifene
    Megestrol
    LHRH agonists: Goscrelin
    Leuprolide acetate
    Anti-androgens: Flutamide
    Bicalutamide
    Retinoids/Deltoids
    Cis-retinoic acid
    Vitamin A derivative: All-trans retinoic acid (ATRA-IV)
    Vitamin D3 analogs: EB 1089
    CB 1093
    KH 1060
    Photodynamic therapies: Vertoporfin (BPD-MA)
    Phthalocyanine
    Photosensitizer Pc4
    Demethoxy-hypocrellin A
    (2BA-2-DMHA)
    Cytokines: Interferon-α
    Interferon-β
    Interferon-γ
    Tumor necrosis factor
    Angiogenesis Inhibitors: Angiostatin (plasminogen
    fragment)
    antiangiogenic antithrombin III
    Angiozyme
    ABT-627
    Bay 12-9566
    Benefin
    Bevacizumab
    BMS-275291
    cartilage-derived inhibitor (CDI)
    CAI
    CD59 complement fragment
    CEP-7055
    Col 3
    Combretastatin A-4
    Endostatin (collagen XVIII
    fragment)
    Fibronectin fragment
    Gro-beta
    Halofuginone
    Heparinases
    Heparin hexasaccharide fragment
    HMV833
    Human chorionic gonadotropin
    (hCG)
    IM-862
    Interferon alpha/beta/gamma
    Interferon inducible protein (IP-
    10)
    Interleukin-12
    Kringle 5 (plasminogen fragment)
    Marimastat
    Metalloproteinase inhibitors
    (TIMPs)
    2-Methoxyestradiol
    MMI 270 (CGS 27023A)
    MoAb IMC-1C11
    Neovastat
    NM-3
    Panzem
    PI-88
    Placental ribonuclease inhibitor
    Plasminogen activator inhibitor
    Platelet factor-4 (PF4)
    Prinomastat
    Prolactin 16 kD fragment
    Proliferin-related protein (PRP)
    PTK 787/ZK 222594
    Retinoids
    Solimastat
    Squalamine
    SS 3304
    SU 5416
    SU6668
    SU11248
    Tetrahydrocortisol-S
    Tetrathiomolybdate
    Thalidomide
    Thrombospondin-1 (TSP-1)
    TNP-470
    Transforming growth factor-beta
    (TGF-b)
    Vasculostatin
    Vasostatin (calreticulin fragment)
    ZD6126
    ZD 6474
    farnesyl transferase inhibitors
    (FTI)
    Bisphosphonates
    Antimitotic agents: Allocolchicine
    Halichondrin B
    Colchicine
    colchicine derivative
    dolstatin 10
    Maytansine
    Rhizoxin
    Thiocolchicine
    trityl cysteine
    Others:
    Isoprenylation inhibitors:
    Dopaminergic neurotoxins: 1-methyl-4-phenylpyridinium ion
    Cell cycle inhibitors: Staurosporine
    Actinomycins: Actinomycin D
    Dactinomycin
    Bleomycins: Bleomycin A2
    Bleomycin B2
    Peplomycin
    Anthracyclines: Daunorubicin
    Doxorubicin (adriamycin)
    Idarubicin
    Epirubicin
    Pirarubicin
    Zorubicin
    Mitoxantrone
    MDR inhibitors: Verapamil
    Ca2+ATPase inhibitors: Thapsigargin
  • Other additional anticancer agents that can be used in the compositions and methods of the present invention include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2α; interferon alfa-2β; interferon alfa-n1; interferon alfa-n3; interferon beta-Iα; interferon gamma-Iβ; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.
  • Further anticancer drugs that can be used in the methods and compositions of the invention include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-acytidine; dihydrotaxol; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum complexes; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agents; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum complexes; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
    • 4.17.1.3 Multi-Modality Therapy for Cancer
  • The Tetracyclic Benzamide Derivatives can be administered to a subject that has undergone or is currently undergoing one or more additional anticancer treatment modalities including, but not limited to, surgery, radiation therapy, or immunotherapy, such as cancer vaccines.
  • In one embodiment, the invention provides methods for treating cancer comprising (a) administering to a subject in need thereof an amount of a Tetracyclic Benzamide Derivative effective to treat or prevent cancer; and (b) administering to said subject one or more additional anticancer treatment modalities including, but not limited to, surgery, radiation therapy, or immunotherapy, such as a cancer vaccine.
  • In one embodiment, the additional anticancer treatment modality is radiation therapy.
  • In another embodiment, the additional anticancer treatment modality is surgery.
  • In still another embodiment, the additional anticancer treatment modality is immunotherapy.
  • In a specific embodiment, the Tetracyclic Benzamide Derivatives are administered concurrently with radiation therapy. In another specific embodiment, the additional anticancer treatment modality is administered prior or subsequent to the Tetracyclic Benzamide Derivative, preferably at least an hour, five hours, 12 hours, a day, a week, a month, more preferably several months (e.g., up to three months), prior or subsequent to administration of the Tetracyclic Benzamide Derivatives.
  • When the additional anticancer treatment modality is radiation therapy, any radiation therapy protocol can be used depending upon the type of cancer to be treated. For example, but not by way of limitation, X-ray radiation can be administered; in particular, high-energy megavoltage (radiation of greater that 1 MeV energy) can be used for deep tumors, and electron beam and orthovoltage X-ray radiation can be used for skin cancers. Gamma-ray emitting radioisotopes, such as radioactive isotopes of radium, cobalt and other elements, can also be administered.
  • Additionally, the invention provides methods of treatment of cancer using the Tetracyclic Benzamide Derivatives as an alternative to chemotherapy or radiation therapy where the chemotherapy or the radiation therapy results in negative side effects, in the subject being treated. The subject being treated can, optionally, be treated with another anticancer treatment modality such as surgery, radiation therapy, or immunotherapy, depending on which treatment is found to be acceptable or bearable.
  • The Tetracyclic Benzamide Derivatives can also be used in an in vitro or ex vivo fashion, such as for the treatment of certain cancers, including, but not limited to leukemias and lymphomas, such treatment involving autologous stem cell transplants. This can involve a multi-step process in which the animal's autologous hematopoietic stem cells are harvested and purged of all cancer cells, the patient's remaining bone-marrow cell population is then eradicated via the administration of high doses of the Tetracyclic Benzamide Derivatives and/or high dose radiation therapy, and the stem cell graft is infused back into the animal. Supportive care is then provided while bone marrow function is restored and the subject recovers.
  • A Tetracyclic Benzamide Derivative and the other therapeutic agent can act additively or, in one embodiment synergistically. In one embodiment a Tetracyclic Benzamide Derivative is administered concurrently with another therapeutic agent. In one embodiment a composition comprising an effective amount of a Tetracyclic Benzamide Derivative and an effective amount of another therapeutic agent can be administered. Alternatively, a composition comprising an effective amount of a Tetracyclic Benzamide Derivative and a different composition comprising an effective amount of another therapeutic agent can be concurrently administered. In another embodiment an, effective amount of a Tetracyclic Benzamide Derivative is administered prior or subsequent to administration of an effective amount of another therapeutic agent. In this embodiment the Tetracyclic Benzamide Derivative is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the Tetracyclic Benzamide Derivative exerts its preventative or therapeutic effect for treating or preventing a Condition.
  • A composition of the invention is prepared by a method comprising admixing a Tetracyclic Benzamide Derivative or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or vehicle. Admixing can be accomplished using methods well known for admixing a compound (or salt) and a pharmaceutically acceptable carrier or vehicle. In one embodiment the Tetracyclic Benzamide Derivative or the pharmaceutically acceptable salt of the Compound is present in the composition in an effective amount.
    • 4.17.3 Kits
  • The invention encompasses kits that can simplify the administration of a Tetracyclic Benzamide Derivative to a subject.
  • A typical kit of the invention comprises a unit dosage form of a Tetracyclic Benzamide Derivative. In one embodiment the unit dosage form is a container, which can be sterile, containing an effective amount of a Tetracyclic Benzamide Derivative and a pharmaceutically acceptable carrier or vehicle. The kit can further comprise a label or printed instructions instructing the use of the Tetracyclic Benzamide Derivative to treat or prevent a Condition. The kit can also further comprise a unit dosage form of another therapeutic agent, for example, a container containing an effective amount of the other therapeutic agent. In one embodiment the kit comprises a container containing an effective amount of a Tetracyclic Benzamide Derivative and an effective amount of another therapeutic agent. Examples of other therapeutic agents include, but are not limited to, those listed above.
  • Kits of the invention can further comprise a device that is useful for administering the unit dosage forms. Examples of such a device includes, but are not limited to, a syringe, a drip bag, a patch, an inhaler, and an enema bag.
  • The following examples are set forth to assist in understanding the invention and should not, of course, be construed as specifically limiting the invention described and claimed herein. Such variations of the invention, including the substitution of all equivalents now known or later developed, which would be within the purview of those skilled in the art, and changes in Formulation or minor changes in experimental design, are to be considered to fall within the scope of the invention incorporated herein.
    • 5. EXAMPLES 5.1.1 Example 1 Preparation of Illustrative Tetracyclic Benzamide Derivatives 5.1.2 General Methods
  • Proton NMR spectra were obtained using a Varian 300 MHz spectrophotometer and chemical shift values (δ) are reported in parts per million (ppm). TLC was performed using TLC plates precoated with silica gel 60 F-254, and preparative TLC was performed using precoated Whatman 60A TLC plates. All intermediates and final compounds were characterized on the basis of 1H NMR and MS data.
    • a) Preparation of 4-Phenyl-3-isocoumarincarboxylic acid (3a)
  • Following the procedure described in Natsugary et al., J Med. Chem. 38, 3106-3120 (1995), compound 3a (Scheme 1) was synthesized. A suspension of 1a (33.9 g, 0.15 mol) (Scheme 1), potassium carbonate (41.4 g, 0.3 mol) and diethyl bromomalonate (28.17 mL, 0.165 mol) in DMF (250 mL) was stirred at room temperature for 15 h. The reaction mixture was then diluted using cold water and extracted into ethyl acetate. The ethyl acetate layer was dried over sodium sulfate, and concentrated in vacuo to afford a crude residue to which was added glacial acetic acid (1.0 L) and concentrated HCl (800 mL). The resulting solution was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and poured on ice water. The solid precipitate was filtered, washed with water and dried using vacuum to provide compound 3a as a white solid. Yield=32.6 g (84%).
    • b) Preparation of 4-Phenyl-3-isoquinolinonecarboxylic acid (4a) (Scheme 1)
  • A stirred suspension of 3a (1.4 g, 0.0052 mol) in ammonia-methanol (7 N, 125 mL) was heated at reflux for 23 h, then cooled to room temperature. The reaction mixture was concentrated in vacuo, and the residue obtained was acidified with 10% aqueous HCI. The resulting solid was filtered, washed with water and dried under vacuum to provide compound 4a. Yield=1.225 g (89%).
    • c) Preparation of 6H,7-oxoindeno[2,1-c]isoquinolinone (5a) (Scheme 1) Using PPA
  • To a stirred suspension of compound 4a (0.225 g, 0.85 mmol) in xylenes (20 mL) was added polyphosphoric acid (0.600 g). The resulting reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and concentrated in vacuo to provide a crude residue, which was poured on ice. The resulting solid was filtered, washed with water, and dried under vacuum to provide compound 5a. Yield=155 mg (74%).
    • Using Chlorosulfonic Acid
  • Similarly, compound 4a (500 mg, 0.0019 mol) was suspended up in chlorosulfonic acid (2.5 mL) at 0° C. for 5 min, and the reaction mixture was stirred at room temperature for 5 min. After the reaction mixture became homogeneous, it was slowly poured on ice. The resultant red-colored solid precipitate was filtered, washed with water, and dried to provide compound 5a. Yield=395 mg (85%).
    • d) Reduction of (5a) to 6H,7H-Hydroxyindeno[2,1-c]isoquinolin-5-one (6a) (Compounds of Formula IIa) (Scheme 1)
  • To a stirred suspension of 5a (1.0 g, 4.0 mmol) in methanol (25 mL) was slowly added solid sodium borohydride (385 mg) at room temperature. The resulting reaction mixture was stirred for 15 min. The reaction mixture was then poured on an ice-cold 1 N HCl solution, and the resulting solid was filtered, washed with water, and dried under vacuum to provide compound 6a (Formula IIa). Yield=0.940 g (93%).
    • e) Preparation of 5-Oxo-5,7-dihydro-6H-indeno[2,1-c]isoquinoline-9-sulfonyl chloride (10a) (Scheme 1)
  • Compound 9a (210 mg, 0.9 mmol) was slowly added to a solution of chlorosulphonic acid (2.0 mL) at 0° C. for 5 min, and at room temperature for 5 min. After the reaction mixture became homogeneous, it was slowly poured on ice. The solid that precipitated was filtered, washed with water, and dried to provide compound 10a (180 mg, 60%).
    • f) 5-Oxo-5,7-dihydro-6H-indeno[2,1-c]isoquinoline-9-sulfonic acid (3-morpholin-4-yl-propyl)-amide (11a) (Scheme 1)
  • A suspension of 10a (110 mg, 0.33 mmol) in methylene chloride (10 mL) was treated with 4-(3-morpholino)-1-propylamine (240 mg, 1.66 mmol) and triethylamine (1 eq), and the reaction mixture was stirred at room temperature for 1 h. The resulting mixture was diluted with ethyl acetate, and the solid that precipitated was filtered, washed with ether and dried to provide compound 11a. Yield=65 mg (45%).
    • g) Preparation of 2-(bromo-methoxycarbonyl-methyl)-benzoic acid methyl ester (α-Bromodimethylhomophthalate) (13a) (Scheme 2)
  • Dimethylhomophthalate (83.1 g, Aldrich Chemical Co.) was dissolved in dichloromethane (2 L), and N-bromosuccinimide (121 g, 1.7 eq) was added. The resulting suspension was irradiated for 18 h with a 500 wt quartz-halogen lamp, which brought the reaction mixture to reflux. The reaction mixture was then washed sequentially with saturated aqueous sodium bicarbonate (4 L), saturated aqueous sodium bisulfite (2 L), and saturated aqueous sodium chloride (2 L). The organic phase was dried using sodium sulfate with a small amount of silica added to remove polar impurities. The organic phase was filtered and concentrated in vacuo to provide compound 13a (Scheme 2) as a dark orange oil. Yield=120.3 g (100%).
    • h) Preparation of 8-Methoxy-6H-11-oxa-6-aza-benzo[a]fluoren-5-one (15a) (Scheme 2)
  • A mixture of α-Bromodimethylhomophthalate (13a) (1.16 g) and 2-hydroxy-5-methoxy-benzonitrile (14b), 0.6 g, 4 mmol, 1.0 eq) was dissolved by warming in acetonitrile (6 mL). Triethylamine (5.6 mL, 10 eq) was then added. The reaction mixture was heated at reflux for 48 h under inert atmosphere, then cooled to room temperature. The reaction mixture was diluted with saturated sodium bicarbonate (40 mL), and the resulting suspension was allowed to stir for 2 h, and was then filtered. The resulting filtercake was washed sequentially with 1 N HCl (2×50 mL), acetonitrile (2×50 mL) and dichloromethane (50 mL), then dried in a vacuum oven at 50° C. fot three days to provide compound 15a as an white solid. Yield=0.81 mg (76%).
    • i) Preparation of 8-Hydroxy-6H-11-oxa-6-aza-benzo [a]lfluoren-5-one (15b) (Scheme 2)
  • 8-Methoxy-6H-11-oxa-6-aza-benzo[a]fluoren-5-one (15a) (5.0 g) was cooled using an ice bath, and boron tribromide (1 M in methylene chloride, 95 mL, 95 mmol, 5 eq) was added in a steady stream under nitrogen. The reaction was heated at reflux under inert atmosphere for 2 h, then cooled to room temperature and poured into water (150 mL). The resulting suspension was allowed to stir for 1 h, filtered, and the solids were washed with water (2×200 mL). The solids were then suspended in of 5 N sodium hydroxide (600 mL), then using heating. The resulting solution was cooled to 0° C. using an ice bath and the solution acidified to pH 1 using con c. HCl. The resulting precipitate was vacuum filtered, and the solids were washed sequentially with water (3×300 mL), and diethyl ether (300 mL), then dried overnight using a vacuum oven at 50° C. to provide compound 15b as a gray solid. Yield=4.74 g (100%).
    • j) Preparation of 6H-11-oxa-6-aza-benzo[a]fluoren-5-one (15c)
  • Using the method of Example h and substituting 14b with 2-hydroxy-benzonitrile (14a), compound 15c was prepared.
    • k) Preparation of 9-Methoxy-6H-11-oxa-6-aza-benzo[a]fluoren-5-one (15d)
  • Using the method of Example h and substituting 14b with 2-hydroxy-4-methoxy-benzonitrile (14c), compound 15d was prepared.
    • l) Preparation of 9-Hydroxy-6H-11-oxa-6-aza-benzo[a]fluoren-5-one (15e)
  • Using the method of Example i and substituting compound 15a with compound 15d, compound 15e was prepared.
    • m) Preparation of Compound 16a (Scheme 2)
  • To a solution of compound 15b (0.755 mmol) in acetone (4 mL) was added 2-bromoacetic acid (2.1 eq) and potassium carbonate (1.04 g, 10 eq). The resultant mixture was heated at reflux for 15 h under nitrogen atmosphere. The reaction mixture was poured into 20 mL of 1 N aqueous sodium hydroxide, stirred 0.5 h, and filtered. The solids were washed twice with 10 mL volumes of water, then stirred for 1 h in 20 mL of 1 N aqueous hydrochloric acid. The solids were vacuum filtered, washed twice with 10 mL of water, twice with 10 mL of ether, and dried in vacuo to provide compound 16a in 75% yield.
    • n) Preparation of Compound 16b
  • Using the method of Example m and substituting 2-bromoacetic acid with 3-bromo-1-propanol, compound 16b was prepared from compound 15b.
    • o) Preparation of Compound 16c
  • Using the method of Example m and substituting 2-bromoacetic acid with 5-bromo-1-pentanol, compound 16c was prepared from compound 15b.
    • p) Preparation of Compound 16d
  • Using the method of Example m and substituting 2-bromoacetic acid with 6-bromo-1-hexanol, compound 16d was prepared from compound 15b.
    • q) Preparation of Compound 16e
  • Using the method of Example m and substituting 2-bromoacetic acid with 5-bromo-1-pentanoic acid, compound 16e was prepared from compound 15b.
    • r) Preparation of Compound 16f
  • To a solution of compound 15c (0.755 mmol) in acetone (4 mL) was added iodomethane (52 μL, 1.1 eq) and potassium carbonate (1.04 g, 10 eq). The resultant mixture was heated at reflux for 15 h under nitrogen atmosphere. The reaction mixture was poured into 20 mL of 1 N aqueous sodium hydroxide, stirred 0.5 h, and filtered. The resultant solids were washed twice with 10 mL of water, then stirred for 1 h in 20 mL of 1 N aqueous hydrochloric acid. The resultant solids were vacuum filtered, washed twice with 10 mL of water, twice with 10 mL of ether, and dried in vacuo to provide 165 mg (78%) of compound 16f.
    • s) Preparation of Acetic acid 11-oxa-6-aza-benzo[a]fluoren-5-yl ester (16g)
  • To a solution of compound 15c (500 mg, 2.13 mmol) in pyridine (10 mL) was added acetic anhydride (4 mL). The resultant mixture was heated at 100° C. for 9 h, then cooled slowly to room temperature overnight. The solvent was removed on the rotary evaporator and the residual oil was extracted into 50 mL ethyl acetate. The organic layer was washed with 50 mL of 1 N aqueous hydrochloric acid, dried (sodium sulfate), and the solvent removed in vacuo to provide 308 mg (52% yield) of compound 16g as a white powder.
    • t) Preparation of 1-(11-Oxa-6-aza-benzo[a]fluoren-5-yloxy)-β-D-glucuronic acid (16h)
  • Figure US20070249653A1-20071025-C00060
    • Preparation of Methyl Ester Intermediate
  • 6H-11-Oxa-6-aza benzo[a]fluoren-5-one (15c) (500 mg, 2.13 mmol) (Scheme 2), silver carbonate (2.35 g, 4 eq), 4 angstrom molecular sieves (1.8 g), and 100 mL toluene were combined in a 500 mL 3-neck flask equipped with a dean-stark trap, a condenser, and an addition funnel. The mixture was brought to reflux under nitrogen atmosphere, and 30 mL of distillate were collected over 1 h. The addition funnel was charged with acetobromo-α-D-glucuronic acid methyl ester (930 mg, 1.1 eq) dissolved in 25 mL toluene, and this solution was added dropwise over 0.5 h to the refluxing reaction mixture. The reaction mixture was heated at reflux for another 6 h, then slowly cooled to room temperature overnight. The resulting suspension was vacuum filtered to remove solids, and the filter cake was washed three times with 100 mL of ethyl acetate. The filtrate was concentrated to an oil on the rotary evaporator. The oil was loaded directly on a column of 30 g silica and purified by flash chromatography, eluting with 19:1 dichloromethane: ethyl acetate to provide of the intermediate compound 1-(11-Oxa-6-aza-benzo[α]fluoren-5-yloxy)2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester as a white powder.
    • Ester Hydrolysis to Provide Compound 16h
  • 1-(11-Oxa-6-aza-benzo[α]fluoren-5-yloxy)-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (779 mg, 1.81 mmol) was dissolved in 30 mL acetone, and 8 mL of 1 N aqueous sodium hydroxide followed by 12 mL water were added dropwise. The resultant mixture was stirred for 0.5 h, over which time a precipitate formed. The reaction mixture was titrated to pH 5 with 1 N aqueous hydrochloric acid and vacuum filtered. The resultant solids were washed with 30 mL of acetone and dried in vacuo to give 288 mg (50%) of compound 16h as a white powder.
    • u) 5,9-Dimethoxy-11-oxa-6-aza-benzo[α]fluorine (16i)
  • 9-Methoxy-6H-11-oxa-6-aza-benzo[α]fluorine-5-one (200 mg, 0.755 mmol) was suspended in 4 mL acetone and to the suspension were added. Methyl iodide (52 μL, 1.1 eq) and potassium carbonate (1.04 g, 10 eq). The mixture was allowed to reflux overnight under nitrogen atmosphere. Additional methyl iodide (25 μL, 0.5 eq) and acetone (4 mL) were added and the reaction refluxed overnight under nitrogen. The reaction mixture was poured into 20 mL of 1 N aqueous sodium hydroxide, stirred 0.5 h, and filtered. The resultant solids were washed twice with 10 mL of water, then stirred for 1 h in 20 mL of 1 N aqueous hydrochloric acid. The solids were vacuum filtered, washed twice with 10 mL of water, then twice with 10 mL volumes of ether. The solids were dried in vacuo to give 165 mg (78%) of compound 16i as a white powder.
    • v) Preparation of Compound 16j
  • Using the method of Example m and substituting: 1) 2-bromoacetic acid with 3-bromo-1-propanol, and 2) compound 15b with compound 15c, compound 16j was prepared.
    • w) Preparation of Compound 16k
  • Using the method of Example m and substituting: 1) 2-bromoacetic acid with 6-bromo-1-hexanol, and 2) compound 15b with compound 15c, compound 16k was prepared.
    • x) Preparation of 9-Methyl-6H-11-oxa-6,10-diaza-benzo[a]fluoren-5-one (26a)
  • To a solution of α-bromodimethylhomophthalate (2.00 g, 6.97 mmol) in DMF (15 mL) was added 3-cyano-2-hydroxy-6-methylpyridine (1.03 g, 1.1 eq) and potassium carbonate (4.82 g, 5 eq). The resulting mixture was allowed to stir at 100° C. for 4 h under inert atmosphere. The reaction was cooled to room temperature and concentrated in vacuo. The resulting solid residue was diluted with 1 N aqueous HCl (60 mL) and stirred for 30 min. The resulting suspension was filtered and the solids were washed with water. The aqueous filtrate was extracted with EtOAc (2×50 mL). The collected solids were added to the combined EtOAc extracts, and the resulting solution was dried over sodium sulfate, filtered and concentrated in vacuo to afford a crude residue. The crude residue was recrystallized from toluene at −20° C. over 18 h, vacuum filtered and dried to provide compound 26a as a yellow solid. Yield=500 mg (29%).
    • 5.1.3 Example 2 Effect of Illustrative Tetracyclic Benzamide Derivatives on PARP Activity in Cultured Macrophapes, Using a Whole-Cell Based Assay and a Purified Enzyme Assay
  • Demonstration of illustrative Tetracyclic Benzamide Derivatives' ability to inhibit PARP and prevent peroxynitrite induced cytotoxicity was shown using methods described in Virag et al., Br. J Pharmacol., 1999, 126(3):769-77; and Immunology 1998, 94(3):345-55. RAW mouse macrophages were cultured in DMEM medium with high glucose and supplemented with 10% fetal bovine serum. Cells were used at 80% confluence in 12-well plates. Cells were pretreated with various concentrations (100 nM-1 μM) of a Tetracyclic Benzamide Derivative for 10 min. Peroxynitrite, a prototypical oxidant which induces DNA single strand breakage, was used to induce PARP activation. Peroxynitrite was diluted in phosphate buffered saline (PBS) (pH 11.0) and added to the cells in a bolus of 50 μl. Cells were then incubated for 20 min. Peroxynitrite was decomposed by incubation for 30 min at pH 7.0, used as a control, and failed to influence the parameter studied. After the 20 min incubation, the cells were spun, the medium was aspirated and the cells were resuspended in 0.5 mL assay buffer (56 mM HEPES pH 7.5, 28 mM KC1, 28 mM NaCI, 2 mM MgCl2, 0.01% w/v digitonin and 0.125 μM NAD+ and 0.5 μCi/ml 3H-NAD+). Following an incubation in assay buffer, (10 min at 37° C.), PARP activity was measured as follows: 200 μl ice cold 50% w/v TCA was added and the samples were incubated for 4 h at 4° C. Samples were then spun (10 min @ 10,000 g) and pellets washed twice with ice cold 5% w/v TCA and solubilized overnight in 250 μl 2% w/v SDS/0.1 N NaOH at 37° C. The contents of the tubes were added to 6.5 mL ScintiSafe Plus scintillation liquid (Fisher Scientific) and radioactivity was determined using a liquid scintillation counter (Wallac, Gaithersburg, Md.). The results shown in Table 3 demonstrate that the illustrative Tetracyclic Benzamide Derivatives significantly and dose-dependently inhibit the activation of PARP in the macrophage assay.
    TABLE 3
    Inhibitory effect of various novel substituted Tetracyclic Benzamide
    Derivatives on PARP activation in cultured murine macrophages.
    % PARP % PARP % PARP
    Compound inhibition at inhibition at inhibition at
    No. 1 μM 300 nM 100 nM
     9a 70 56 NT
    11  70  9 NT
    16a 56 64 47
    16b 29 26 25
    16c 68 47 39
    16d NT 38  3
    16e 57 56 33
    16f 56 59 40
    16g 67 66 40
    16h NT 56 32
    26a 61 54 36

    NT—Not Tested
  • The potency of inhibition on purified PARP enzyme was subsequently determined for selected Tetracyclic Benzamide Derivatives, and the potency was compared with that of 3-aminobenzamide, a prototypical benchmark PARP inhibitor. The assay was performed in 96 well ELISA plates according to instructions provided with a commercially available PARP inhibition assay kit (Trevigen, Gaithersburg, Md.). Briefly, wells were coated with 1 mg/mL histone (50 μl/well) at 4° C. overnight. Plates were then washed four times with PBS and then blocked by adding 50 μl Strep-Diluent (supplied with the kit). After incubation (1 h, room temperature), the plates were washed four times with PBS. Appropriate dilutions of PARP inhibitors were combined with 2× PARP cocktail (1.95 mM NAD+, 50 μM biotinylated NAD+ in 50 mM TRIS pH 8.0, 25 mM MgCl2) and high specific activity PARP enzyme (both were supplied with the kit) in a volume of 50 μl. The reaction was allowed to proceed for 30 min at room temperature. After 4 washes in PBS, incorporated biotin was detected by peroxidase-conjugated streptavidin (1:500 dilution) and TACS Sapphire substrate. The assay confirmed the results of the macrophage-based PARP assay. For example, the PARP inhibitor 16a exerted 56% inhibition of PARP activity in this assay at 1 μM, and thus was approximately 56,000 times more potent than the reference compound 3-aminobenzamide at this concentration. These results indicate that compounds 9a, 11, 16a-16h and 26a, illustrative Tetracyclic Benzamide Derivatives, are useful for treating or preventing a Condition.
  • The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
  • A number of references have been cited, the entire disclosures of which have been incorporated herein in their entirety.

Claims (17)

1-27. (canceled)
28. A method for treating an inflammatory disease, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00061
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the inflammatory disease.
29-35. (canceled)
36. A method for treating a reperfusion disease, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00062
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the reperfusion disease.
37-43. (canceled)
44. A method for treating or preventing diabetes, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00063
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat or prevent the diabetes.
45-51. (canceled)
52. A method for treating cancer, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound of having the formula:
Figure US20070249653A1-20071025-C00064
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the cancer.
53-59. (canceled)
60. A method for treating renal failure, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00065
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the renal failure.
61-67. (canceled)
68. A method for treating a vascular disease, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00066
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the vascular disease.
69-75. (canceled)
76. A method for treating an ischemic condition, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00067
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))-, or —CH(NR11R12)— wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the ischemic condition.
77-81. (canceled)
82. A method for treating a diabetic complication, comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt or hydrate of a compound having the formula:
Figure US20070249653A1-20071025-C00068
wherein:
R5 is O, NH or S;
R6 is —H or C1-C4 alkyl;
X is —C(O)—, —CH2—, —CH(halo)-, —(C(OH)((CH2)nCH3))—, —(C(OH)(aryl))- or —CH(NR11R12)—, wherein n is an integer ranging from 0-5;
R11 and R12 are independently -hydrogen or —C1-C9 alkyl, or N, R11 and R12 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle);
R1, R2, R3, R4, R7, R8, R9 and R10 are independently -hydrogen, -halo, -hydroxy, —O—(C1-C5 alkyl), —C1-C10 alkyl, halo-substituted-(C1-C5 alkyl), —C2-C10 alkenyl, —C3-C8-cycloalkyl, -aryl, —NH2, amino-substituted-(C1-C5 alkyl), —C(O)OH, —C(O)O(C1-C5 alkyl), —OC(O)(C1-C5 alkyl), NO2 or -A-B;
A is —SO2—, —SO2NH—, —NHCO—, —NHCONH—, —O—, —CO—, —OC(O)—, —C(O)O—, —CONH—, —CON(C1-C4 alkyl)-, —NH—, —CH2—, —S— or —C(S)—;
B is —C1-C10 alkyl, —C2-C10 alkenyl, -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), -(nitrogen-containing 7- to 10-membered bicyclic heterocycle), -(3- to 7-membered monocyclic heterocycle), -(7- to 10-membered bicyclic heterocycle), —C3-C8 cycloalkyl, -aryl, —NZ1Z2, —(C1-C5 alkylene)-NZ1Z2, amino-substituted-(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), —(C1-C5 alkyl)-(3- to 7-membered monocyclic heterocycle), or —(C1-C5 alkyl)-(7- to 10-membered bicyclic heterocycle), —(H2NC(O))-substituted aryl, —(H2NC(O))-substituted pyridyl, —C(O)OH, —C(O)O—(C1-C5 alkyl), —C(O)O-phenyl or —C(NH)NH2, each of which is unsubstituted or substituted with one or more of —O—(C1-C5 alkyl), -halo, halo-substituted-(C1-C5 alkyl), HO-substituted-(C1-C5 alkyl), amino-substituted-(C1-C5 alkyl), -hydroxy, —NO2, —NH2, —CN, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)(C1-C5 alkyl), -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), 7- to 10-membered bicycloheterocyclic amine, —C1-C10 alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, -aryl, -benzyl, —(H2NC(O))-substituted(C1-C5 alkyl), carboxy-substituted-(C1-C5 alkyl), —C(O)OH, —C1-C5-alkylene-C(O)O—(C1-C5 alkyl) or —C1-C5 alkylene-OC(O)—(C1-C5 alkyl); and
Z1 and Z2 are independently —H or —C1-C10 alkyl, which is unsubstituted or substituted with one or more of -halo, —OH or —N(Z3)(Z4), where Z3 and Z4 are independently, —H or —C1-C5 alkyl, which is unsubstituted or substituted with one or more of -halo, -hydroxy or —NH2; or N, Z3 and Z4 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle) or a -nitrogen-containing 7- to 10-membered bicyclic heterocycle); or N, Z1 and Z2 are taken together to form a -(nitrogen-containing 3- to 7-membered monocyclic heterocycle), or a -(nitrogen-containing 7- to 10-membered bicyclic heterocycle),
in an amount effective to treat the diabetic complication.
83. The method according to claim 52, wherein said method further comprises administering radiation therapy.
US11/786,627 2003-02-28 2007-04-12 Tetracyclic benzamide derivatives and methods of use thereof Abandoned US20070249653A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/786,627 US20070249653A1 (en) 2003-02-28 2007-04-12 Tetracyclic benzamide derivatives and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45092503P 2003-02-28 2003-02-28
US10/788,228 US7217709B2 (en) 2003-02-28 2004-02-26 Tetracyclic benzamide derivatives and methods of use thereof
US11/786,627 US20070249653A1 (en) 2003-02-28 2007-04-12 Tetracyclic benzamide derivatives and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/788,228 Continuation US7217709B2 (en) 2003-02-28 2004-02-26 Tetracyclic benzamide derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
US20070249653A1 true US20070249653A1 (en) 2007-10-25

Family

ID=34102592

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/788,228 Expired - Fee Related US7217709B2 (en) 2003-02-28 2004-02-26 Tetracyclic benzamide derivatives and methods of use thereof
US11/786,627 Abandoned US20070249653A1 (en) 2003-02-28 2007-04-12 Tetracyclic benzamide derivatives and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/788,228 Expired - Fee Related US7217709B2 (en) 2003-02-28 2004-02-26 Tetracyclic benzamide derivatives and methods of use thereof

Country Status (11)

Country Link
US (2) US7217709B2 (en)
EP (1) EP1603567A4 (en)
JP (1) JP2007501857A (en)
KR (1) KR20050118169A (en)
CN (1) CN100398519C (en)
AU (1) AU2004258801A1 (en)
BR (1) BRPI0407757A (en)
CA (1) CA2517260A1 (en)
PL (1) PL378331A1 (en)
RU (1) RU2005130169A (en)
WO (1) WO2005009398A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228007A1 (en) * 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US20100137976A1 (en) * 2008-12-02 2010-06-03 Medtronic Vascular, Inc. Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors
US8686144B2 (en) 2009-07-28 2014-04-01 Commissariat a l'Energie Atomique et aux Energie Alternative Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2
RU2585622C2 (en) * 2009-06-10 2016-05-27 Чугаи Сейяку Кабусики Кайся Tetracyclic compounds
US9714229B2 (en) 2014-04-25 2017-07-25 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
US10344014B2 (en) 2014-08-08 2019-07-09 Chugai Seiyaku Kabushiki Kaisha Amorphous form of tetracyclic compound
US10350214B2 (en) 2014-04-25 2019-07-16 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
US10646468B2 (en) 2010-08-20 2020-05-12 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
US11939322B2 (en) 2018-09-04 2024-03-26 Chugai Seiyaku Kabushiki Kaisha Method for producing tetracyclic compound

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CN100398519C (en) * 2003-02-28 2008-07-02 伊诺泰克制药公司 Tetracyclic benzamide derivatives and methods of use thereof
EP1722796A4 (en) * 2004-02-26 2008-01-23 Inotek Pharmaceuticals Corp Tetracyclic lactam derivatives and uses thereof
CA2571001A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
KR20070116011A (en) * 2005-02-25 2007-12-06 이노텍 파마슈티컬스 코포레이션 Tetracyclic amino and carboxamido compounds and methods of use thereof
JP2008531563A (en) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション Tetracyclic sulfonamide compounds and methods of use thereof
MX2007010335A (en) * 2005-02-25 2007-11-06 Inotek Pharmaceuticals Corp Isoqunoline compounds and methods of use thereof.
WO2007017436A2 (en) * 2005-08-08 2007-02-15 Boehringer Ingelheim International Gmbh Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts
RU2008110955A (en) * 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) INDENOISOCHINOLINONE ANALOGUES AND WAYS OF THEIR APPLICATION
US9399660B2 (en) 2005-11-14 2016-07-26 Purdue Research Foundation N-substituted indenoisoquinolines and syntheses thereof
ES2601525T3 (en) 2005-11-14 2017-02-15 Purdue Research Foundation N-substituted indenoisoquinolines and synthesis thereof
WO2007117289A2 (en) * 2005-12-14 2007-10-18 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
CA2677046A1 (en) * 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
WO2008114114A2 (en) * 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
WO2009041566A1 (en) * 2007-09-26 2009-04-02 Santen Pharmaceutical Co., Ltd. Preventive or remedy for posterior eye diseases containing quinazolinone derivative or quinoxaline derivative as the active ingredient
JP2009096804A (en) * 2007-09-26 2009-05-07 Santen Pharmaceut Co Ltd Prophylactic or therapeutic agent for keratoconjunctival disorder comprising quinazolinone derivative or quinoxaline derivative as active ingredient
US20100261706A1 (en) * 2008-12-08 2010-10-14 Inotek Pharmaceuticals Corporation Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof
ITFI20090005A1 (en) * 2009-01-19 2010-07-20 Alberto Chiarugi PHARMACEUTICAL FORMULATIONS FOR INDUCING IMMUNOSUPPRESSION THROUGH THE INHIBITION OF THE PHENOMENON OF EPITOPE SPREADING AND THEIR USE.
KR101034051B1 (en) * 2009-07-13 2011-05-11 (재)광주테크노파크 Novel isoindolo[2,1-b]isoquinolinone derivatives and anti-cancer agents including them
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2528440A4 (en) 2010-01-27 2013-08-07 Purdue Research Foundation Substituted norindenoisoquinolines, syntheses thereof, and methods of use
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
CN102250000A (en) * 2010-05-17 2011-11-23 中国人民解放军第二军医大学 Indenoquinolinone compounds, and preparation method and application thereof
US9249172B2 (en) * 2010-05-24 2016-02-02 Hande Pharma Limited Pyrazole derivatives
US9073920B2 (en) 2010-08-17 2015-07-07 Purdue Research Foundation Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor
TW201307347A (en) 2010-11-01 2013-02-16 Arqule Inc Substituted benzo-imidazo-pyrido-diazepine compounds
WO2012162513A2 (en) * 2011-05-25 2012-11-29 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
US9682990B2 (en) 2011-05-25 2017-06-20 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
US8912213B2 (en) 2012-04-13 2014-12-16 Purdue Research Foundation Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors
US9034870B2 (en) 2012-07-13 2015-05-19 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
US8686146B2 (en) 2012-07-13 2014-04-01 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
WO2014063189A1 (en) * 2012-10-23 2014-05-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating a stress induced cardiomyopathy
WO2014199637A1 (en) * 2013-06-11 2014-12-18 出光興産株式会社 Material for organic electroluminescent elements, organic electroluminescent element using same, and electronic device
DE102016214092A1 (en) 2016-07-29 2018-02-01 Alligator Ventilfabrik Gmbh Fastening device for fastening a measuring sensor, in particular tire pressure sensor, and method for mounting a measuring sensor
US20200129476A1 (en) 2017-04-28 2020-04-30 Akribes Biomedical Gmbh PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
US20220024944A1 (en) * 2018-10-23 2022-01-27 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin
CN118146221B (en) * 2024-05-13 2024-10-25 南京市鸿舜医药科技有限公司 Pyrrolo [3,2-b ] pyridine topoisomerase inhibitor, preparation method, pharmaceutical composition and application thereof
CN118221674A (en) * 2024-05-27 2024-06-21 南京市鸿舜医药科技有限公司 Pyrrolo [3,2-b ] pyridine Top/HDAC double-target inhibitor, preparation method, pharmaceutical composition and application thereof

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4113731A (en) * 1975-08-27 1978-09-12 Gruppo Lepetit S.P.A. Fused isoquinoline derivatives
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US5079246A (en) * 1988-12-09 1992-01-07 Beacham Group P. L. C. Novel indoloquinlones
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5597831A (en) * 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
US5710162A (en) * 1994-05-20 1998-01-20 Taiho Pharmaceutical Co., Ltd. Condensed-indan derivatives and pharmaceutically acceptable salts thereof
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6346535B1 (en) * 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US20030039628A1 (en) * 1998-08-24 2003-02-27 Kristoffer Hellstrand Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agents
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20040039009A1 (en) * 2001-08-31 2004-02-26 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US6723733B2 (en) * 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
US20040077667A1 (en) * 2000-12-11 2004-04-22 Nobuya Matsuoka Quinazolinone derivatives
US20040120926A1 (en) * 1999-07-16 2004-06-24 Kristoffer Hellstrand Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment
US6828319B2 (en) * 2001-08-31 2004-12-07 Inotek Pharmaceuticals Corporation Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
US20050228007A1 (en) * 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
US20060019980A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceutical, Corp. Methods for treating or preventing erectile dysfunction or urinary incontinence
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
US20060287311A1 (en) * 2005-02-25 2006-12-21 Inotek Pharmaceuticals Corporation Tetracyclic Sulfonamide Compounds and methods of use thereof
US20060287312A1 (en) * 2005-02-25 2006-12-21 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
US20060287313A1 (en) * 2005-02-25 2006-12-21 Inotek Pharmaceuticals Corporation Isoquinoline compounds and methods of use thereof
US20070049555A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US7217709B2 (en) * 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2025932B (en) * 1978-06-13 1982-10-27 Sumitomo Chemical Co Indoloisoquinolines and processes for producing them
US4623304A (en) * 1981-12-08 1986-11-18 Sanyo Electric Co., Ltd. Hermetically sealed rotary compressor
CZ281473B6 (en) * 1991-08-29 1996-10-16 Vúfb, A.S. 2-HYDROXYETHYLAMINO SUBSTITUTED DERIVATIVES OF 5,11-DIOXO-5,6-DIHYDRO-11H-INDENO£1,2-c|ISOQUINOLINE, PROCESS PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
JP3643916B2 (en) * 1995-11-17 2005-04-27 大鵬薬品工業株式会社 Novel condensed indene derivative or salt thereof
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6250301B1 (en) 1997-08-28 2001-06-26 Hortal Harm B.V. Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
JP2002515490A (en) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Condensed tricyclic compounds that suppress PARP activity
US6509344B1 (en) 1998-10-14 2003-01-21 The United States Of America As Represented By The Department Of Health And Human Services Indenoisoquinolines as antineoplastic agents
AU765224B2 (en) 1998-11-03 2003-09-11 Basf Aktiengesellschaft Substituted 2-phenylbenzimidazoles, the production thereof and their use
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
RS50031B (en) 1999-01-11 2008-11-28 Agouron Pharmaceuticals Inc., TRICYCLIC POLY INHIBITORS (ADP-Ribose) POLYMERASE
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
JP2003267888A (en) 2002-03-15 2003-09-25 Seishi Yoneda Cardiac arrest fluid
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
JPWO2004043959A1 (en) 2002-11-12 2006-03-09 持田製薬株式会社 Novel PARP inhibitor
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
AU2004294790B2 (en) 2003-12-01 2010-03-11 Kudos Pharmaceuticals Limited DNA damage repair inhibitors for treatment of cancer

Patent Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4113731A (en) * 1975-08-27 1978-09-12 Gruppo Lepetit S.P.A. Fused isoquinoline derivatives
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5079246A (en) * 1988-12-09 1992-01-07 Beacham Group P. L. C. Novel indoloquinlones
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5597831A (en) * 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5710162A (en) * 1994-05-20 1998-01-20 Taiho Pharmaceutical Co., Ltd. Condensed-indan derivatives and pharmaceutically acceptable salts thereof
US5733918A (en) * 1994-05-20 1998-03-31 Taiho Pharmaceutical Co., Ltd. Condensed-Indan derivatives and pharmaceutically acceptable salts thereof
US6028079A (en) * 1994-05-20 2000-02-22 Taiho Pharmaceutical Co., Ltd Condensed-indan derivatives and pharmaceutically acceptable salts thereof
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US20030039628A1 (en) * 1998-08-24 2003-02-27 Kristoffer Hellstrand Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agents
US6498194B2 (en) * 1999-01-29 2002-12-24 Basf Aktiengsellschaft Fungicidal mixtures
US6346535B1 (en) * 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
US20020099063A1 (en) * 1999-01-29 2002-07-25 American Cyanamid Company Fungicidal mixtures
US20040120926A1 (en) * 1999-07-16 2004-06-24 Kristoffer Hellstrand Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6723733B2 (en) * 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
US20040077667A1 (en) * 2000-12-11 2004-04-22 Nobuya Matsuoka Quinazolinone derivatives
US6828319B2 (en) * 2001-08-31 2004-12-07 Inotek Pharmaceuticals Corporation Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
US20040039009A1 (en) * 2001-08-31 2004-02-26 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US7217709B2 (en) * 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
US20050228007A1 (en) * 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
US20060019980A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceutical, Corp. Methods for treating or preventing erectile dysfunction or urinary incontinence
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
US20060287311A1 (en) * 2005-02-25 2006-12-21 Inotek Pharmaceuticals Corporation Tetracyclic Sulfonamide Compounds and methods of use thereof
US20060287312A1 (en) * 2005-02-25 2006-12-21 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
US20060287313A1 (en) * 2005-02-25 2006-12-21 Inotek Pharmaceuticals Corporation Isoquinoline compounds and methods of use thereof
US20070049555A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228007A1 (en) * 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US20100137976A1 (en) * 2008-12-02 2010-06-03 Medtronic Vascular, Inc. Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors
RU2585622C2 (en) * 2009-06-10 2016-05-27 Чугаи Сейяку Кабусики Кайся Tetracyclic compounds
US9440922B2 (en) 2009-06-10 2016-09-13 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
RU2725140C2 (en) * 2009-06-10 2020-06-30 Чугаи Сейяку Кабусики Кайся Tetracyclic compounds
US8686144B2 (en) 2009-07-28 2014-04-01 Commissariat a l'Energie Atomique et aux Energie Alternative Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2
US10646468B2 (en) 2010-08-20 2020-05-12 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
US11633402B2 (en) 2012-09-25 2023-04-25 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
US10350214B2 (en) 2014-04-25 2019-07-16 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
US9714229B2 (en) 2014-04-25 2017-07-25 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
US11433076B2 (en) 2014-04-25 2022-09-06 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
US10344014B2 (en) 2014-08-08 2019-07-09 Chugai Seiyaku Kabushiki Kaisha Amorphous form of tetracyclic compound
US10774067B2 (en) 2014-08-08 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Amorphous form of tetracyclic compound
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
US11896579B2 (en) 2015-01-16 2024-02-13 Chugai Seiyaku Kabushiki Kaisha Combination drug
US11939322B2 (en) 2018-09-04 2024-03-26 Chugai Seiyaku Kabushiki Kaisha Method for producing tetracyclic compound

Also Published As

Publication number Publication date
EP1603567A4 (en) 2006-10-18
WO2005009398A3 (en) 2005-09-29
AU2004258801A1 (en) 2005-02-03
PL378331A1 (en) 2006-03-20
BRPI0407757A (en) 2006-02-14
CN1780624A (en) 2006-05-31
CA2517260A1 (en) 2005-02-03
EP1603567A2 (en) 2005-12-14
CN100398519C (en) 2008-07-02
US20040229895A1 (en) 2004-11-18
KR20050118169A (en) 2005-12-15
RU2005130169A (en) 2006-05-10
US7217709B2 (en) 2007-05-15
JP2007501857A (en) 2007-02-01
WO2005009398A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
US7217709B2 (en) Tetracyclic benzamide derivatives and methods of use thereof
US7652028B2 (en) Indenoisoquinolinone analogs and methods of use thereof
EP2033645A1 (en) Isoquinoline derivatives and methods of use thereof
US20060287313A1 (en) Isoquinoline compounds and methods of use thereof
US7381722B2 (en) Tetracyclic amino and carboxamido compounds and methods of use thereof
US8119654B2 (en) Indenoisoquinolinone analogs and methods of use thereof
US20060287311A1 (en) Tetracyclic Sulfonamide Compounds and methods of use thereof
US20050261288A1 (en) Tetracyclic lactam derivatives and uses thereof
US20100261706A1 (en) Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION